

Citation: Mbondji-wonje C, Dong M, Wang X, Zhao J, Ragupathy V, Sanchez AM, et al. (2018) Distinctive variation in the U3R region of the 5' Long Terminal Repeat from diverse HIV-1 strains. PLoS ONE 13(4): e0195661. <u>https://doi.org/</u> 10.1371/journal.pone.0195661

Editor: Zhefeng Meng, Fudan University, CHINA

Received: November 28, 2017

Accepted: March 27, 2018

Published: April 17, 2018

Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <u>Creative</u> <u>Commons CC0</u> public domain dedication.

Data Availability Statement: All relevant data are available in the paper, its Supporting Information files, and from the GenBank database. For a list of GenBank accession numbers, please see the Supporting Information table.

Funding: This work was supported by the National Heart, Lung, and Blood Institute (NHLBI) (IAA No A-HL-12-002), <u>https://www.nhlbi.nih.gov/</u>; Division of AIDS/National Institute of Allergy and Infectious Diseases: IAA No AAI 17073; HHSN272201700061C, <u>https://www.niaid.nih.gov/</u>

<u>about/daids</u>. The funders had no role in study

RESEARCH ARTICLE

Distinctive variation in the U3R region of the 5' Long Terminal Repeat from diverse HIV-1 strains

Christelle Mbondji-wonje^{1,2#}*, Ming Dong³, Xue Wang¹, Jiangqin Zhao¹, Viswanath Ragupathy¹, Ana M. Sanchez⁴, Thomas N. Denny⁴, Indira Hewlett^{1#}*

1 Laboratory of Molecular Virology, Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America, 2 Department of Molecular Biology, Faculty of Medicine, Pharmacy and Biomedical sciences, University of Douala, Douala, Cameroon, 3 U.S. Military HIV Research Program, Silver Spring, Maryland United States of America, 4 Department of Medicine, Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States

¤ Current address: Laboratory of Molecular Virology, CBER/FDA, Silver Spring, MD, United States of America

* Christelle.mbondji@fda.hhs.gov (CM); Indira.hewlett@fda.hhs.gov (IH)

Abstract

Functional mapping of the 5'LTR has shown that the U3 and the R regions (U3R) contain a cluster of regulatory elements involved in the control of HIV-1 transcription and expression. As the HIV-1 genome is characterized by extensive variability, here we aimed to describe mutations in the U3R from various HIV-1 clades and CRFs in order to highlight strain specific differences that may impact the biological properties of diverse HIV-1 strains. To achieve our purpose, the U3R sequence of plasma derived virus belonging to different clades (A1, B, C, D, F2) and recombinants (CRF02_AG, CRF01_AE and CRF22_01A1) was obtained using Illumina technology. Overall, the R region was very well conserved among and across different strains, while in the U3 region the average inter-strains nucleotide dissimilarity was up to 25%. The TAR hairpin displayed a strain-distinctive cluster of mutations affecting the bulge and the loop, but mostly the stem. Like in previous studies we found a TATAA motif in U3 promoter region from the majority of HIV-1 strains and a TAAAA motif in CRF01_AE; but also in LTRs from CRF22_01A1 isolates. Although LTRs from CRF22_01A1 specimens were assigned CRF01_AE, they contained two NF-kB sites instead of the single TFBS described in CRF01 AE. Also, as previously describe in clade C isolates, we found no C/EBP binding site directly upstream of the enhancer region in CRF22_01A1 specimens. In our study, one-third of CRF02 AG LTRs displayed three NF-kB sites which have been mainly described in clade C isolates. Overall, the number, location and binding patterns of potential regulatory elements found along the U3R might be specific to some HIV-1 strains such as clade F2, CRF02_AG, CRF01_AE and CRF22_01A1. These features may be worth consideration as they may be involved in distinctive regulation of HIV-1 transcription and replication by different and diverse infecting strains.



design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Introduction

The high diversity of HIV-1 has led to its classification into four groups named M, N, O and P. Group M which is the most prevalent worldwide has been further subdivided into at least nine genetically distinct subtypes or clades (A-D, F-H, J, and K), several circulating recombinant forms (CRFs) and unique recombinant forms (URFs) [1]. Several studies have reported the impact of HIV-1 strains on transmission, replication, pathogenesis, diagnosis and response to therapy $[\underline{2}, \underline{3}]$. Thus, subtype A was shown to be less pathogenic than non-A subtypes and to have a lower replication rate than subtype C [4, 5]. The heterosexual transmission rate of HIV-1 appeared to be higher in subtype A compared with D, and in CRF01_AE compared with subtype B [6, 7]. Subtype D has been associated with faster disease progression compared with subtype A, C and CRFs [8-10]. The overall influence of inter- and intra-clade genetic variability on the biological properties of HIV-1 is not fully understood. However, there is increasing evidence that the genetic diversity of the LTR has the potential to affect the replication rate and expression of HIV-1 [11–14]. For example, it was shown that a single mutation changing one of the two canonical targets for NF-κB into a binding site for GABP transcription factor, results in higher replication rate and transmission efficiency of CRF01 AE compared with subtype B [15]. Also, mutations in the sequence motifs targeted by the CCAAT/enhancer-binding proteins (C/EBP) and specificity proteins 1 (Sp1) were correlated with disease severity and neurologic impairment [16, 17].

During the life cycle of HIV-1, transcriptional regulation of the integrated provirus is a key step ahead of viral replication and expression. This early step is regulated by a synergistic interaction of host transcription factors and viral proteins that bind to specific targets in the 5'LTR of the HIV-1 genome. The HIV-1 5'LTR is a complex structure of approximately 640 bp in length with a high concentration of transcription factor binding sites (TFBS). It has been divided into the U3, R and U5 functional regions. The U3 region located upstream of the transcription start site was subdivided into the modulatory (nt -454 to -104), the enhancer (nt -105 to -79) and the promoter (nt -78 to -1) segments [13, 18]. The modulatory segment contains numerous TFBS [19], and in certain HIV-1 variants, this segment is extended with an insert of 15 to 34 nucleotides known as the Most Frequent Naturally occurring Length Polymorphism (MFNLP) [20-22]. The enhancer region contains binding sites for the NF-kB family of transcription factors, and the promoter region carries the TATA box and three binding sites for Sp1 [18]. Following the promoter, the R region which is, by definition, the transcription initiation site comprises the trans-activating responsive (TAR) element that mediates activation of transcription through its binding to the viral Tat protein [23, 24], and the polyadenylation signal (poly A) involved in the addition of the 3'-poly (A) tail [25]. Along with these elements, various binding sites for different families of transcription factors have also been described in the R region [26-29]. Interaction between the TAR element and the viral protein Tat is required to enhance transcriptional elongation and gene expression of HIV-1 [30, 31]. However, prior to the presence of Tat, the 5'LTR is able to support basal transcription that results in the production of short transcripts allowing viral proteins such as Tat to be made [31]. This capacity of the 5'LTR to control HIV-1 basal transcription is driven by TFBS in the U3 promoter and enhancer segments primarily [31], but also involves cooperative action of regulatory elements in the U3 modulatory segment [32]. Besides its role in transcription, the U3 and the R region of the 5'LTR (U3R) have also been involved in HIV-1 replication, expression and silencing [33-38]. Therefore, characterization of the U3R from different HIV-1 strains is of great importance as it might contribute to a better understanding of the influence of HIV-1 variants on the fitness, pathogenicity and disease progression. To date, only few studies have

investigated the genetic diversity the HIV-1 5'LTR in non-B and non-C strains and in most of them the common approach was the clone-based Sanger sequencing methodology [<u>39</u>– <u>41</u>]. This method is costly, time-consuming and labor intensive. Also, it may be limited by preferential selection that can occur during molecular cloning and only a few hundred clones can be generated and sequenced [<u>42</u>, <u>43</u>]. Next-generation sequencing (NGS) technology is a relevant alternative to overcome these limitations by allowing massively parallel amplification at high coverage of thousands of reads per base pair. Thus, NGS provides the potential to reduce the time and facilitate the detection of intra-specimen variability without the need for cloning PCR amplicons before sequencing. The main objective of this study is to describe the genetic variability of the U3R from viruses representing various clades and diverse CRFs isolated from plasmas samples, by using NGS Illumina sequencing technology.

Materials and methods

Specimens and RNA isolation

Sixty five high titer virus derived from de-identified plasma specimens obtained from DUKE EQAPOL viral diversity program [44], and five CRF02_AG virus isolated from stored and de-identified plasma specimens [45–47] as previously described [48] were selected for this study. The study was approved by the Duke University Institutional Review Board for clinical investigation (Pro0029507) and the Review Board of the US HHS/Food and Drug Administration Research in Human Subjects Committee (exempt reference number 01-044B). The selected seventy virus stocks included clade B (n = 18), clade A1 (n = 10), clade C (n = 9), clade D (n = 8), clade F2 (n = 3), clade G (n = 4), CRF02_AG (n = 9), CRF01_AE (n = 5), CRF22_01A1 (n = 4). Viral RNA was extracted using Virus QIAamp Viral RNA Mini Kit (QIAGEN) according to the manufacturers' instructions.

Primer design

References and consensus sequences representing the first 1000 nucleotides of the HIV-1 genome from multiple subtypes and CRFs were downloaded from Los Alamos National Laboratory HIV database and aligned in MEGA version 7 software [49]. Regions with the highest degree of conservation were screened and used to design PCR primers that were optimized for melting temperatures, GC content and reduced hairpin and/or primer dimer formation (NCBI/primer3-BLAST; SMS). Due to mismatches in some strains, selected primers were designed with degenerate nucleotides to match all group M isolates.

cDNA synthesis, PCR amplification and purification

Reverse transcription was performed by using Superscript III First-strand synthesis System for RT-PCR (Invitrogen 18080–051). The cDNA was amplified by touchdown (TD) polymerase chain reaction (PCR) procedure with 2 rounds of amplification. Each amplification run was performed in a 50µl reaction volume using Promega PCR master mix (Promega, Madison, WI, USA cat M7505) supplemented with 0.4µM of primer <u>Table 1</u>. Cycling conditions for both outer and nested TD-PCR was as follows: initial incubation at 95°C for 3 min followed by 10 cycles at 95°C for 30 s, 64°C for 30 s with a 1°C decrement per cycle, and 72°C for 50 s. Subsequently, 25 cycles were performed at 95°C for 30 s, 55°C for 30 s, and 72°C for 50 s followed by a final extension of 5 min at 72°C. The second round PCR amplicons were separated by gel electrophoresis. The expected PCR product size of about 850 pb were excised from the gel and purified using QIAquick Gel Extraction Kit (Qiagen).

Table 1. Primers used for amplification of the 5'end of the HIV-1 genome.

Primers	Reaction	Sequence (5'to 3')	Position ^a
HF01F (+)	cDNA	TGGAAGGGCTAATTTGGTCCCA	1-22
UNINEF 7' (-)		GCACTCAAGGCAAGCTTTATTGAGGCTT	9605-9632
HF01Fd (+)	1 st PCR	TGGAWGGGYTAATTTGGTCCCA	1-22
RVN910_M (-)		GCTCCCTGCTTGCCCATACT	891-910
5'NCF1_M (+)	2 nd PCR	GGMTWCTTCCCTGATTGGCA	66-85
PBSBR (-)		CTTAATACCGACGCTCTCGCACCCAT	790-815

(+), forward primer; (-) Reverse primer;

^a Position according to the HXB2 coordinates

https://doi.org/10.1371/journal.pone.0195661.t001

Ultra-deep sequencing

Miseq (Illumina, San Diego, CA) sequencing of the gel purified PCR product was carried out at the core facility of the Food and Drug Administration (FDA, White oak, MD, USA). Briefly, concentration of purified amplicons was measured by using Qubit dsDNA BR Assay System (Covaris, Woburn, MA, USA) and (2 ng of DNA purified product was processed for NGS library preparation using the Nextera XT DNA Sample Preparation Kit. Specimens were run in the Miseq instrument using a MiSeq v2 kit (500 cycles) to produce paired-end reads of approximately 250pb. After automated cluster generation in MiSeq, the sequencing was processed and fastq files were generated.

Sequence analysis

All fastq files were imported into CLC Genomics Workbench version 9.0 (CLC bio/Qiagen, Aarhus, Denmark) using default option. Reads were paired and trimmed to obtain reads with an average Phred score ≥ 20 . Contigs were generated using de novo assembly tools with the default options. The reads were mapped back to contigs using previous published parameters [50]. For characterization of the 5'LTR region, the minimum contig length was set at 400bp. For each specimen, contigs with a minimum coverage of 1000 reads were exported from the assembly and used for further analysis. The subtype of each full length LTR contig was assigned using COMET HIV-1 subtype tool [51]. Sequences from the same subtypes were aligned in MEGA 7 using the 5'end of HXB2 sequence (from nucleotide 76 to 850, K03455) as a reference to position the U3R sequence and to locate regulatory motifs. Mutations were identified by comparing sequences from each HIV-1 studied strain to the reference HXB2 and within matched subtype. Identification of potential TFBS was based on similarity with a reported binding site pattern and prediction with the Match 1.0 Public program available online (http://gene-regulation.com/pub/programs.html). A pairwise comparison in CLC Genomics Workbench was used to calculate the percentage of identity.

Results

Subtype assignment

Near full length LTR sequences were not obtained for 11% (8/70) of selected specimens due to failure in amplification and /or sequencing. From the 62 specimens successfully sequenced, more than one contig was obtained for several specimens. Thus, we retrieved a total of 80 contigs that were subtyped as follows: clade B (n = 20), CRF12_BF (n = 5), clade C (n = 8), clade D (n = 10), clade F2 (n = 5), clade G (n = 3), clade A1 (n = 10), CRF02_AG (n = 9) and CRF01_AE (n = 10). For majority of the sequences analyzed, the subtype assigned to the 5'LTR of the HIV-1

isolate was concordant with its previously reported primary genotype [44–46, 52]. However, we found that additional contigs from 5 clade B specimens were subtyped as CRF12_BF (BF), one of the two contigs from a CRF02_AG (AG) specimen was assigned to be F2, and all the LTR sequences retrieved from the CRF22_01A1 (01A1) specimens were subtyped as CRF01_AE (AE) Table 2.

Variability of the U3R region of the 5'LTR

Compared to HXB2, the U3 region was the most conserved in clade B with about 88% nucleotide identity versus less than 80% in average for all the other strains. The variability of the U3 region was less than 12% between sequences from the same strains and increased to an average of 23% between sequences from different strains. For most of our studied strains, the highest variability was found in the U3 modulatory segment with less than 75% of nucleotide identity. Nevertheless, the enhancer segment of clade C 5'LTRs share less than 65% of identity with the other strains. Although the number of mutations were higher in the modulatory segment than in the other segments of the U3 region, it also appears to be well conserved within sequences from the same HIV-1 strain (>85% of nucleotides identity). In the enhancer segment the intra-strain diversity varied from 2% (CRF01_AE) to 26% (CRF02_AG), while it was about 6% in the promoter segment. With an average nucleotide identity of 85%, this latter segment of the U3 region displayed few changes when sequences from different strains were compared.

Variability of the U3 region

U3 modulatory spanning nucleotides -378 to -176. Numerous transcription factors have been described in this portion of the U3 modulatory segment [13]. Nucleotide sequence from -378 to -364 which encompasses targets for proteins related to the NF-1 and CREB/ATF family of transcription factors [53, 54], include the CTGATTGGC motif (nt -378 to -370) that was conserved in 56% of the sequences analyzed. Its variant CAGATTGGC was mainly observed in the CRFs as well as in clades G and D specimens, while CAGACTGGC was shown in 1/3 of the CRF02_AG specimens (Fig 1A). The adjacent sequence (nt -369 to -364) with the consensus motif AGAA (C/T) T was conserved in 55% of the sequences analyzed, while other variants such as ACAACT were mainly found in CRF01_AE and CRF22_01A1 viruses (Fig 1A). TFBS such as COUP-TF, AP-1, ETS-1 and GATA have been reported within the sequence spanning nt -356 to -325 [55–57]. In our dataset, the first half of the binding site for COUP/AP-1 (AG GGCCA; nt -356 to -350) was highly conserved (80%) with few variants such as the consensus G(G/C) GACCA found in clade C LTRs (Fig 1A). On the contrary, the second half of this TFBS (nt -349 to -343) which includes a functional target for AP-1 family of proteins (AP-1 (II)), was more variable (Fig 1A). AP1 (II) overlaps a GATA binding site (nt -343 to -338) with the motifs AGATT (T/C) mostly found in F2, CRF12_BF, G and CRF02_AG LTRs, and AGATA (T/C) predominant in all the other studied strains. Further downstream (nt -333 to -327), the TGACCTT consensus for the reported AP-1(I), was found in all the strains studied except in CRF01_AE, CRF22_01A 1 and in clade A1 viruses. Indeed, the AP-1 (I) variant TATGTTT was shared by 80% of CRF01_AE and 40% of CRF22_01A1 specimens. In the remaining sequence from CRF22_01A1 viruses, the consensus sequence TGTG (T/C) TT was found. In clade A1 LTRs, the variant TAACATT generates with its 3'end overlapping nucleotides a CATTTG motif (nt -330 to -325), that matches the E-box consensus CANNTG ($\underline{Fig 1A}$).

Contiguously, the GATA-like binding site GGATGG (nt -326 to -319) [58], was mutated to GGGTGG in CRF02_AG LTRs and in some sequences from various other strains (Fig 1A). The consensus TGCTACAAG (C/T) (nt -320 to -310) of the first half of the binding site for the negative regulator of transcription (NRT-1)[59], was mainly conserved in CRF22_01A1 (80%)



Table 2. Specimens description and LTR subtype assignment.

Original ID	Country of origin	Primary genotype	Source Genbank	LTR ID	LTR subtype	Genbank
DEMB10US007	USA	В	KC473828	DEMB10US007	В	MH045863
DEMB10US011	USA	В	KC473830	DEMB10US011	В	MH045864
DEMB10US003	USA	В	KC473826	DEMB10US003	В	MH045865
DEMB10US004	USA	В	KC473827	DEMB10US004	В	MH045866
DEMB11US004	USA	В	KC473832	DEMB11US004	В	MH045867
DEMB10US009*	USA	В	KC473829	DEMB10US009_1	В	MH045868
				DEMB10US009_2	CRF12_BF	MH045869
DEMB05FR001	France	В	JX140652	DEMB05FR001	В	MH045870
DEMB08FR002*	France	В	JX140654	DEMB08FR002_1	В	MH045871
				DEMB08FR002_2	В	MH045872
DEMB10CN002*	China	В	JX140658	DEMB10CN002_1	В	MH045873
				DEMB10CN002_2	В	MH045874
DEMB10VE001	Venezuela	В	JX140659	DEMB10VE001	В	MH045875
DEMB03JP004*	Japan	В	KC473846	DEMB03JP004_1	В	MH045876
				DEMB03JP004_2	В	MH045877
				DEMB03JP004_3	CRF12_BF	MH045878
DEMB10ES003*	Spain	В	KC473843	DEMB10ES003_1	В	MH045879
				DEMB10ES003_2	CRF12_BF	MH045880
DEMB10ES002	Spain	В	KC473842	DEMB10ES002	В	MH045881
DEMB09ES007	Spain	В	KC473841	DEMB09ES007	В	MH045882
DEMB12JP001	Japan	В	KF716498	DEMB12JP001	В	MH045883
DEMB09FR001*	France	В	KF716494	DEMB09FR001_1	В	MH045884
				DEMB09FR001_2	CRF12_BF	MH045885
DEMB09BO001*	Bolivia	В	JX140656	DEMB09BO001_1	В	MH045886
				DEMB09BO001_2	CRF12_BF	MH045887
DEMC08ZA011	South Africa	С	JX140666	DEMC08ZA011	С	MH045888
DEMC09MW007	Malawi	С	KP109524	DEMC09MW007	С	MH045889
DEMC09MW009	Malawi	С	KP109526	DEMC09MW009	С	MH045890
DEMC00IN009	India	С	KP109484	DEMC00IN009	С	MH045891
DEMC12ZA087	South Africa	С	KP109516	DEMC12ZA087	С	MH045892
DEMC00IN006*	India	С	KP109481	DEMC00IN006_1	С	MH045893
				DEMC00IN006_2	С	MH045894
DEMC00IN007	India	С	KP109482	DEMC00IN007	С	MH045895
DEMD07UG007	Uganda	D	KF716503	DEMD07UG007	D	MH045896
DEMD07UG002*	Uganda	D	KC596071	DEMD07UG002_1	D	MH045897
				DEMD07UG002_2	D	MH045898
DEMD08UG001	Uganda	D	KC596072	DEMD08UG001	D	MH045899
DEMD10UG004*	Uganda	D	KF716479	DEMD10UG004_1	D	MH045900
				DEMD10UG004_2	D	MH045901
DEMD11UG003*	Uganda	D	KF716480	DEMD11UG003_1	D	MH045902
				DEMD11UG003_2	D	MH045903
				DEMD11UG003_3	D	MH045904
DEMD10CM009	Cameroon	D	JX140670	DEMD10CM009	D	MH045905
DEMF110ES001	Spain	F1	JX140671	DEMF110ES001	F2	MH045906
DEMF210CM001*	Cameroon	F2	JX140672	DEMF210CM001_1	F2	MH045907
				DEMF210CM001_2	F2	MH045908
DEMF210CM007	Cameroon	F2	JX140673	DEMF210CM007	F2	MH045909

(Continued)

Table 2. (Continued)

PLOS ONE

Original ID	Country of origin	Primary genotype	Source Genbank	LTR ID	LTR subtype	Genbank
NYU6542*	Cameroon	CRF02_AG	NA	NYU6542_1	F2	MH045910
				NYU6542_2	CRF02_AG	MH045911
DE00208CM004	Cameroon	CRF02_AG	JX140647	DE00208CM004	CRF02_AG	MH045912
DE00208CM001	Cameroon	CRF02_AG	JX140646	DE00208CM001	CRF02_AG	MH045913
MDC-021	Cameroon	CRF02_AG	NA	MDC-021	CRF02_AG	MH045914
MDC-024	Cameroon	CRF02_AG	NA	MDC-024	CRF02_AG	MH045915
MDC-046	Cameroon	CRF02_AG	NA	MDC-046	CRF02_AG	MH045916
MDC-055*	Cameroon	CRF02_AG	NA	MDC-055_1	CRF02_AG	MH045917
				MDC-055_2		MH045918
MDC-067	Cameroon	CRF02_AG	NA	MDC-067	CRF02_AG	MH045919
DEMG09KE001	Kenya	G	KF716477	DEMG09KE001	G	MH045920
DEMG09ES002	Spain	G	JX140675	DEMG09ES002	G	MH045921
DEMG10CM008	Cameroon	G	JX140676	DEMG10CM008	G	MH045922
DE00109CN003	China	CRF01_AE	KC596061	DE00109CN003	CRF01_AE	MH045923
DE00109CN004	China	CRF01_AE	KC596062	DE00109CN004	CRF01_AE	MH045924
DE00110CN001	China	CRF01_AE	KC596063	DE00110CN001	CRF01_AE	MH045925
DE00111CN003	China	CRF01_AE	KC596065	DE00111CN003	CRF01_AE	MH045926
DE00111CN002	China	CRF01_AE	KC596064	DE00111CN002	CRF01_AE	MH045927
DE02210CM010	Cameroon	CRF22_01A1	KF716460	DE02210CM010	CRF01_AE	MH045928
DE02210CM011	Cameroon	CRF22_01A1	KF716461	DE02210CM011	CRF01_AE	MH045929
DE02210CM014	Cameroon	CRF22_01A1	KF716463	DE02210CM014	CRF01_AE	MH045930
DE02210CM012*	Cameroon	CRF22_01A1	KF716462	DE02210CM012_1	CRF01_AE	MH045931
				DE02210CM012_2		MH045932
DEMA03RW001	Rwanda	A1	KF716499	DEMA03RW001	A1	MH045933
DEMA11KE001	Kenya	A1	KF716475	DEMA11KE001	A1	MH045934
DEMA110UG001	Uganda	A1	KF859745	DEMA110UG001	A1	MH045935
DEMA108RU003	Russia	A1	KF716491	DEMA108RU003	A1	MH045936
DEMA108RU004	Russia	A1	KF716492	DEMA108RU004	A1	MH045937
DEMA106ES002	Spain	A1	JX140651	DEMA106ES002	A1	MH045938
DEMA110UG009	Uganda	A1	KF716486	DEMA110UG009	A1	MH045939
DEMA105TZ001	Tanzania	A1	JX140650	DEMA105TZ001	A1	MH045940
DEMA07RW002*	Rwanda	A1	KP109528	DEMA07RW002_1	A1	MH045941
				DEMA07RW002_2		MH045942

NA, not available;

*highlighted in gray are specimens in which more than one contig was retrieved

https://doi.org/10.1371/journal.pone.0195661.t002

isolates. It was changed to a TGCTTCAAG(C/T) consensus in a majority of non -CRF02_AG, non- clade G and D specimens, and to TG(C/T)TTCAAAC variant in clade G and CRF02_AG LTRs. The second half of the NRT-1 was reported to include an E-box/c-Myb and AP-1 sites [60]. In our study, the E-box consensus (CANNTG, nt -303 to -298) was not found in clade G and CRF02_AG LTRs. It was replaced by the non-specific variant CA(A/G)TGG also shared with others strains such as CRF22_01A1 isolates (Fig 1A). This latter variant also modified the overlapping AP-1 motif (nt -299 to -293). The contiguous GATA target [60, 61], displayed two major variants in our study (Fig 1A), GGTAGA (45%) and AGTAGA (26%) that were closely related but not identical to the canonical (A/T)GATA(A/G) binding site for GATA factors. Nucleotides spanning the AP1-1 and GATA binding sites (nt -296 to -283) lead to a consensus

													- Johnson	Decelopping of upping	Perceted TERS	Vana	ark frequ	auch in	carit	ANT SOLD	ieg star	n (56)	Batastial TERP	Corospons
A Po	ailion		-	Veri	ant frequen	nov in each	h HV-1 st	udied stra	ain (%)		-	D	to HXB2	Predominant variant	Nepulca 1-02	BF F2	B () C	A1	g AG	AE	01A1	- Potendar (Pos	Quilacilada
to h	etive -0xB2	Prodominant variant	Reported THDS	BF F2	B D	C A1	G AG	G AE	01A1	Potential TFBS	Consensus	В	1000	RATAGA	GATA	100, 100	10	n 12	20 3	13 67	20		GATA	WGATAR
rt	-378	CTGATTGGC	NF-1/CREB/ATF	80 80	80 20	100 90		20	20		1		nt -297	AGTAGA		100 100	00 1	75	70 (17	20	100	0616	55 MO (201
h	370	CAGATTGGC	NF-1/CREB/ATF	20 20	15 80		100 61	7 80	80				10 -202	ROTOGA			25	n	10	22				
		AGAAYT		100 100	65 20	90	100 6.	r						RAAGGC		100 80	25	0	70				GABLE	CCCAAR
nt In	-369	AAAACT			10 80	88		40	20					AGAGGC			30 2	0 75	20	00 07				
		ATAACT			5		11	1	20				to -276	AGARGA			15	0 13		66 67				
et	-356	AGGGCCA	COUP-TF	100 80	96 100	90	100 56	5 100	80					GGARGA							100	20		
to	-350	GSGACCA		20		63	1 3.	3	20					RGAGAR		100 100	70	50	10	33		80		
		OGGATCA		20	20	10 30		40	43					ACTGARG		105 100	9	0	40 3	13				
nt	349	OGGGTCA	AP-1 (II)	20 80 AU	20 10	60 30 10	10	1	40					AACAAAG				13		22	100	40	LEF-1/TOF	GWAACWW
bc	-343	GOGACTA		20	10 40	10	70 40	9					to -268	ACTOSAG			15			22		00		
		GGGATTA			40		30 20	0 60						ACCGAAG			10	38						
	343	AGATAY	GATA	40	70 70	60 50	30 20	0 60	100					AAYGAGG ACTAGGG					30	7				
to	-338	AGATTY		100 60	30	10 30	70 60	0 40					-1.070	MAGGAG	NEAT	100 100	50 B(88	20 3	1 100	60 1	100	EIS/NFAT	MGGAW
		TGACCTT	AP-1	80 100	60 50	80 10	100 90	0					to 265	AGGGAG			1	0	70					
rt	333	TOTOYIT			20	10			60					GGGGAG		100-108	60 7	0 63	30	17	40	49	Ebovie-meb	VALCEG
to	-327	TATGTT				79		80	40				nt -280	YAACAG		100 100	20	38	60 8	7 100	-	-14	Locatoniya	THORE
		TAACCTT		20	20	and a							to -255	CAGCTG							60	60	AP-4	CAGCTG
nt	330	COTTIG		100 100	70 80	100	100_10	100	80					CAMYTG	000004-000		10 3	0 0 06	44				Ebox	CANNTG
to	-325	CATTIG				80	1			E-pax	CANNTO			CTTRTTACA	C/EBP (US3)	20	50 E	0 25	10	7				
r.t.	326	OCTITG OCATOR		an an	20	50 60	70	100	20	QIT6	WGATAR		nt-254	TTIRCTROA	C/EBP		5	0 50		11				
te	-319	OGGTGG		20 20	50 20	50 40	30 10	0		VAIA	1000000		to -246	COTGITACA		100 30	15	13	20	13 56	100	100		
		TOCTACAAGY		20	10	30 30	400.0	000 000	äC					COTATIACA			1	0	70			199		
rt	-320	TGCTTCAAGY		100 80	90	80 70	10	0 100	20					TCTATTAGA		100 00		0 20		33			0.171	000740
	-310	TGYTTCGAGC			50									CCCATG		40	5	0 /0	10		100	80	UNIA	WORLAN
		CANNTG	Ebez/c-mvb	80 80	70 90	60 80		100	40				nt -244	CCOMTC					1	00 100				
rt	303	CARTOG	o-myb-like		15	10	100 10	0	40				to -239	COTSIG			3	0 25						
bc	-298	CAGTWR		50 50	10 10	10			20					CCTSTA			- 1	× .	20					
		CCGTKG		20 20	8	25								TATGAR		20	60	38	20					
		TGABOCA	AP-1	80 80	65 60	75 70		100	40					CATGAR		20 60 40	20 5	14			100	80	ISIAA	
nt	-299	TGATGCA			ə 30	13 10	100 10	9	40				rt -242	CATCTG					1	00 89			E-box/AP-4	CAGATG
tu	294	CAROCCA		20 20		13							to -237	THIGIG			3	0 50	30					
		AGAGCAA BCMAGABVAGGTRG			10									TSTGAG			ŝ	0	30					
	1	YCCAGAGGAGGTAG		100 100						EbJINFAT	MGGAW			тасата			3	0						
. et	226	BCCAGADGAARTRG			20	70			20	ELENFAT				TGAGCCW		20 40	50 3	0 38	20		40	80	AP-1/ATF/ CREB	TGASTCA
to	-293	CCCAAGGGAAGTAG			10	63				LIGHTON				TAAGCCW		80 60	35		10			20		
		TCCAGCAGAARTAG					100	60					nt -240 ho -234	TGTGCCW			3	0 50	30	00 100				
	1	CCCAAMAGARGTAG						00	50					TGAACCW			15				60			
													Position	COTOCCA	1945 - 1172 - 14	10e	2 dant fra	0	io acab	ally 1 ab	and of a	an (W)		5 0.55
													Position relative to HXB	Predominant variant	Reported TFBS	Va BF F	aniant free 2 B 86	0 puency D (in each C A1	HIV-1 stu G AG	ucled stra 6 AE	ain (%) 01A1	Palentiel TFBS	Consensus
<u></u>													Postion relative to HXB	Predominant variant RGCMTTNORNCA RGCATTNANNCA	Reported TFBS C/ES/?	Va BF F	iant fres 2 B 95	uency D (in each <u>A1</u> 20 40	HIV-1 stu G AG 40	udied stra S AE	an (%) 01A1	Palential TFBS	Сответние
	osition	Prodominant variant	Reported TFBS	Vi	niert frequ	ency in ca	sch HIV-1	andieds	train (%)	Poterbal TFBS	Consensus	ח ا	Position relative to HXB	Predominant variant RECMITINGENCA RECATINANNCA NECACROAGACA PEGATINANNCA	Reported TFBS C/ES/?	Va BF F	iant free 2 B 95	uency D (8	in each 2 A1 20 40 8	HIV-1 stu G AG 40	ucled sha S AE)	ain (%) 01A1 40	Palential TFBS	Condensue
	osifion elative : FXB2	Prodominant variant	Reported TFBS	Ve BF F	niart frequi 2 B L	ency in ca D C 4	ich HIV-1 A1 G J	studied s	train (%) : 01A1	Potertial TFBS	Consensus	D	Position relative to HXB nL -176 fn -165	Predominant variant Predominant variant REGMITINORINGA REGATINARINGA REGATINGARGA AGEMITIGARGA	Reported TFBS C/ESI?	Va BF F B0 0	riant free 2 B 90 90	0 puency D (8 100	in each <u>A1</u> 20 40 8	HIV-1 stu G AG 40 39	uched stra 3 AE)	ain (%) 01A1 40	Potential TFBS E-box AP-1/ATF/CREB	Conbeneue Canintig Tgaktica
	osition eletive FXB2	Predominant variant RCAYGGAATGGA	Reported TF8S	Vr BF F 20 6	niert freque 2 B C 0 10 7	ency in ca <u>3 C 4</u> 10 75 8	ach HIV-1 A1 G J 30 33	atudiods A <u>G AE</u> 67 40	train (%) : 01A1 : 90	Potential TFBS 	Consensus MGGA(#) W25T68	D	Position relative to HXB nl =176 fn =165	Predominant variant RGGMTINGTNGA RGGATTINGTNGA RGGATTIGARGA AGCIMITGARGA AGCANGGAGAGAGA	Reported TFBS C/ESP	Va BF F 80 6 20 2	iant free 2 B 95 0 0	0 puency D (8 100	in each) A1 20 40 8	HIV-1 stu G AG 40 33	ucled stra <u>3 AE</u>) 3	ain (%) 01A1 40 40	Potential TFBS E-box AP-1/ATF/CREB	Condensus Canntg Tgaktca
	oaition elative + FXB2	Predominent varient RCAYOGAATOGA CCATOCOATOGA	Reported TFBS	Ve BF F 20 6	niert froqu 2 B C 0 10 7 30	епоу in са D С 4 10 75 6 13 1	sch HIV-1 A1 G J 30 33	studieds A <u>G AB</u> 67 40	train (16) : 01A1 : 80	Potential TFBS EbsrGATA	Cansensus MGGA(II / WGATAR	D	Position relative to HXB nl - 175 to - 165	Predominant variant REGMITINOTINGA REGATTINOTINGA REGATTIGARGA AGCANIGAGAGA AGCAMGAGAGA AGCAMGAGAGACA	Reported TFBS C/ESI?	Va BF F 80 6 20 2	iant free 2 B 90 0	о риепсу D (100	in each 20 40 8	HIV-1 stu G AG 40 33 67	u clied stra B AE D B BD	ain (%) 01A1 40 40	Patential TFBS E-box AP-1/ATF/CREB	Condeneure Cannitg TSAKTCA
	tosifion elative FD(B2 to 232	Predominant variant RCAYGGAATGGA GCATGGGATGGA ACATGGGATGGA	Reported TFBS	Ve BF F 20 6 80 4	niert froque 2 B C 0 10 7 90 0	ency in ca 3 C 4 10 75 6 13 1	ach HIV-1 A1 <u>G</u> 80 33 10	studiodis AG AE 67 40	train (%) : 01A1 : 80	_ Poteniial TFBS ElseGATA	Cansensus MGGA(#) WGATAR	D	Position relative to HXB nt -176 fn -165	Predominant variant REGUTTNOTINGA REGATTINATINGA NEGACROAGAGA REGATTIGARGA AGGAGAGAGA AGGAGAGAGA AGGAGAGAGA AGGAGAGAGA GGACAGAGAGACA GACRTGGC	Roported TFBS C/ESI? USF-1	Va BF F 80 0 20 2	3 niant free 2 B 95 95 0 0 0 70	0 puency D (100 1	in esch 20 40 8	HIV-1 stu G AG 40 33 67	uclied stra <u>3 AE</u>) 3 80	ain (%) 01A1 40 40 20	Potential TFBS E-box AP-1/ATF/CREB	Consensus Canning TSAKTCA
	fosifion elative FDXB2 t- 232 c -222	Prodominant variant RCAYGGAATGGA GCATGGGATGGA ACATGGAATAGA GCATGGAATAGA GCATGGAATAGA GCATGGAATAGA	Reported TFBS	Ve BF F 20 6 80 4	nient froqu 2 B C 0 10 7 30 0	ency in ea 0 C 4 10 75 6 13 1 13	ach HIV-1 A1 G J 80 33 10	atudiod s AG AE 67 40 22 20	train (36) <u>5 01A1</u> 93	Poteriäal TFBS EselGATA	Cansensus MGGAW/ WGATAR	D	Position relative to HXB nl -175 fn -165	Precomment variant Recomment variant Recommen	Reported TFRS C/ESI? USF-1	Va BF F 80 0 20 2	3 niant free 2 B 95 95 9 9 9 9 9 9 9	0 puency D (100 1 5	in each 2 A1 20 40 8 3 0	HIV-1 stu G AG 40 33 67	uclied stra <u>5 AE</u>) 8 80	ain (%) 01A1 40 40 20	Palentiai TFBS E-box AP-1/ATF/CREB E-box	Consonsus CANNTG TSAKTCA CANNTG
	tosifion elative + D(B2 t- 232 e -222	Produminant variant RCAYGGAATGGA GCATGGGATGGA ACATGGGATGGA SCATGGGATAGA SCATGGGGATAGA ACATGGGGCAGA	Reported TPBS	V# BF F 20 6 80 4	niert freque 2 <u> B C</u> 0 10 7 80 0 3	ency in ca <u> 3 C 4</u> 10 75 6 13 1 13 10	wh HIV-1 A1 <u>G</u> 30 33 10 67	atudiodis AG AE 67 40 22 20	train (%) : 01 <u>A1</u> : 80	_ Potential TFBS Ebs/GATA	Cansensus MGGA(H) WGATAR	D	Position relative to HXB nl - 175 fn - 165 nl - 165	Precomment variant Recomment variant Recomment variant Recommendation Recommendat	Reported TFBS C/ESI? USF-1	Va BF F 80 0 20 2 100 8	11ant free 2 B 90 0 70 15 15	0 puency D (100 1 5 100	in each 20 40 8 3 0 20	HIV-1 stu G AG 40 33 33 67 33 44	a clied stra B AE D B B0 F 100	ain (%) <u>01A1</u> 40 40 20 80	Potential TFBS E-box AP-1/ATF/CREB E-box Ets	Conbordere CANNITG TSAKTCA CANNITG WGGAW
	tosifion elative : FDXB2 t- 232 c -222	Prodominant variant RCAVGGAATGGA GCATGGGATGGA ACATGGGATGGA RCATGGACGAGA ACATGGACGAGA GCATGGGATGGG TRADORS	Reported TFBS	V# BF F 20 6 80 4	niert freque <u>2 B C</u> 0 10 7 30 0 3 70 5	ency in ca <u> </u>	wh HIV-1 81 G 1 50 33 10 67 10	atudieds A <u>G AB</u> 67 40 22 20 40	train (%) : 01 <u>A1</u> : 80	Potential TFBS DerGATA	Consensus MGGAW/ WGATAR	D	Position relative to HXB nt -176 to -166 to -166	Precontinent verient ReGATTNORNGA REGATTNORNGA REGATTNARNGA REGATTOANCA ACCAREGAGAGA ACCAREGAGAGA ACCAREGAGAGA ACCAREGAGAGA CANTIGGO CANTIGO CAN	Reported TFBS C/ESI? USF-1	Va BF F 80 0 20 2 100 8	3 riant fres 2 B 90 0 0 70 0 15 15	0 puency D (100 1 100	in esch 20 40 8 3 0 20 20 30	HIV-1 stu G AG 40 33 67 33 44 33 44	a clied stra 3 AE 0 8 80 8 103 8	ain (%) <u>01A1</u> 40 40 20 80	Patential TFBS E-box AP-1/ATF/CREB E-box Ele	Consonsee Cannitg TSAKTCA CANNTG WCGAW
	tosifion elative 1 DIB2 t- 232 c -222	Predominant warant RCAYOGAATOGA CONTOGATIGA ACATOGANTIGA CONTOGANTIGA ACATOGANTIGA ACATOGANTIGA CONTOGANTIGA CONTOGANTIGA CONTOGANTIGA CATOGANTIGA TOATOCK	Reported TF8S	V# BF F 20 6 80 4	niert froqu 2 B L 0 10 7 30 0 33 70 1	ency in ea 3 C 4 10 75 6 13 1 13 10 13 13 13 13 13 13 13 13 13 13	sch HIV-1 50 33 10 67 10 80	etudiodis A <u>G AE</u> 67 40 22 20 40	train (36) <u>: 01A1</u> 90 ; ; ;	Potential TFBS BarGATA AP-1(ATF)/CREB	Cansensus MGGAW/ WGATAR TGAKTCA	D	Position relative to HXB nl -176 to -185 nl -165 to -159	Precomment variant Recomment variant Recomment	Reported TFBS C/ESI? USF-1	Va BF F 80 0 20 2 100 8	iant free 2 B 90 0 70 15 15	0 puency D (100 100 20	in each 20 40 8 3 0 20 30 80	HIV-1 stu G AG 40 33 67 33 44 67 100	a check stra <u> <u> </u> </u>	ain (%) 01A1 40 40 20 80	Potential TFBS E-box AP-1/ATF/CREB E-box Ete	Consensus Ganntig TSAKTCA CANNTG WOOGAW
	toeilion eletive 1 0387 t- 232 t- 232 t- 222	Productinent variant RCAYGGAATGGA CCATGGA/TGGA ACATGGA/TGGA CCATGGA/TGGA CCATGGA/TGGA CCATGGA/TGGA CCATGGA/TGGA CCATGGA/TGGA TGA/CCA TGA/CCA TGA/CCA CCATGGA/TGA/ TGA/CCA CCATGGA/TGA/ TGA/CCA CCATGGA/ CCATGGA	Repoted TPBS	VF BF F 20 6 80 4	niert frequ 2 B L 0 10 7 30 0 3 70 1	ency in ca 3 C 4 10 75 6 13 1 13 10 13 13 13 13 13 13 13 13 13 13	wh HIV-1 K1 G A 80 33 10 67 10 80	atudied s AG AE 67 40 22 20 40 40	train (16) <u>01A1</u> 90 1 1 60 1 10 10 10 10 10 10 10 10 10	Potential TFBS DerGATA AP-1/ATFICREB	Consensus MGGAW/ WGATAR TQAKTCA	D	Position relative to HXB nL -176 to -166 to -166	Precentinent variant Recent Transford Recent Transford Recent Transford NeckART Transford Account of the Contract Account of the Contract Account of the Contract Con	Reported TFBS CYESI? USF-1	Va BF F 90 0 20 2 100 8 100 8	2 B 1980 90 0 10 15 15 55 0 15	0 puency D (100 100 20 30	in each 2 <u>A1</u> 20 40 8 3 0 20 30 50 10	HIV-1 stu G AG 40 33 67 33 44 67 100 22	actied stra <u> <u> </u> </u>	ain (%) 01A1 40 40 20 80	Potential TFBS AP-1/ATF/CREB E-box Ete	Coneoneue Cannitg TSAKTCA CANNITG WGGAW
	to:ifion elefive + 10382 t- 232 c - 222 t - 222 t - 222	Prodominant variant RCAYGGAATGGA CONTIGGATGGA ACATGGAATGGA ACATGGAATGGA CONTGGAATGGG TGATGGA TGATGAB TGATGAB TGATGAM GGATGAA GGATGAA	Reported TFBS	VF BF F 20 6 80 4 20 5 20 6	niert froqu 2 B L 0 10 7 90 0 3 70 1 0 0	ency in ca 3 C 4 10 75 6 13 1 13 10 13 13 13 13 13 13 13 13 13 13	wh HIV-1 K1 G A 80 33 10 67 10 80	etudied s AG AE 67 40 22 20 40 22 40 22 60	train (36) <u>5 OTA1</u> 90 90 60 60 40	Potenial TFBS BarGATA AP-1 (ATF/CREB	Consensus MGGA/I/ WGATAR TQAKTCA	D	Position relative to HXB nl = 176 to = 165 to = 156	Precontinent versient Precontinent versient REGATTNORNAA NGCARDARAGARAA ACCAMICAACAAA ACCAMICAACAA ACCAMICAACAA ACCAMICAACAA ACCAMICAACAA ACCAMICAACAA ACCAMICAACAA ACCAMICAACAA ACCAMICAACAA ACCAMICAACAA ACCAMICAACAA ACCAMICAACAA ACCAMICAACAA ACCAMICAACAA ACCAMICAACAA ACCAMICAACAA ACCAMICAACAA ACCAMICAACAA ACCAMICAACAAA ACCAMICAACAA ACCAMICAACAA ACCAMICAACAAA ACCAMICAACAAAAAAAA ACCAMICAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	Reported TFBS CYESI? USF-1	Va BF F 80 0 20 2 100 8 100 8	2 B 95 95 70 15 15 55 55 30	0 puercy D (100 100 20 30 1(in each 2 41 20 40 8 3 0 20 30 30 30 10 00	HIV-1 stu G AG 40 33 67 33 44 67 100 22	a clied stra 3 AE 3 8 8 8 103 5 103 2	ain (%) 01A1 40 40 20 90	Potential TFBS AP-1/ATTFICREB E-box E1e	Condensue Canate Tsaktca Canate Mogikin
	toeilion eletive t-032 e-222 t-221 t-221 t-221	Prodominant variant RCAYGGAATGGA CCATGBOATCGA ACATGBOATCGA CONTGGAYTAGA CCATGGACGAGA CCATGGACGAGA CCATGGACGAG CCATGGACGAG CCATGGACGAG CCATGGACGA CCATGGACGAG CCATGGA CCATGAA CCATGGACGA CCATGAA CCATGGACGA CCATGAA CCATGGACGA CCATGAA CCATGGACGA CCATGAA CCATGGACGA CCATGAA CCATGGACGA CCATGAA CCATGGACGA CCATGGAC CCATGGACGA CCATGGAC	Reported TFBS	Ve BF F 20 6 80 4 20 5	nierk froque 2 B E 0 10 7 30 0 70 1 0 0 5 7	ency in ea <u> </u>	ach HIV-1 80 33 10 67 10 80	etudiod s AG AB 67 40 40 40 22 60	train (36) <u>01A1</u> 90 90 60 60 40	Potential TTPES DevIGATA AP-1/ATF/CREB	Concensus MGGA/97 WGATAR TGAKTCA	D	Position relative to HXB al -176 to -185 to -185 to -155	Precentinal variant ReGATTNORNGA REGATTNORNGA REGATTNANCA REGATTOANCA RECATTOANCA ADDAGGARGIAA ADDAGGARGIA ADDAGGARGIA ADDAGGARGIA ADDAGGARGIA CANATAGC CANATAGC CANATAGC CANATAGC CANATAGC CANATAGC COCAGA CCCAAG CCCAAG CCCAAG CCCAAG CCCAAG CCCAAG CCCAAG CCCAAG CCCAAG CCCAAG CCCCAG CCCAAG CCCCAG CCCAAG	Reported TFBS C/ESI? USF-1	Va BF F 80 0 20 2 100 8 100 8	3 riant free 2 B 90 0 70 70 15 15 55 55 30	0 puercy D (100 100 20 30 1(in each 2 A1 20 40 8 3 0 20 30 30 30 10 00	HIV-1 stu G AG 40 33 33 67 33 44 33 47 22 33 33	accied strat 3 AE 3 4 100 5 100 5 5 5	ain (%) 01A1 40 40 20 80	Potential TFBS E-box AP-1/ATF/CREB E-box Ele	Conference Cannito Torketor Cannito Mocaw
	toeilion eletive +10282 	Ресклівані чагаті РСАУОВААТОСА ССАТОСАЛІССА АСАТОСАЛІССА ССАТОБАЛІСА ССАТОБАЛІСА ССАТОБАЛІСА ТОАСОСЯ ТОАСОСЯ ТОАСОСЯ ССАТОБАЛІСА ССАТОБА	Reported TP8S	Ve BF F 20 6 80 4 2 100 6	niert froque 2 B U 0 10 7 30 0 70 1 0 0 5 7	ency in ca 3 C 4 10 75 6 13 1 13 10 13 13 10 13 13 10 13 10 13 10 13 10 10 10 10 10 10 10 10 10 10	ach HIV-1 <u>A1 G J</u> 80 33 10 67 10 80 67 10	etudied s AG AE 67 40 22 20 40 22 22 60	train (%) : 01A1 33	Potential TTBS BarGATA AP-1(ATF)/CREB	Consensus MGGAM/ WGATBR TGAKTCA	D	Position relative to HXB at -175 to -165 to -165 to -156 to -156	Precomment variant Precomment variant Precomment Pr	Reported TFBS C/ESI? USF-1	Va BF F 80 0 20 2 100 8 100 8	2 B start free 2 B 305 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 puency D (100 100 20 30 1(30	in each 2 A1 20 40 8 3 0 20 30 30 30 30 10 00 0	HIV-1 stu G AG 40 33 33 67 33 44 67 33 44 67 22 23 33 33	acciect strategy 3 <u>AE</u> 3 4 100 5 100 2 3 3 3	am (%) 01A1 40 40 20 80	Potential TFBS E-box AP-1/ATF/CRED E-box Ete	Coteneue Cannite Tsekttca Cannite Mogawi
	t-221 t-222 t-221 t-221 t-221	Prodominant warrant RCAYIGGAATGGA CCATGGAATGGA CCATGGAATGGA CCATGGAATGGA	Reported TFBS	Ve BF F 20 0 80 4 80 4 2 100 6	niert froque 2 B E 0 10 7 30 0 3 70 1 0 0 5 7	ency in ca <u> </u>	ach HIV-1 At <u>G</u> 50 33 10 67 10 50 67 10 67	etudied s AG AE 67 40 22 20 40 22 22 60	train (%) 2 01A1 80 90 60 60 80 80	Potential TFBS DariGATA AP-1/ATFICREB	Consensus MGGAIN WOATER TGAKTCA	D	Post.cc relative to HXB nl -176 to -165 to -156 to -156 to -156	Precentinent variant Precentinent variant RegetTimoStruck NegaADTIMOStruck NegaADTIMOStruck NegaADTIMOStruck NegaADTIMOStruck NegaADA NegaA	Reported TFBS CYESI? USF-1	Va BF F 80 0 20 2 100 8 100 8	2 B stant free 2 B 305 0 0 0 15 15 30 30 10 55	0 puency D (100 100 20 30 10 30 10 10	in esch 20 40 8 3 0 20 30 50 30 50 50 50 50 50 50 50 50 50 50 50 50 50	HIV-1 stu G AG 40 33 33 67 33 44 67 33 44 67 22 23 33 31 100 22 23 33	acciect strategy of the second strategy of th	am (%) 01A1 40 40 20 80 103 40	Potential TFBS AP-1/ATF/CREB E-box Ete Ete	Consonsue CANNTG TGAKTCA CANNTG MOGAW WGATAR
	toeilion eletive + URP2 - 232 c - 222 t - 221 t - 221 t - 221 t - 218 c - 212	Prodominant warrant RCAYGGAATGGA CotTIGGATGGA ACATGGAATGGA CotTIGGATGGA CotTIGGATGGA CotTIGGATGGA CotTIGGATGGA CotTIGACOA CotTIGGATGGA CotTIGATGA CotTIGACOA CotTIGACOA CotTIGGA CotTIGA COTIGGA CotTIGA COTIGGA CotTIGGA CotTIGGA CotTIGGA CotTIGGA CotTIGGA COTIGA COTIG COTIG COTIG COTIG COTIGGA COTIGGA COTIGGA COTIGGA COTIGA COTIG COTIG COTIG COTI	Repoted TFBS	Ve BF F 20 0 80 4 100 6	nierkfroqu 2 8 0 0 10 7 30 3 70 1 0 5 7 0 0 5 7 0	ency in ca 3 C J 10 75 E 13 1 13 13 13 13 13 13 13 13 13 1	nch HIV-1 50 33 10 10 50 50 67 10 50 67 10 20 20	etudied s AG AE 67 40 22 20 40 22 22 60 22 22 60	train (%) <u>01A1</u> 80 60 60 80 70	Poterial TFBS BarGATA AP-1/ATFICREB	Consensus MGGA/I/J WGATDR TGAKTCA	D	Post co to HXB relative HXB nl - 176 to - 166 to - 166 to - 154 to - 154	Precontinent verient Precontinent verient REGATTMORICA REGATTMORICA REGATTMORICA REGATTMORICA AGENERGAGEGA AGENERGAGEGA AGENERGAGEGA CANATTAGE COMMAGE COM	Reported TFBS C/ESI? USF-1	Va BF F 80 6 20 2 100 8 100 8	2 stant flex 2 85 95 15 15 36 15 36 10 55 55 0 20	0 puency D (100 110 20 20 100 100 100 100	in esch 20 40 8 3 0 20 30 30 50 50 50 50 50 50 50 50 50 50 50 50 50	HIV-1 stu G AG 33 33 67 33 44 67 100 22 33 33 11 100 33 11	a cueled strat a AE a AE AE AE AE AE AE AE AE AE AE	103 103 103 103 103 103 103	Potential TFBS AP-1/ATTPICREB E-box Ete GATA LEF-//TCF	Consensue CANNTG TSAKTCA CANNTG WOOAW WOATAR GWAACW//
	toeilion eletive + 0002 t- 232 c - 222 t- 221 t- 221 t- 221 t- 218 c - 212	Predominant warant PCAYGGAATGGA GCATGGAATGGA GCATGGAATGGA GCATGGAATAGA GCATGGAATAGA GCATGGAATAGA GCATGGACAAG GGACGAA GGACGAA GGACGAA GGACGAA GGACGAA GGACGAA TGAACAAM TGAACAAM TGAACAAR TGAACAAR	Repoted TFBS	V BF F 20 6 80 4 100 6 2	niertfrequ 2 B C 0 10 7 0 3 70 1 0 5 7 0	enny in ce <u>c</u> 4 10 75 6 13 1 13 10 10 13 18 18 18 10 10 13 13 13 13 13 13 13 13 13 13	nch HIV-1 50 33 10 67 10 80 80 80 80 80 80 80 80 80 80 80 80 80	etudied = AG AE 67 40 22 20 40 22 22 60 22 22 60 22 11 11	train (36) <u>01A1</u> 90 60 60 60 60 70	Potenbal TRBS DerGATA AP-1/ATF/CREB AP-1/ATF/CREB	Concensus MGGAN/ WGATBR TQAKTCA TQAKTCA	D	Post.oc. to HXB nl - 176 to - 160 to - 160 to - 160 to - 160 to - 160 to - 160 to - 160	Precentinal variant Report Transca Report Transca Report Transca Report Transca Report Transca Apple Constraints Apple Constraints Apple Constraints Apple Constraints Apple Constraints C	Reported TFBS CVESI? USF-1	Va BF F 20 2 100 8 100 8 100 8	2 stant free 2 85 90 0 0 70 15 15 30 15 30 15 30 15 30 20	0 puency D (100 110 100 20 30 10 30 10 8	in each 2 A1 20 40 8 3 20 30 20 30 30 10 10 10 10 30 8 10 10 10 10 10 10 10 10 10 10	HIV-1 stu G AG 33 33 67 33 44 67 33 44 67 33 33 41 100 33 31 100	an a	am (%) 01A1 40 40 20 80 103 40 40 40 20	Potential TFBS E-box AP-1/ATF/OREB E-box Ete GATA LEF-1/TCF	Coneneue Cannitg Tsakitoa Cannitg Mogaw Wgatar Gynacowy
	to:ifion oleftive t-0087 t-232 c-222 t-221 t-218 t-218 t-218	Рескліваті чагаті РСАУОБААТОСА ССАТОСАНІССА АСАТОСАНІССА ССАТОСАНІССА ССАТОСАНІССА ССАТОСАНІССА ССАТОСАНІССА ССАТОСАНІССА ССАТОСАНІССА ССАТОСАНІССА ССАТОСАНІССА ССАТОСАНІССА СОАСОСЯ ТОАНСОМ СОАСОСЯ СОАС	Reported TFBS	VF BF F 20 0 80 4 20 2 100 6 2 2 2	niart froqu 0 10 7 0 3 70 1 0 0 0 5 7 0 20 9	ency in ca <u>3</u> <u>C</u> <u>7</u> 10 75 <u>E</u> 13 13 13 13 13 13 13 13 13 13	nch HIV-1 20 33 10 67 10 80 80 80 80 80 80 80 80 80 80 80 80 80	etudied s AG AE 67 40 22 20 40 22 22 60 22 22 60 22 11 11	train (%) : 01A1 30 : : : : : : : : : : : : :	Peterbal TFBS BarGATA AP-1(ATF)/CREB AP-1(ATF)/CREB AP-1(ATF)/CREB	Consensus MGGAM/ WGATDA TQAKTCA TQAKTCA	D	Post.or relative to HXB nl - 176 to - 168 nl - 168	Precomment variant Precomment variant Precomment variant Precomment Precom	Reported TFBS C/ESI? USF-1	Va BF F 80 6 20 2 100 8 100 8	2 B 90 70 15 15 55 30 10 55 30 20	0 puency D (100 1 1 1 1 1 1 1 1 1 1 1 1 1	in esch 2 A1 20 40 8 20 30 20 30 30 10 10 10 10 10 10 10 10 10 1	HIV-1 stu G AG 40 33 33 67 33 44 57 100 22 33 33 100 22 33 31 11 100 33 11	a cied stra 3 AE 3 a0 4 100 5 100	atin (%) 01A1 40 40 40 20 80 103 40 40 20	Potential TFBS AP-1/ATF/CREB E-box Ete Ete GATA LEF-//TCF	Conserve CANNTS TSINTCA CANNTS WORKW WIGHTAR QTMARCW/
	to:ifion eleftive t-0087 t-232 c-222 t-221 t-218 t-218 t-218	Ресостіваті чалагі: ВСАЧОБААТОБА ССАТОБАНТОВА СОХТОБАНТОВА СОХТОБАНТОВА СОХТОБАНТОВА СОХТОБАНТОВА СОХТОБАНТОВА СОХТОВАНТОВА СОХТОВАНТОВА СОХТОВАНТОВА СОХТОВАНТОВА СОХТОВАНТОВА СОХТОВАНТОВА СОХТОВАНТОВА СОХТОВАНТОВА СОХТОВАНТОВА СОХТОВАНТОВА СОХТОВАНТОВА СОХТОВАНТОВА СОХТОВАНТОВА СОХТОВАНТОВА СОХТОВАНТОВА СОХТОВАНТОВА СОХТОВАНТОВАНТОВА СОХТОВАНТОВАНТОВАНТОВАНТОВАНТОВАНТОВАНТОВАН	Reported TFBS	Vi BF F 20 0 80 4 20 2 100 6 2 2 2 2 2	niert froque 2 8 1 0 10 7 3 3 7 3 1 0 0 5 7 0 5 5 7 0 23 9 45	anny in ca <u>J</u> <u>C</u> <u>7</u> 13 1 13 1 13 1 13 1 13 1 14 15 12 12 13 12 13 12 13 12 13 12 13 13 13 13 13 13 13 13 13 13	nch HIV-1 <u>80</u> 33 10 67 10 20 20 20 20 10 10 10 10 10 10 10 10 10 1	etudiod s AG AE 67 40 22 20 40 22 60 22 22 60 22 22 11 11	tran (%) 0141 (%) 90 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Peterial TFBS BarGATA AP-1/ATF/CREB AP-1/ATF/CREB AP-1/ATF/CREB C/EEP	Consensus MGGAIN WGATDA TGAKTCA TGAKTCA TGAKTCA MTTNCNMA	D	Prostace to HXB nl - 176 to - 160 to - 150 to - 150 to - 150 to - 150 to - 150 to - 150 to - 150	Precontinent verient Precontinent verient REGATTNORNCA REGATTNORNCA REGATTNORNCA REGATTOANCA ACCMMICAECA ACCMMICAECA ACCMMICAECA COMMICAECA	Reported TFBS CYESI? USF-1	Vu BF F 80 6 20 2 100 8 100 8 100 8	2 B stant free 2 B 95 90 0 15 15 90 90 55 90 90 90 90 90 90 90	puercy D (100 20 30 10 30 10 8 90 10	in each 2 A1 20 40 8 3 0 20 30 80 10 0 20 30 80 10 0 20 30 80 10 0 20 30 80 10 10 10 10 10 10 10 10 10 1	HIV-1 stu G AG 40 33 33 67 33 44 67 33 44 67 22 33 33 100 22 23 33 33 11 100 33 11 22 23 33 22 23 33 23 20 22 23 33 33 21 22 23 23 23 23 23 23 23 23 23 23 24 24 25 25 25 25 25 25 25 25 25 25 25 25 25	a cied sitra a cied sitra b AE b AE a 0 a 0 b AE a 0 a 0 b AE a 0 a 0 b AE a 0 a 0 a 0 a 0 a 0 a 0 a 0 a 0	ain (%) 01A1 40 40 20 80 100 100 40 40 20 80	Potential TFBS AP-1/ATTFOREB E-box Ete GATA LEF-1/TCF	Солеалии САМИТВ ТЗАКТСА ОАМИТВ МОСАИИ WGATAR GWAACW///
	t-221 t-222 t-222 t-222 t-222 t-228 t-218 t-218	Prodominant warrant RCAYGGAATGGA COLTIGOATGGA ACATGGAATGGA COLTIGOATGGA COLTIGOATGGA COLTIGOATGGA COLTIGOATGGA TGATGAA COLTIGOATGGG TGATGAA GGATGAA GGATGAA GGATGAA GGATGAA GGATGAA GGATGAA GGATGAA GGATGAA GGATGAA CAAGGAAGGTG GAAGAGAAGTG GAAGAGAAGTG	Reported TFBS	Va BF F 20 6 80 4 100 6 2 100 6	niertfoque 2 B L 0 10 7 33 70 1 5 7 0 5 7 0 0 5 7 0 23 9 25 0 0	anov in ca 3 C J 10 75 E 13 1 13 1 14 1 15	nch HIV-1 80 33 10 87 10 80 80 87 10 80 87 10 80 80 80 80 80 80 80 80 80 80 80 80 80	etudiod s AG AE 67 40 22 20 40 22 60 22 22 60 22 11 11 11	train (%) 01A1 930 040 040 040 040 040 040 040 0	Potenikal TIPES DevIGATA AP-1/ATF/CREB AP-1/ATF/CREB AP-1/ATF/CREB C/EBP	Сапсельця МССАЧУ/ WCATAR TGAKTCA TGAKTCA TGAKTCA MTTNCNMMA	D	Postor relative to HXB at - 1757 to - 165 to - 155 at - 155 to - 155 at - 165 to - 155	Precontriant variant REGATTMORNOA REGATTMORNOA REGATTMORNOA REGATTMORNOA REGATTMORNOA REGATTGAACA ADDAGGAGRAGA ADDAGGAGRAGA ADDAGGAGRAGA ADDAGGAGRAGA ADDAGGAGRAGA ADDAGGAGRAGA ADDAGGAGRAGA CANTRAGC CANANAGO COMANAG COMAN	Reported TFBS C/ES/? USF-1	Va BF F B0 0 20 2 100 3 100 3 1	3 stant free 2 B 95 95 15 15 30 55 30 10 55 30 10 55 30 10 55 30 10 55 30 10 55 30 10 55 30 10 55 30 10 55 30 15 55 30 15 55 30 15 55 30 15 55 55 30 15 55 55 30 15 55 55 30 15 55 55 55 55 55 55 55 55 55	U U U U U U U U U U U U U U	in esch 2 A1 20 40 8 3 0 20 30 80 10 0 20 30 80 10 0 20 30 80 10 0 10 0 10 0 10 0 10 0 10 1	HIV-1 slu G AG 40 33 47 57 100 22 33 100 110 100 33 111 22 100 85 100 22 100 100 111 100 100 100	a cited strate 3 3 3 8 8 100 5 100 5 100 5 8 8 8 8 2 20 100	ain (%) 01A1 40 40 20 80 103 40 20 20 80 20 80	Potential TFBS E-box AP-1/ATF/CREB E-box Ete GATA LEF-//TCF AD-1/ATE/CREB	Contensue CAINITG TGAKTCA CAINITG MCGAW WGAT/R GYAACW//
	t-221 t-222 t-222 t-222 t-222 t-223 t-218 t-218 t-218 t-218 t-216	Produminant warant RCAYIGBAATGGA CCATIGGAATGGA CCATIGGAATGGA CCATIGGAATAGA CCATIGGAATAGA CCATIGGAATAGA CCATIGGAATAGA CCATIGGAATGAG GGACGMA GGACGMA GGACGMA CCACC CCACCC CCACCCC CCA	Reported TFBS	V1 BF F 20 0 80 4 100 6 100 4	niert froqu 2 8 0 0 10 7 3 3 7 3 1 0 0 5 7 0 5 7 45 45	eney in ca 0 C J 10 75 6 13 1 13 10 13 10 13 10 13 10 25 1 53 2 2 1 13 13 10 13 10 13 13 13 13 13 13 13 13 13 13	nch HIV-1 K1 G J 10 10 10 10 10 10 10 10 20 20 20 10 10	etudiodis AG AE 67 40 22 20 40 22 20 22 60 22 11 11 11 11 11 11 55	tran (%) 2 01A1 33 4 60 40 40 20 20 20 20 20 20 20 20 20 2	Peterbal TFBS DerGATA AP-1/ATFICREB AP-1/ATFICREB C/EEP GATA	Cancensus MGGAW/ WGATDR TGAKTCA TGAKTCA TGAKTCA MTTRCHTMA WGATJR	D	Postico relative to HXB al - 176 to - 165 to - 165 to - 164 to - 164 to - 164 to - 164 to - 164 to - 164	Precentinant variant Precentinant variant REGATTVANNCA NGCARDGAGAG AGDAGGAGGAGA AGDAGGAGGAGA AGDAGGAGGAGA AGDAGGAGGAGA AGDAGGAGGAGA AGDAGGAGGAGA CANATIGAC COCASA COC	Reported TFBS CVESI? USF-1	Va BF F B0 0 20 2 100 3 100 3 100 3 100 3 100 3 20 2 20 20 20 20 20 20 2 20 2 20 2 20 2 20 2 20 2 20 2 20 2 20 2	3 stant free 2 B 95 0 0 15 15 30 55 30 10 55 30 20 0 0 0 0 0 0 0 0 0 0 0 0 0	U U U U U U U U U U U U U U	in esch 2 A1 20 40 8 3 0 20 30 30 30 30 8 10 0 20 30 30 8 10 0 0 0 0 0 0 0 0 0 0 0 0 0	HIV-1 slu G AG 40 33 33 67 33 44 67 33 44 67 33 44 67 33 100 22 33 100 33 11 100 59 11 100 59 11 100 11 100 100 100 100 100	acceled strate 3 AE 3 AE 3 AE 3 AE 3 AE 4 100 5 100 5 100 5 100 6 100 7 3 8 2 9 30 9 100	ain (%) 01A1 40 40 20 80 103 40 40 20 80 80 103	Potential TFBS E-box AP-1/ATF/CREB E-box Ete GATA LEF-4/TCF AP-1/ATF/CREB	Conensue Cannitg Tsakitca Cannitg Nockw Wgatar Gynacowy
	t-216 t-212 t-221 t-221 t-218 t-218 t-218 t-218 t-218	Рескліваті чалаті Рескліваті чалаті Ресклідоді Года Солтодолі Года Солтодолі Года Солтодолі Года Солтодолі Года Солтодолі Года Года Сода Года Со	Reported TFBS	V3 BF F 20 0 80 4 22 100 6 2 2 100 6	niertfroqu 2 8 1 0 10 7 3 3 70 1 0 5 7 0 5 7 0 23 9 45 0 0	enny in ca 3 C J 0 75 E 13 1 13 13 0 1 53 0 1 53 25 1 53 25 1 13 13 13 13 13 13 13 13 13 1	nch HIV-1 50 33 10 67 10 80 80 80 80 80 80 80 80 80 80 80 80 80	etudiodis AG AE 67 40 22 20 40 22 40 22 20 22 60 22 22 60 22 11 11 11 11 100 55	thrain (56) <u>01411</u> 30 40 40 40 20 20 20 20 20 20	Potential TTBS BarGATA AP-1(ATF)/CREB AP-1(ATF)/CREB AP-1(ATF)/CREB AP-1(ATF)/CREB C/EBP GATA	Consensus MGGA/J/ WGAT/J/ TGAKTCA TGAKTCA TGAKTCA MTTNCNMA MTTNCNMA	D	Post or the second seco	Precomment variant Precomment variant Precomment variant Precomment Precom	Reported TFBS C/ESI? USF-1	Va BF F 80 6 20 2 100 8 100 8 100 8 100 8 20 2 20 2 100 8 100 8 100 9 100	3 itant free 2 B 805 0 0 70 0 15 15 55 0 15 55 0 20 0 0 0 0 0 0 0 0 0 0 0 0 0	U U U U U U U U U U U U U U	in esch 2 A1 20 40 8 3 0 20 30 30 30 8 10 0 20 30 8 10 0 0 0 0 0 0 0 0 0 0 0 0 0	HIV-1 slu G A/G 40 33 47 40 33 47 40 33 44 67 33 44 67 33 33 41 100 22 33 33 11 100 11 11 100 11 11 100 11 11	and and 3 AE 3 AE 4 100 5 40 4 100 5 100 5 100 5 100 5 100 5 100 5 100 6 100 7 100 8 100 9 100 100 100	ain (%) 01A1 40 40 20 80 103 40 40 20 80 103 103	Potential TFBS AP-1/ATF/CREB E-box Ete Ete GATA LEF-//TCF AP-1/ATF/CREB LEF-//TCF	Солеолии САНАЛТВ ТЗАКТСА ОАНАЛТВ МОДАИ ШКАСИИИ ТЗАКТСА СЛИААСИИИ
	t-216 c-222 t-218 c-218	Ресостіваті чалагі: RCAYGGAATGGA CCATGGAATGGA CCATGGAATGGA CCATGGAATGGA CCATGGAATGAA CCATGGAATGAA CCATGGAATGAA CCATGGAATGAA CCATGGAATGAA CGATGGAA	Repoted TFBS	Vs BF F 20 6 80 4 2 100 6 2 2 100 6	niert froqu 2 <u>B</u> 10 70 3 3 70 1 0 5 7 0 20 9 45 0	ency in ca 3 C / 10 75 6 13 1 13 1 10 1 13 1 14 16 14 15 14 15 14 15 14 15 15 15 15 15 15 15 15 15 15	nch HIV-1 NI G J 50 33 10 67 10 80 67 10 10 10 10 10 30 30	atudiod a AG AE AG 40 22 20 40 22 20 22 20 22 20 22 11 11 11 11 100 55	tran (%) <u> 0 0141</u> 30 40 40 40 40 40 40 40 40 40 4	Potenial TFBS BarGATA AP-1(ATF)CREB AP-1(ATF)CREB C/EBP GATA Es	Consensus MGGAM/ WGATAR TGAKTCA TGAKTCA TGAKTCA MTTNCHMM3 MTTNCHMM3 MGATAR MGAAW	D	Post.or relative to HXB nl -1767 to -155 to -152 nl -165 to -154 to -155 to -155 to -154 to -155 to -154 to -155 to -154 to -155 to -155 to -155 to -155 to -154 to -155 to -155 to -155 to -154 to -155 to -155 to -154 to -1	Precontraint variant Precontraint variant REGATTWORKA REGATTWORKA NGCARDAGADA ACCENTRATCA ACCENTRATCA ACCENTRATCA ACCENTRATCA CONTRAC CANATOC CANATOC CANATOC CANATOC COCARA COCACARA COCACA COCARA COCACARA COCACAC COCACARA COCACAC COCACARA COCACAC	Reported TFBS C/ESI? USF-1	Va BF F 80 6 20 2 100 8 100 8 1	3 itant free 2 B 95 95 15 15 15 15 15 15 15 15 15 1	0 100 100 100 100 100 20 30 10 30 10 30 10 8 90 10 10 10 10 10 10 10 10 10 1	in esch 2 A1 20 40 8 3 20 30 8 30 30 8 10 0 20 30 8 10 0 10 0 10 10 10 10 10 10	HIV-1 stu G AC 40 33 33 67 33 44 67 33 44 67 22 33 33 100 22 23 33 31 11 100 33 11 100 59 100 69 100 69 67 22	B AE 0 AE 100 AE 100 <td>ain (%) 01A1 40 40 20 80 103 40 40 20 80 103 103</td> <td>Potential TFBS AP-1/ATTPORED E-box Ete GATA LEF-1/TCF LEF-1/TCF LEF-1/TCF</td> <td>Солеалии САЛИТСА ТЗАКТСА ОАЛИТСВ ИССАИИ ИССАИИ ИССАИИ СУЛАССИИИ</td>	ain (%) 01A1 40 40 20 80 103 40 40 20 80 103 103	Potential TFBS AP-1/ATTPORED E-box Ete GATA LEF-1/TCF LEF-1/TCF LEF-1/TCF	Солеалии САЛИТСА ТЗАКТСА ОАЛИТСВ ИССАИИ ИССАИИ ИССАИИ СУЛАССИИИ
	t-232 c-222 t-222 t-221 t-218 c-212 t-218 c-212 t-218 c-212 t-218 c-212 t-218 c-212	Рескопіваті малагі: РСАЧОВАНТІСА. ССАТОВОАТІСА. СОХТОВАНТОВА. СОХТОВАНТОВА. СОХТОВА. СОХТОВА. СОХТОВАНТОВА. СОХТОВА. СОХТОВА. СОХТОВА. СОХТОВА. СОХТОВА. СОХТ	Reported TFBS	Vi BF F 20 0 80 4 2 100 6 2 100 4 100 4	nierthoque 2 <u>8 1</u> 0 10 7 0 9 70 1 0 0 5 7 0 0 20 9 45 0 0 0 10 0 10 0 10	anny in ca 3 C / 13 1 13 1 13 1 13 1 13 1 13 1 13 1 13 1 14 1 15 2 15 2	sch HIV-1 41 G J 40 33 10 67 10 87 10 87 10 87 10 87 10 80 80 80 80 80 80 80 80 80 8	studied s AG AE 40 40 40 40 40 40 40 40 40 40 40 55 55	train (%) <u>OTAT</u> 30 40 40 40 40 40 40 40 40 40 4	Potenikal TIPES DevIGATA AP-1/ATF/CREB AP-1/ATF/CREB AP-1/ATF/CREB C/EBP GATA EBS LEP-1/TCF	Сапсельця МССАЧУ/ WCATAR TGAKTCA TGAKTCA TGAKTCA MTTNCNMMR INGATAR MCGAAV GUNACOW	D	Post.oc. relative to HXB nl - 1767 to - 165 to - 156 to -	Precentinant variant Precentinant variant REGATTMORNOA NGCARDGIAGA AGCARDGIAGA AGCARDGIAGA AGCARDGIAGA AGCARDGIAGA AGCARDGIAGA AGCARDGIAGA CANARGIA CANARGIA CANARGIA CANARGIA CANARGIA CONSAC	Reported TFBS C/ES/? USF-1	Va BF F 20 2 100 3 100 3 100 3 100 3 20 2 100 3 20 2 100 2 20 2 2 100 2 2 0 0 100 3 20 2 2 100 3 20 2 2 20 2 20 2 20 2 20 2 20 2 20	2 B stant free 2 B 325 0 0 15 15 30 15 30 15 30 15 30 15 30 15 30 10 55 55 55 55 50 15 30 10 50 10 10 50 10 10 50 10 10 50 10 10 15 15 10 15 15 10 15 15 10 15 15 10 15 15 10 15 15 10 15 15 10 15 15 10 15 15 10 15 15 15 15 15 10 15 15 10 15 15 10 15 15 10 15 15 10 15 15 10 15 15 10 15 15 10 15 15 10 15 15 10 15 15 10 15 15 10 15 15 10 15 15 10 15 15 10 15 15 10 15 15 10 15 15 10 15 10 15 15 10 15 15 10 15 15 10 15 15 10 15 15 10 15 10 15 10 15 10 15 10 15 10 15 10 15 10 15 10 15 10 15 10 10 15 10 10 15 10 10 15 10 10 10 10 10 10 10 10 10 10 10 10 10	0 100 100 100 100 100 100 100 1	in esch 2 A1 20 40 8 30 20 30 8 30 30 8 10 0 20 30 8 10 0 10 0 10 10 10 10 10 10	HIV-1 stu G A/G 40 33 33 67 33 44 67 33 40 22 33 33 33 100 11 100 89 110 100 89 111 78 67 22 57 57 57 57 57 57 57 57 57 57 57 57 57	B AE 0 AE 0 B 0 B 0 B 0 B 0 B 0 B 0 B 0 B 0 B 0 B 0 B 0 B 0 B 0 B 0 B 0 B 0 B 0 B	ain (%) 01A1 40 40 20 80 103 40 40 20 20 80 103 103	Potential TFBS E-box AP-1/ATF/CREB E-box Ete Ete GATA LEF-/TCF AP-1/ATF/CREB LEF-/TCF TATAA AF-1	Солеаление САЛИТСА ТСАКТСА САЛИТСВ ИССАИИ ИССАИ ИССАИИ ИССАИИ ИССАИИ ИССАИ И ИССАИ ИССАИ И ИССАИ И ИССАИ И И И
	t-2016 t-2017 t-2017 t-2018 t-2018 t-2018 t-2018 t-2018 t-2018 t-2018 t-2018	Produminant warrant PCAYIGBAATIGGA CCATIGGAATIGGA CCATIGGAATIGGA CCATIGGAATIGGA CCATIGGAATIGGA CCATIGGAATIGGA CCATIGGAATIGGA CCATIGGAATIGGA CGACACM	Reported TFBS	VF BF F 20 0 80 4 100 6 2 100 4 100 4	niert froque 2 B L 0 10 7 30 30 30 30 5 7 45 0 0 20 9 45 0 0 5 10 10 10 10 10	eney in call a C 2 10 75 6 11 1 13 1 1 13 1 1 13 1 1 13 1 1 13 1 1 13 1 1 13 1 1	sch HIV-1 (10 33 10 67 10 67 10 67 10 67 10 67 10 7 20 30 20 30 30 33 30 33 30 33	atudiod s AG ABG 67 40 22 20 40 22 22 60 22 22 60 22 22 60 22 23 55 55 57 100	train (%) <u>0141</u> 90 0 0 0 0 0 0 0 0 0 0 0 0 0	Peterbal TFBS De#GATA AP-1/ATF/CREB AP-1/ATF/CREB C/EEP GATA LEF-1/1/CF	Сапсеница МССАЧУ/ WSATDR ТОАКТСА ТОАКТСА МТПОСНТА ИТПОСНТА ИТПОСНТА ИТПОСНТА ИТПОСНТА ИТПОСНТА ИТПОСНТА ИТПОСНТА ИТПОСНТА И	D	Postor relative to HXB at 1757 to 1050 to 1050	Precontinent versient RegortThoRNoo RegortThoRNoo RegortThoRNoo RegortThoRnoo RegortThoRnoo RegortThoRnoo RegortThoRnoo AdDexegorgene AdDexegorgene AdDexegorgene AdDexegorgene AdDexegorgene AdDexegorgene AdDexegorgene AdDexegorgene AdDexegorgene Cantage Cantage Contr	Reported TFBS CVESI? USF-1	Va BF F 20 2 100 3 100 3 100 3 100 3 100 3 100 3 20 2 20 2 20 2 20 2 20 2 20 2 20 2	2 B stant frex 2 B 30 0 70 0 15 15 30 55 30 10 55 30 10 55 30 10 55 30 10 55 30 10 55 30 10 55 30 15 15 30 15 15 30 15 15 30 15 15 30 15 15 30 15 15 30 15 15 30 15 15 30 15 15 30 15 15 30 15 15 30 15 15 30 15 15 15 15 15 15 15 15 15 15	0 puercy D (8 100 100 20 30 10 30 10 30 10 8 90 10 10 10 10 10 10 10 10 10 1	11 esch 2 A1 20 40 8 3 0 20 30 20 30 30 0 20 30 0 20 30 0 20 30 0 20 30 0 20 30 0 20 30 0 20 30 0 20 30 0 20 30 0 20 30 0 20 30 0 20 30 0 20 30 0 20 30 0 20 30 0 20 30 0 20 30 0 20 20 20 20 20 20 20 20 20	HIV-1 sta G AG 33 67 33 44 67 33 44 73 33 44 72 33 33 100 11 100 11 100 11 100 11 100 65 12 100 65 12 100 100 100 100 100 100 100 100 100	acched star a AE a AE AE AE AE AE AE AE AE AE AE	am (%) 01A1 40 40 20 80 103 40 40 20 80 90 103 103	Potential TFBS Potential TFBS E-box Ebox Ele Ele GATA LEF-47TOF LEF-47TOF LEF-47TOF LEF-47TOF LEF-47TOF	Солиялии Саните ТЗИНТСА САНИТЕ ИОСИИ ИОСИ ИОСИ ИОСИ ИОСИ ИОСИ ИОСИ ИОСИ ИОСИ ИОСИ ИОСИ ИОСИ ИОСИ ИОСИИ ИОСИ И
	t-216 c -203 t -218 c -217 t -218 c -218 c -203 t -208	Рескліпастичантя Рескліпастичантя ССАТОБАНТОВА ССАТОБАНТОВА СОСТОВАНТОВАНТОВАНТОВАНТОВАНТОВАНТОВАНТОВАН	Reported TFBS	V8 BF F 20 0 80 4 2 100 6 100 4 100 8 100 8	niertfroqu 2 8 (0 0 10 7 0 3 70 1 70 1 70 1 70 1 70 1 70 1 70 1 70 1	eney in case 10 75 6 13 1 13 1 13 1 13 1 13 1 13 1 13 1 14 1 15 2 15 2 1	No.h HIV-1 G J 50 33 33 10 67 10 67 10 10 67 20 20 10 87 20 30 30 50 53 33 30 50 53 33 50 53 55 56	atudiod s AG AE 67 40 22 20 40 22 60 22 22 60 22 11 11 11 11 100 55 57 100 77	tran (%) <u>OIAI</u> 30 60 60 60 60 70 70 70 70 70 70 70 70 70 7	Peterial TFBS BarGATA AP-1/ATF/CREB AP-1/ATF/CREB AP-1/ATF/CREB C/EBP CATA E8 LEF-1/T/CF	Consensus MGG4/// WGAT/// TGAKTCA TGAKTCA TGAKTCA MITINCHMAR IMGATAR MGGAW GWAACAW	D	Postor relative to HXB at - 176 to - 156 to - 130 to - 13	Precentherit verient Precentherit verient Precentherit verient Precentherit verient Precentherit verient Precentherit verient Precentherit verient Precentherit verient Precentherit verient Precenterit Pr	Reported TFBS CYESI? USF-1	Va BF F B0 6 20 2 100 3 100 3 100 3 20 2 100 3 20 2 100 2 20 2 20 2 100 100	2 B isant frex 2 B 355 0 0 70 70 15 55 3 20 55 3 20 10 55 3 20 0 10 0 10 0 25 10 0 45 10 0 5 5 5 10 10 10 10 15 15 15 15 15 15 15 15 15 15	0 100 100 100 100 100 20 30 100 20 30 10 30 10 10 10 10 10 10 10 10 10 1	3 3 3 3 3 3 3 3 3 3 3 3 3 3	HIV-1 sta G AG 33 67 33 44 67 33 44 67 33 44 67 22 33 33 100 22 23 33 33 100 22 23 33 33 100 22 23 33 33 11 100 85 100 11 76 77 22 100 85 100 100 11 76 100 100 100 100 100 100 100 100 100 10	a A	am (%) 01A1 40 40 20 80 103 40 40 20 80 103 103	Potential TFBS AP-10ATF/CREB E-box Ete Ete GATA LEF-10CF AP-10ATF/CREB LEF-10CF TATAA AF-1	Солеалии САМИТВ ТЭАКТСА ОАМИТВ МОДАИ WGATAR GYNAACHIYI TGAKTCA GYNAACHIYI TGACTCT
	t-221 t-222 t-222 t-222 t-2215 t-218 e-212 t-218 e-203 t-208 t-208	Ресостіпалі чалагік ВСАУІЗБААТЗБА ССАТВСААТЗБА СОХТВСАТЗБА СОХТВСАТЗБА СОХТВСАТЗ	Repoted TFBS	Vi BF F 20 0 80 4 100 5 100 4 100 8 2 100 8	niert froque 2 B C 0 10 7 0 3 70 1 70 1 70 1 70 1 70 1 70 1 70 1 70 1	eney in ca 3 C J 1 (75 c) 1 (75 c	ach HIV-1 30 33 67 10 80 67 10 80 67 10 80 80 80 80 80 80 80 80 80 8	atudiod s AG AE 67 40 22 20 40 22 40 22 22 22 60 22 22 60 22 11 11 11 11 11 10 55 57 100 27 27 10	train (16) <u> OTAT</u> 333 5 5 6 6 76 76 76 76 76 76 70 70 70 70 70 70 70 70 70 70	Peterial TFBS BarGATA AP-1/ATFICREB AP-1/ATFICREB AP-1/ATFICREB C/EBP C/EBP CATA E8 LEF-1/1CF AP-1/ATFICREP	Consensus MGGAY// WGATAR TGAKTCA TGAKTCA MTTNCNMMR WGATAR MGGAW GWAACXWW	D	Postor relative to HXB nl - 1767 to - 1600 to - 1560 to	Precontraint variant Precontraint variant REGATTWORNCA REGATTWORNCA REGATTWORNCA REGATTWORNCA REGATTOANCA ACCEMICACCA ACCEMICACCA ACCEMICACCA CONTRACC CANATAGO CONTRAC CO	Reported TFBS C/ESI? USF-1	Va BF F B0 6 20 2 100 3 100 3 100 3 100 3 100 3 100 3 100 3 100 3 20 2 30 3 20 2 30 100 20 100 100 100	2 B siant free 2 B 95 95 95 95 95 95 95 95 95 95	0 100 100 100 100 100 100 100 1	in esch 2 A1 20 3 0 20 30 30 30 30 30 30 30 30 30 3	HIV-1 stu G A6 40 33 33 67 33 44 67 33 44 67 33 100 22 33 33 100 22 33 33 100 22 23 33 44 67 22 33 33 44 67 22 33 33 44 67 57 57 57 57 57 57 57 57 57 57 57 57 57	L cled strat A AE AE AC AC AC AC AC AC AC AC AC AC	am (%) 01A1 40 40 20 80 103 40 20 20 20 20 20 103 103	Potential TFBS AP-1/ATTPORED E-box Ete GATA LEF-1/TOF LEF-1/TOF LEF-1/TOF TATAA AP-1	Солеалии САЛИТСА ТЗАКТСА ОАЛИТСВ ИСОАИИ ИСОАИИ ИСОАИИ ИСОАИИИ САЛИТСА СИМАСИИИ ТСАКТСА
	t-232 t-232 t-232 t-232 t-221 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-221 t-221 t-221	Ресклатася налах РСАУОВААТОСА ССАТОВААТОСА СОТОВОАТОСА СОТОВОАТОСА СОТОВОАТОСА СОТОВОАТОСА СОТОВАТОВАТОСА СОТОВАТОСА СОТОВАТОСА СОТОВАТОСА СОТОВАТОСА СОТОВАТОСА СОТОВАТОСА СОТОВАТОВАТОСА СОТОВАТОВАТОВАТОВАТОВАТОВАТОВАТОВАТОВАТОВ	Reported TFBS	Ve BF F 20 0 80 4 100 6 100 4 100 8	aniert freque 2 B L 2 0 10 7 3 0 0 3 3 3 70 1 3 3 3 0 5 7 3 3 0 5 7 3 3 0 23 9 45 3 0 55 8 5 7 0 15 6 23 9	eney in ca 3 C J 10 75 6 11 13 13 13 13 13 13 13 13 13 13	ach HIV-1 (G) 10 33 10 67 10 67 10 67 10 67 10 67 10 0 10	abudied s AG AE 67 40 22 20 40 22 60 22 22 60 22 22 60 22 22 55 57 100 57 100 57 100 57 100	tran (%) C DIAL 30 40 40 40 40 20 50 60 70 50 100 50 100 50 100	Peterbal TRBS De/GATA AP-1/ATFICREB AP-1/ATFICREB C/EBP GATA LEF-1/I/CF AP-1/ATFICREB	Consensus MGGAW/ WGATBR TGAKTCA TGAKTCA MTTACKAMA WGATJR WGGATJR WGGATJR WGGATJR	D	Postor relative to HXB nt - 176 to - 166 to - 16	Precontriant variant Precontriant variant REGATTMORVAG REGATTMORVAG REGATTMORVAG REGATTMANCA NOCACROGAGINA ADDAVGGAGINA	Reported TFBS C/ES/? USF-1	Va BF F 20 2 100 3 100 3 100 3 100 3 100 3 20 2 20 2 20 2 20 2 20 2 100 5 20 2 20 2 100 5 20 2 20 2 20 2 20 2 20 2 20 2 20 2	2 B siant free 2 B 30 0 70 0 15 15 30 10 55 0 15 30 10 55 0 20 10 55 0 20 10 55 0 20 15 15 15 15 15 15 15 15 15 15	0 0 0 0 0 0 0 0 0 0 0 0 0 0	in esch 2 A1 20 40 8 3 20 20 30 50 10 10 10 10 10 10 10 10 10 1	HIV-1 sk G AG 40 33 40 33 40 33 40 33 40 57 33 44 57 22 33 100 11 100 80 11 100 80 11 100 80 11 100 80 11 100 80 11 100 80 11 100 80 11 100 80 11 100 80 11 100 80 100 10	a clead share 3 AE 3 AE 3 AE 3 AE 4 100 5 100 5 2 5 2 6 100 7 20 2 20 2 20 2 20 2 20 2 50 2 50 2 50 3 100	an (%) 0141 40 40 20 80 109 40 40 20 80 109 109 109	Potential TFBS E-box AP-1/ATF/CREB E-box Ete SATA LEF-/TCF AP-1/ATF/CREB LEF-/TCF TATAA AP-1	Солеалии САЛИТСА ТСАКТСА САЛИТС ИСАЛИТС ИСАЛИТСА СИМАСИИИ ТСАКТСА СИМАСИИИ ТСАКТСТ
	t-2016 t-2022 t-222 t-221 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-212 t-212 t-212 t-212 t-212 t-212 t-212 t-212 t-212 t-212 t-212 t-212 t-212 t-212 t-212 t-212 t-212 t-212 t-218 t	Produminant warrant RCAYOGAATOGA CCATOGAATOGA CCATOGAATAGA CCATOGAATAGA CCATOGAATAGA CCATOGAATAGA CCATOGAATAGA CCATOGAATAGA CCATOGAATAGA GGATGAA GGAGGAA GGAGGAA GGATGAA GGAGGAA GGAGGAA GGAGGAA GGATGAA GGAGGAA	Reported TFBS	V8 BF F 20 0 80 4 100 5 100 4 100 8	niert froque 2 8 10 7 0 90 7 3 7 3 1 0 53 8 0 53 8 13 8 15 6 20 2 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2	enny in ce 3 C 75 13 1 13 1 13 1 14 1 15 1	ach HIV-1 41 G / 67 10 67 10 80 67 10 80 87 30 30 30 30 30 30 30 30 30 30	etudiod s AG AE67 40 40 22 22 60 22 22 60 22 11 11 11 100 55 57 100 57 100 27 100	train (%) <u>0141</u> 90 60 60 60 70 70 70 70 70 70 70 70 70 7	Peterbal TFBS DerGATA AP-1/ATFICREB AP-1/ATFICREB C/EEP GATA EE® LEF-1/1CF AP-1/ATFICREB	Concensus MGGAW/ WGATBR TGAKTCA TGAKTCA MTRCHMAB WGATAR MGGAW OWACWW TGAKTCA	D	Postor relative to HXB at 1727 at 1765 at 1765	Precontinent verient RegortThoRNoo RegortThoRNoo RegortThoRNoo RegortThoRnoo RegortThoRnoo RegortThoRnoo RegortThoRnoo AdDextographic AdDextographic AdDextographic Cathernoo C	Reported TFES CVESI? USF-1 USF-1 RBE III	Value Value BF F B0 6 20 2 100 8 100 8 20 2 100 8 20 2 80 8 20 2 100 1 20 2 100 1	2 B siant free 2 B 395 395 0 0 15 15 30 0 15 15 30 0 15 30 0 15 30 0 20 0 10 55 0 20 0 10 55 0 20 0 15 15 30 0 15 15 20 15 20 15 20 15 20 15 20 15 20 15 20 20 20 20 20 20 20 20 20 20	0 puercy D (100 20 30 10 20 30 10 30 10 10 10 10 10 10 10 10 10 1	in esch 20 3 0 20 30 30 30 30 30 30 30 50 30 30 30 30 30 30 30 30 30 30 30 30 30	HIV-1 sk G A6 40 33 33 67 33 44 67 33 44 67 22 33 100 25 33 100 25 56 111 100 25 100 55 100 100	a AE 3 AE 3 AE an AE	an (%) 01A1 40 40 20 80 103 103 103 103 103	Potential TFBS AP-1/ATF/CREB E-box Ete Ete SATA LEF-/TCF AP-1/ATF/CREB LEF-/TCF TATAA AF-1	Солеолии Самита ТЗАНТСА САМИТА МОСАМ ИКАТИЯ ОТИААСИИ ТЗАНТСА СТАНТСА
	t-216 c -203 t -216 c -203 t -216 c -203 t -206 c -203 t -206 c -203 t -206 c -203	Ресклупалтичити RCAYGGAATGGA CCATGGA/TGGA CCATGGA/TGGA CCATGGA/TGGA CCATGGA/TGGA CCATGGA/TGGA CCATGGA/TGGA CCATGGA/TGGA TGA/CGAM GGA/TGGA GGA/CGAA GGA/TGGA TGA/CGAM GGA/TGGA TGA/CGAM GGA/TGGA TGA/CGAM GGA/TGGA CAAGAGA/ANGTG C	Reported TFBS	V8 BF F 20 0 80 4 20 2 100 6 2 100 4 100 8	niert froque 0 10 7 0 0 3 70 1 0 5 7 0 5 7 0 5 7 0 5 8 0 10 0 13 0 15 6 15 6 23 3	enry in ce 3 C 4 13 1 13 1 13 1 14 1 15 1 16 2 16 2 17 2 18 1 18 1	ach HIV-1 (2) (3) 80) (3) 67) 10 80) 67 10 80) 67 10 80) 80) 80) 80) 80) 80) 80) 80	atudiod s AG AE 67 40 22 20 40 22 22 60 22 22 60 22 22 60 22 23 55 57 100 55 57 100 27 70 100 100	train (%) I OLAI 1 93 6 6 6 6 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 7 7 7 7 7 7 7 7 7 7 7 7	Peterial TFBS BarGATA AP-1/ATF/CREB AP-1/ATF/CREB C/EEP GATA LEF-1/TCF AP-1/ATF/CREB AP-1/ATF/CREB	Consensus MGGA7/// WGATAR TGAKTCA TGAKTCA MTRAKTCA MGGAN/ OUVAHCAW TGAKTCA	D	Postor relative to HXB nl - 1767 to - 1660 to - 16600 to -	Precontraint variant Precontraint variant REGATTWORNA REGATTWORNA REGATTWORNA REGATTWORNA REGATTOANCA ACCENTRACA ACCENTRACA ACCENTRACA CONTRACA C	Reported TFBS CYESI? USF-1 USF-1 PBE III AP-1(ATF)CREE	Va BF F B0 6 20 2 100 3 100 3 100 3 100 3 100 3 100 3 100 3 100 3 100 3 100 3 100 3 100 100 100 100	2 B siant free 2 B 955 0 15 15 55 0 15 30 0 15 55 0 15 30 0 55 0 15 30 0 55 0 15 30 0 55 0 15 30 0 15 15 30 0 15 15 15 15 15 15 15 15 15 15	D D D D D C D C D C D C D C C C C D C C C C C C C C C C C C C	in esch 2 A1 20 40 8 20 30 20 30 20 30 50 30 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 1	HIV-1 sk G AG 40 33 33 67 33 44 67 33 44 67 22 33 33 100 33 100 35 100 85 100 85 100 85 100 85 100 85 100 85 10 10 85 10 10 10 85 10 10 10 10 10 10 10 10 10 10 10 10 10	a cied sith 3 AE 3 AE 4 103 5 103 5 103 5 103 5 103 5 20 7 103 6 20 7 103 7 105 7 100 7 100 7 100 7 100 7 1	40 0141 40 40 40 20 20 20 20 20 20 20 20 20 20 20 20 20	Potential TFBS AP-10ATF/OREB E-box Ete GATA LEF-47TOF LEF-47TOF LEF-47TOF TATAA AP-1	Солеалии САМИТС ТСАКТСА САМИТС МОССКИ WGATAR СУКАССИИ ТСАКТСА СУКАССИИ ТСАКТСА
	t-208 t-202 t-202 t-208	Predominant warant PCAYOGAATOGA COLTOGAATOGA COLTOGAATOGA COLTOGAATOGA COLTOGAATOGA COLTOGAATOGA COLTOGAATOGA COLTOGAATOGA COLTOGAATOGA COLTOGAATOGA COLTOGAATOGA COLTOGAATOGA COLTOGAATOGA COLTOGAA COLT	Reported TIFBS	Ve BF F 20 0 80 4 2 100 6 2 100 4 100 8 100 10	niert froque 2 B L 0 10 7 3 0 3 - 3 70 1 - - 0 5 7 - - 0 5 7 - - - 0 5 7 -	entry in ca 3 C J 10 75 6 11 13 10 13 1	ach HIV-1 M G J 10 3 67 10 67 10 67 10 67 10 67 10 67 10 50 10 50 10 50 10 57 10	atudiod s AG AB 67 40 22 20 40 22 40 22 40 22 40 22 20 22 50 22 11 11 11 11 11 11 11 10 55 57 100 100 77 100	train (%) <u>OTAT</u> 333 4 4 4 4 4 4 4 4 4 4 4 4 4	Potenikal TEPS DevGATA AP-1/ATFICREB AP-1/ATFICREB AP-1/ATFICREB AP-1/ATFICREB AP-1/ATFICREB AP-1/ATFICREB	Contentus MGA797 WGATAR TGAKTCA TGAKTCA MTTNCNMMR INGATAR MGAAN GUNACAWW TGAKTCA	D	Postor relative to HXB nl - 1767 nl - 1665 nl	Precenthant variant Precenthant variant REGATTNORNCA NGCARDGAGAD ACCARDGAGAD ACCARDGAGAD ACCARDGAGA ACCARDGAGA ACCARDGAGA ACCARDGAGA ACCARDGAGA ACCARDGAGA ACCARDCARDA ACCARD	Reported TFBS CYESI? USF-1 USF-1 RPE III AP-1/ATF/CREE	Va BF F B0 6 20 2 100 3 100 3 100 3 100 3 100 3 100 3 100 3 100 3 20 2 80 3 20 2 80 3 20 2 80 100 20 100 100 3 100 3	2 B siant free 2 B 385 395 0 15 15 55 0 15 15 0 15 15 0 25 0 20 0 10 0 55 0 20 0 10 0 10 0 10 15 15 0 20 0 10 15 15 0 20 0 10 15 15 0 20 0 10 15 15 0 20 0 10 15 15 0 20 15 15 0 20 10 10 10 10 10 10 10 10 10 1	D D D D 1 1 1 1 1 1 1 1 1 1 1 1 1	in esch 2 A1 20 40 8 3 0 20 30 20 30 30 20 30 30 20 30 30 30 30 30 30 30 30 30 3	HIV-1 sk G AC 40 33 67 33 44 67 33 44 67 22 33 33 100 25 23 33 100 11 100 85 67 100 85 11 100 85 11 11 11 11 11 11 11 11 11 1	B0 B0 2 100 3 100 4 100 5 100 6 2 7 100 8 100 9 100 9 100 9 100 9 100 9 100 9 100 9 100 9 100 9 100 9 100	an (%) 01A1 40 40 20 80 100 100 100 100 100 100 100 80	Potential TFBS AP-1/ATF/CREB E-box Ete GATA LEF-7/TCF AP-1/ATF/CREB LEF-7/TCF TATAA AF-1	Солеалии САЛИТСА ТСАКИТСА ОСАЛИТСА ОСАЛИТСА ОСАЛИТСА ОТЛАКТИЯ СЛИАССИИ ТСАКТСА
	t-2016 t-2022 t-222 t-222 t-222 t-2215 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-212 t-212 t-212 t-212 t-212 t-212 t-212 t-212 t-212 t-212 t-212 t-218	Produminant warrant PCAYIGGAATIGGA CCATIGGAATIGGA CCATIGGAATIGGA CCATIGGAATIGGA CCATIGGAATIGGA CCATIGGAATIGGA TGACCOR TGACCOR TGACCOR TGACCOR GGACGMA GGA	Reported TFBS	Ve BF F 20 0 80 4 100 5 100 4 100 8 100 8	unient freque 2 B L 2 0 10 7 0 0 3 3 0 0 3 3 0 0 5 7 0 5 7 4 0 5 7 4 0 5 5 7 0 5 5 7 0 5 5 7 0 5 5 7 0 15 6 23 15 6 23 3 20 2 3 3	eney in ea 3 C J 10 75 6 13 13 13 13 13 13 13 13 13 13	ach HIV-1 50 33 10 67 10 67 10 67 10 67 10 67 10 67 10 67 10 67 10 57 10 53 10 57 10 53 10 57 10 53 10 57 10 57	abudiod s AG ABG 22 20 40 22 40 22 20 22 60 22 11 11 11 11 100 55 57 100 77 100	tran (%) C DIAL 30 40 40 40 40 40 40 50 60 50 60	Peterbal TTBS DerGATA AP-1/ATFICREB AP-1/ATFICREB C/EBP GATA LEF-1/ITCF AP-1/ATFICREB AP-1/ATFICREB	Cancensus MGGAT// WGAT/DR TGAKTCA TGAKTCA MTINCNIMA WGAT/AR WGGAT/AR WGGAT/A TGAKTCA TGAKTCA	D	Postor relative to HXB at -176 to -166 to -166	Precontrivent versiont Regort Truchicola Regort Truchicola Regort Truchicola Regort Truchicola Regort Truchicola Regort Truchicola Regort Truchicola Regort Truchicola Regort Truchicola Regort Truchicola Calvert Truchicola Calvert Truchicola Calvert Truchicola Control Calvert Control Calvert Calvert Calvert Calvert Calvert Control Calvert Control Calvert Control Calvert Control Calvert Calvert Calvert Calvert Calvert Calvert Calvert Calvert Calvert Calvert Calvert Calvert Calvert Calver	Reported TFBS CVESP USF-1 USF-1 RBE III AP-164TPCREE	Va BF F BF 7 100 9 100 9 100 9 100 9 100 9 20 2 100 5 20 2 100 5 20 2 100 10 20 2 100 10 20 2 20 2 20 2	2 B miant free 2 B 555 0 15 15 555 0 15 15 555 0 20 0 55 0 20 0 55 0 20 0 55 0 20 0 55 0 20 0 55 0 20 0 2	0 D (1) 100 8 1100 8 1100 8 1100 7 100 7 100 7 100 7 100 7 100 7 100 8 100	in esch 2 A1 20 40 8 3 0 20 30 8 0 20 30 80 10 0 20 30 80 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 1	HIV-1 sku G AG 33 40 33 67 33 44 67 33 44 33 100 33 100 33 100 33 100 33 100 33 100 33 100 33 100 100	a cied strin 3 AE 3 AE 4 100 5 100 5 20 2 20 2 20 3 30 5 20 2 20 2 20 2 20 3 30 5 20 2 20 2 20 3 30 5 30 5 30 5 30 6 4 100 6 4 100 6 4 100 6 4 100 6 4 100 6 4 100 7 4 1000 7 4 100 7 4 1000 7 4 100 7 4 1000 7 4 1000 7 4 1000 7 4 10	am (%) 01A1 40 40 20 80 100 100 100 100 100 100 100 100 100	Potential TFBS AP-1/ATF/CREB E-box Ete Ete GATA LEF-/TTOF AP-1/ATF/CREB LEF-/TTOF TATAA AP-1	Солелии Санитс ТЗИЛТСА САНИТСА САНИТСА ИОСАИИ ИОСАИИ ТЗИЛАСИИИ ТЗАКТСА СУЛАСИИИ
	t-232 e-222 t-221 t-216 e-203 t-216 e-203 t-216 e-203 t-206 e-203 t-188 e-182	Productional variant RCAYOGAATOGA CCATOGAATOGA CCATOGAATOGA CCATOGAATAGA	Reported TFBS	V3 BF F 20 0 80 4 20 2 100 4 100 4 100 8 100 8 100 1	niert froque 2 8 10 7 0 10 7 0 3 7	enny in ca 3 C 7 0 75 6 13 1 14 1 15	ach HIV-1 10 10 10 10 10 10 10 10 10 1	abadied e AG AE 67 40 40 22 20 40 22 60 22 22 60 22 22 60 22 57 100 27 77 100	tran (%) OLAT OLAT 30 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40	Peterial TFBS BarGATA AP-1/ATF/CREB AP-1/ATF/CREB C/EBP GATA EP- LEF-1/1/CF AP-1/ATF/CREB AP-1/ATF/CREB	Consensus MGGAW/ WGATBR TGAKTCA TGAKTCA MTINCHMMA WGATAR MGGANY GWAACSWW TGAKTCA TGAKTCA	D	Postor relative to HXB al 1723 al 1724 al 1724	COTODOA Precontruent variant REGATTWORNOA REGATTWORNOA REGATTWORNOA NOGARDOAGAN NOGARDOAGAN AGDANGARDOAGAN AGDANGAGAN AGDANGAGAN AGDANGAGAN AGDANGAGAN AGDANGAGAN AGDANGAGAN AGDANGAGAN AGDANGAGAN COMMAN AGDANGAGAN COMMAN AGDANGAG COMMAN AGDANAN COMMAN AGDANAN COMMAN AGDANAN COMMAN AGDANAN COMMAN AGDANAN COMAN AGTIGUT AGDANAN AGTIGUT AGDANAN AGTIGUT AGTI	Reported TFBS CYESI? USF-1 USF-1 RBE III AP-1/ATPORTER	Va BF F B0 6 20 2 100 3 100 3 100 3 100 3 100 3 100 3 100 3 100 3 100 3 100 3 100 3 100 3 100 3 100 3 100 3 20 2 100 3 100 3 20 100 100 3 20 2 100 3 200 100 200 2 200 3 200 3 200 3 200 3 200 3 200 3 200 3	2 B miant free 2 B 365 0 15 15 55 0 15 15 55 0 15 10 10 10 10 10 10 10 10 10 10	0 1 0 0 0 0 0 0 0 0 0 0 0 0 0	in esch 20 20 30 20 30 20 30 30 20 30 30 20 30 50 20 30 50 20 30 50 20 30 50 20 30 50 20 30 50 20 30 50 20 30 50 20 30 50 20 30 50 20 30 50 50 50 50 50 50 50 50 50 5	HIV-1 sku G AG 40 33 40 33 40 33 40 33 40 22 23 33 41 100 22 23 33 100 25 20 20 20 20 20 20 20 20 20 20	x cited strain 3 AE 0 3 3 AE 0 3 8 100 2 100 2 100 2 100 2 100 2 50 2 50 2 50 2 50 2 50 2 50 2 50 3 100 4 100 5 100 6 100 6 100	atin (%) 01A1 40 40 20 80 103 103 103 103 103 103 103 20 80 80 80 80 80 80 80 80 80 80 80 80 80	Potential TFBS AP-1/ATF/CREB E-box Ete Ete GATA LEF-/TTCF AP-1/ATF/CREB LEF-/TTCF TATAA AF-1	Солеолии САНАТСА ТЗАКТСА ОАААТКА ОУААСИИИ ТЗАКТСА СИНАСИИИ ТЗАКТСА
	t-221 t-221 t-221 t-221 t-215 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-218 t-219	Prodominant warnerk RCAYIGGAATGGA CCATGGAATGGA CCATGGAATGGA CCATGGAATGGA	Reported TFBS	Vi BF F 20 0 80 4 2 100 5 100 4 100 8 100 11	niert froque 2 B 0 0 10 7 0 3 70 1 0 5 7 0 5 7 0 5 7 0 5 7 0 5 7 0 13 0 5 8 0 13 0 15 6 23 8 0 15 6 23 8 0 15 6 23 8	eney in ca 3 C 4 13 1 13 1 1 1 1 1 1 1 1 1 1 1 1 1 1	ach HIV-1 (2) 10 (2	atudiod s AG AEE 67 40 40 22 20 40 22 40 22 20 22 20 20 22 20 20 22 20 20 22 20 20 22 20 20 22 20 20 22 20 20 22 20 20 22 20 20 20 20 20 20 20 20 20 20 20 20 20 2	train (16) <u> OTA1</u> 33 6 6 6 76 76 76 76 76 76 76 7	Peterial TFBS BarGATA AP-1/ATFICREE AP-1/ATFICREE AP-1/ATFICREE AP-1/ATFICREE AP-1/ATFICREE AP-1/ATFICREE	Consensus MGGAY// WGATJAR TGAKTCA TGAKTCA MTTNCNMMR WGATJAR MGGAAV OWAACJAW TGAKTCA TGAKTCA	D	Postor relative to HXB nl - 1767 to - 1600 to - 1560 to	Precontrant variant Precontrant variant REGATTNORNA REGATTNORNA REGATTNORNA REGATTOANCA REGATTOANCA RECATTOANCA RECATTOANCA RECATTOANCA RECATTOANCA CONTRAC CONTRA	Reported TFBS C/ESI? USF-1 USF-1 PBE III AP-1/ATFICREE RBE IIIAP-1 C/ESP	Va BF F B0 6 20 2 100 3 100 3 100 3 100 3 100 3 100 3 100 3 20 2 100 5 20 2 100 10 20 100 100 10 100 2 80 2 80 10 20 2 80 10 100 2 80 2 80 2 80 10 100 3 20 2 80 2 80 2 80 3	2 8 miant free 2 8 950 70 0 15 15 0 15 15 0 15 15 0 15 15 0 20 10 0 55 0 20 0 55 0 10 0 55 15 0 20 0 15 15 15 0 20 0 15 15 15 0 20 0 15 15 15 0 20 0 15 15 15 15 15 15 15 15 15 15	0 0 0 0 0 0 0 0 0 0 0 0 0 0	in esch 2 A1 20 40 8 20 30 50 20 30 60 10 0 70 20 30 60 10 0 70 20 30 60 10 0 70 20 30 8 10 0 70 20 30 50 10 10 10 10 10 10 10 10 10 1	HIV-1 slak G AG 33 67 33 44 67 33 44 67 22 33 33 100 22 33 33 100 22 33 33 100 22 100 33 11 11 100 22 100 86 11 11 100 80 11 11 100 80 41 11 100 80 41 11 100 80 41 11 100 80 41 11 11 100 80 41 11 11 11 100 80 41 11 11 11 100 80 41 11 11 11 11 11 11 11 11 11 11 11 11	a ciec d sina 3 AE 3 AE 4 100 5 5 5 5 5 5 5 5 5 5 5 5 5	40 0141 40 40 40 20 80 103 103 103 103 103 103 103 103	Potential TFBS AP-1/ATTFORED E-box Eta GATA LEF-1/TCF AP-1/ATTF/CRED LEF-1/TCF TATAA AP-1	Солеалии САЛИТСА ТЗАКТСА ОАЛИТСА ИССАИИ WGANW WGANW WGANW WGANW WGANW WGANW WGANW WGANW WGANW WGANW WGANW WGANW WGANW WGANW WGANW WGANW WGANW WGANW
	toeilion elefive (10/07 4-232 c-222 t-221 t-2216 e-215 t-216 e-203 t-216 c-203 t-208 e-203 t-208 e-202 t-208 e-202 t-208 e-202 t-208 e-202 t-208 e-202	Produminant wariant PCAYOGAATGGA CCATOGAATGGA CCATOGAATGGA CCATOGAATGGA CCATOGAATGGA CCATOGAATGGA CCATOGAATGGA CCATOGAATGGA CCATOGAATGGA CCATOGAATGGA CCATOGAATGGA CCATOGAATGGA CCATOGAATGGA CCATOGAATGGA CCATOGAATGGA CCATOGAA CCATOGAATGGA CCATOGAA C	Reported TFBS	Ve BF F 20 0 80 4 20 0 2 100 6 2 100 4 100 8 2 100 1	niert froque 2 B L 0 10 7 3 0 3 3 3 70 1 5 7 0 5 7 5 0 5 7 5 0 5 5 7 0 5 7 1 0 5 7 1 0 5 7 1 0 5 7 1 0 5 7 1 0 5 7 1 0 5 8 1 1 0 15 6 23 3 10 3 3 1 6	anoy in ca a C A a C A a C A a C A b 13 3 a C A b 0 1 b 0 1 c 25 1 c 25 1 c 25 1 c 25 1 c 3 2 c 3 3 c 13 3 c 1 1 c 1 1 c 1 1 c 1 1 c 100 1	ach HIV-1 10 33 67 10 67 10 67 10 67 10 67 10 10 10 57 10 50 10 57 10 50 10 57 10 57 10 50 10 11 10 57 10 10 10 57 10 10 10 10 1	abudod s AG AB 67 40 22 20 40 22 40 22 40 22 10 22 10 11 11 11 100 55 5 57 100 77 10 77 10	train (%) C OLAL 4 30 4 4 4 4 4 4 4 4 4 4 4 4 4	Potenbal TIPES DeviGATA AP-1/ATFICREB AP-1/ATFICREB AP-1/ATFICREB C/EBP GATA EP-1/ATFICREB AP-1/ATFICREB AP-1/ATFICREB	Contentuus MGGAW/ WGATDR TQAKTCA TGAKTCA MTTNONMA WGATAR WGATAR WGATAR WGATAR TGAKTCA TGAKTCA	D	Postor relative to HXB nt - 1767 nt - 1665 nt	Precontrivent versiont REGATTNORNAL REGATTNORNAL REGATTNORNAL REGATTNORNAL REGATTORACA ACCMARITAACA ACCMARI	Reported TFBS CYESI? USF-1 USF-1 RBE II AP-1/ATPORTER RBE IUAP-1 C/ESP	Va BF F B0 6 20 2 100 8 100 8 100 8 100 8 100 8 100 8 100 8 100 8 100 8 100 100 100 100 100 8 100 2 00 100 100 8	2 B international freeses 2 B 300 0 15 15 300 15 300 15 300 15 300 10 55 0 20 45 10 10 10 10 10 10 10 10 10 10	0 puercy D (1100 20 30 110 20 30 10 20 30 10 30 10 80 10 10 10 10 10 10 10 10 10 1	in esch 20 20 30 20 30 60 10 70 8 10 70 8 10 70 8 10 70 10 70 10 70 10 70 70 70	HIV-1 sku G A43 40 33 67 33 44 67 33 44 67 33 44 67 22 33 100 59 110 100 59 110 67 22 100 69 111 78 67 22 100 69 111 33 69 44 33 69	a cie d situ 3 AE 3 AE 3 AE 3 AE 4 100 5 30 5 30 5 30 6 300 8 30 9 30 9 30 9 100	am (%) 0141 40 40 20 80 100 100 100 100 100 100 80 80 20 20 20 20 20 20 20 20 20 20 20 20 20	Potential TFBS AP-1/ATF/CREB E-box Ete GATA LEF-4/TCF TATAA AF-1	Солевляне САЛИТСА ТСАКИТСА ОСАЛИТСА ИССАИИ ИССАИИ ИССАИИ ИССАИИ ТСАКИТСА СИНАСИИИ ТСАКИТСА СИНАСИИИ ТСАКИТСА
	t-221 t-222 t-222 t-222 t-221 t-216 c-212 t-216 c-202 t-208 t	Produminant variant RCAYOGAATOGA CCATOGAATOGA CCATOGAATOGA CCATOGAATAGA CCATOGAATAGA CCATOGAATAGA CCATOGAATAGA CCATOGAATAGA CCATOGAATAGA CCATOGAATAGA CCATOGAATAGA COATOGAA C	Reported TFBS	V8 BF F 20 0 80 4 20 5 100 5 100 8 100 8 10	niert froque 2 8 10 7 0 10 7 0 3 70 1 0 0 5 7 10 0 0 55 7 0 10 10 0 10 10 15 6 15 6 15 6 20 3 15 6 20 3 30 90 1 8	enny in ca 3 C 75 6 12 13 1 1 10 13 1 1 10 13 1 1 1 10 13 1 1 1 11 13 2 1 1 12 1 1 2 1 1 15 3 2	ach HIV-1 10 67 10 80 10 10 80 10 87 10 10 10 10 10 10 10 10 10 10	abudied s AG AE 67 40 22 20 40 22 20 22 20 22 22 60 22 22 50 22 22 50 22 22 50 22 22 70 20 22 20 20 22 20 20 22 20 20 20 20 20	Irain (56) <u>OTA1</u> 90 90 90 90 90 90 90 90 90 90	Peterial TFBS DarGATA AP-1/ATF/CREB AP-1/ATF/CREB AP-1/ATF/CREB C/EBP GATA E8 LEP-1/1/CF AP-1/ATF/CREB AP-1/ATF/CREB	Concensus MGGAW/ WGATDR TGAKTCA TGAKTCA MTINCHMA WGATAR WGGATAR MGGAAN' OWAACSWW TGAKTCA	D	Postor relative to HXB at 1757 to 166 to 150 to 150	Precentherit versient Precentherit versient Precentherit versient Precentherit versient Precentherit versient Precentherit versient Precentherit versient Precentherit versient Precenterit ve	Reported TFBS CYESI? USF-1 USF-1 RBE II RBE III RBE IIIAP-1 CYESIP	Va BF F B0 6 20 2 100 3 100 3 100 3 100 3 100 3 20 2 100 100 100 3 200 2 100 100 100 3 201 20 1000 3 200 20 1000 3 200 2 1000 3 200 2 1000 3 200 2 1000 3 200 3 200 3 200 3 200 3 200 3 200 3 200 3 200 3 200 3	2 B inianal freese 2 B 2 B 2 B 2 B 2 B 2 B 2 B 2 B	U U D (D (D (D (D (D (D (D (100 20 30 10 30 10 30 10 10 20 100 7 11 8 40 3	in esch 2 A1 20 3 0 20 30 30 10 5 10 5 10 5 10 5 10 5 10 5 10 5 10 5 10 5 10 5 10 5 10 5 10 5 10 5 10 10 10 10 10 10 10 10 10 10	HIV-1 sku G AG 33 33 67 33 44 33 67 33 44 33 67 33 40 33 100 33 11 100 33 67 22 33 31 100 33 11 100 33 67 41 100 89 11 72 100 89 100 100 100 100 100 100 100 100 100 10	a cied shr 3 AE 3 AE 4 100 5 100 5 5 5 5 5 5 5 5 5 5 5 5 5	atin (%) 01A1 40 40 20 80 103 103 103 103 80 20 103	Potential TFBS AP-1/ATF/CREB E-box Ete Ete SATA LEF-/TCF AP-1/ATF/CREB LEF-/TCF TATAA AP-1	Солеолии Саналта ТЗАКТСА ОААМТВ МОДАУ/ ЧИСАТИЯ СУАСТИЯ ТЗАКТСА СУАСТСТ АСУ/8СТСА

Fig 1. Variability in the U3 modulatory region of diverse HIV-1 subtypes and CRFs. N = any base; W = A or T; R = A or G; Y = C or T; K = G or T; M = A or C; S = G or C; D = A, G or T; H = A, C or T; B = C, G or T.

https://doi.org/10.1371/journal.pone.0195661.g001

with a fairly high variability in LTRs from clades B and A as well as CRF02_AG specimens, but with some specific patterns in the other strains analyzed. The HXB2 sequence GCCAGAGAA GTTAG was mutated to <u>CCCAAGGGAAG</u>TAG in clade C, to <u>T(G/C)CAAAGGAGG(C/T)</u> AG in clade D, and to <u>TCCAAGAGAAG</u>TAG in CRF22_01A1 isolates. These variants probably contain specific TFBS, as observed with the clade D included motif <u>AAGGAG</u> that matches a recognition site for Ets-2 [<u>62</u>].

In the subsequent sequence, motifs such as (G/A) AAGGC (nt -283 to -277), fitting the canonical motif for GABP factors [63], was observed in all F2 and CRF12_BF as well as in A1 (70%) and B (25%). The AACAAAG motif (nt -274 to -268) conformed to the LEF-1/TCF consensus [64], was conserved only in LTRs from CRF01_AE (100%) and CRF22_01A1 (40%). In 60% of CRF22_01A1 and in 33% of CRF02_AG isolates, the LEF-1/TCF motif was changed to a homologue of the polyadenylation signal motif AATAAA (Fig 1B). The overlapping consensus (A/C) AGGAG (nt -270 to -265) which resembles a binding site for NFAT and Ets-2 factors [62, 65–67], was fairly well conserved across almost all our analyzed sequences except for majority of sequences from clades A1 and G isolates (Fig 1B). Overlapping the NFAT footprint [68], the consensus motif CAACTG (nt -260 to -255) perfect fit to the E-box /c-Myb consensus [69, 70], was mainly found in non-A1, non-G and non-CRFs specimens. In 60% of the sequence assigned to be CRF01_AE, we found the variant CAGCTG similar to the recognition site for the AP4 factor [71]. On the other hand, the c-Myb variant (C/T) AACAG, predominant in sequences from CRF02_AG (100%), G (67%) and A1 (60%) specimens, was also found in clades C (38%) and B (20%).

Although it displayed one nucleotide mismatch with the (C/A) TTNCNN (C/A) A consensus described as the best fit for the binding of the C/EBP family of transcription factors [72–74], the sequence CTTGTTACA in HXB2 (nt -254 to -246) was reported as a C/EBPβ target (US3). In our study, the US3 consensus (CTTNTNNCA) was found in at least 60% of clades B, D and G assigned LTRs, and the variant TTTNCNNCA mainly found in clade C LTR was also shown to be able to bind C/EBP proteins [74-76]. In most of the other studied strains, variants of the US3 generally included more than one nucleotide mismatches with the C/EBP consensus motif (Fig 1C). The adjoining sequence (nt -244 to -234) seemed to include various overlapping TFBS with some strain specific motifs (Fig 1C). Thus, at the relative location of the GATA-like motif CCTAT (G/A) (nt -244 to -239) that was found in non-clade G and non-CRFs isolates, the CCCATG variant was shown in LTRs subtyped as CRF01_AE only, while CCCATC was found in clade G and CRF02_AG only. Subsequently, we observed a CREB/ATF/AP-1-like binding site in several studied isolates, except for clade G and CRF02_AG. In these latter specimens, we found an E-box with the sequence motif CATCTG. Majority of sequences subtyped as F2 (60%), CRF12_BF (80%) as well as some clade B (25%) displayed a TATAA motif within nucleotides spanning this location (Fig 1C). Further downstream, the nucleotide sequence includes a potential Ets/GATA- like element (nt- 232 to -222) and other various potential TFBS such as TGACCC (A/G) in clade B or TGA (G/T) GA (A/G) in clade A1 which resemble were a CREB/ATF/AP-1 target (nt -221 to -212).

The sequence GAGAGAGAGTG in HXB2 (nt -216 to -203), reported to encompass a second NFAT footprint in this segment of the U3 region [65, 68], was mainly conserved in clade D isolates. In our dataset, this NFAT footprint displayed strain specific mutations generating motif that might potentially be recognized by other transcription factor (Fig 1C). For example, the GAGAAGAGT (G/A) consensus was mainly found in clade B LTRs (45%) include C/EBPlike motif, while the GA (C/T) A (G/A) A (G/A) ARGTG variant predominant in CRF02_AG isolates includes a GATA-like motif. The highest variability of this NFAT footprint was found in clade A1 isolates in which we noticed that 50% of the variants contain a GAAACAT motif (nt -208to -202) closely related to the LEF-1/TCF recognition site [64]. The adjacent motif TAGAGTGGA (nt -201 to -193) displayed some specific motifs in most of the HIV-1 non-B strains with some the variant containing an AP-1/ATF/CREB-like motif (Fig 1C). The following nucleotide sequence (nt -188 to -182) was characterized by low intra-clade variability and majority of the variants found contain a motif homologous to the AP-1/ATF/CREB family of proteins target (Fig 1C).

U3 modulatory spanning nucleotides -176 to -106. Several consensus binding sites for transcription factors such as C /EBP, USF-1, Ets, LEF-1 and RBF-2 have been described within the nucleotide sequence from position -176 to the end of the modulatory segment [41, 73, 77–79]. In this part of the U3 region, the US2 and US1 targets for C/EBP proteins were reported within the HXB2 sequence AGCATTTCATCA (nt -176 to -165) and AGCTTGCTACA (nt -116 to -106) respectively [80]. In our study, the consensus motif (A/G) GC (A/C) TTNC (A/G) NCA found in clades B (95%) and A1 (20%) was the only US2 variant conformed to the canonical binding site for C/EBP proteins. Non-canonical distinct variants were observed among non-B strains and some of them displayed up to three nucleotides mismatches with the consensus (Fig 1D). The consensus (A/G) GCATTNANNCA was found in about 40% of A1 and 45% of CRF02 AG LTRs, while NGCAC (A/G) CAGACA predominant in sequences from clade C (88%) was also found in LTRs from CRF22_01A1 specimens (40%). In our study, the sequence CGCAGACA included in this latter US2 variant was no longer strictly associated to clade C isolates as previously reported [39, 81], as it was also found in the emerging CRF22_01A1 recombinant. On the other hand, we observed that the US2 consensus AGCA (C/A) GAAAACA was only displayed by CRF01_AE specimens. In all the clade D and in some CRF02_AG LTRs, the US2 variant (A/G) GCATTTGA (A/G) CA includes the E-box motif CATTTG similar to what we reported earlier in clade A1 viruses (nt- 330 to -325); whereas the AGC (C/A) (C/A) TGAGACA consensus in CRF12_BF (80%) and F2 (60%) LTRs, contains a TGAGACA motif closely related to an AP-1/CREB/ATF target.

Overlapping with the US2 target, the nucleotide sequence CACATGGC in HXB₂ (nt -166 to -159) contains the well described E-box consensus motif CAC (G/A) TG recognized by bHLHzip proteins such as USF-1 or TF3 [75, 82, 83]. This USF-1 consensus was mainly found in clade B LTRs (70%), in some CRF22_01A1 (20%), and in few clade C isolates (13%). At this position, additional E-boxes with non-USF-1 consensus motifs were found in clade C (50%), while none of the variants found in the other studied strains match the CANNTG consensus (Fig 1D). According to a previous study, these non-CANNTG variant do not interact with a recombinant USF-1 factor in vitro [84]. We noticed that the A5T mutation of the USF-1 variant CACAAGGC displayed by the clade D and few clade B LTRs, generates an Ets-like core motif (AAGGC). The sequence downstream of the USF-1 motif (nt -153 to -146), includes a potential GATA motif with a high variability across our dataset (Fig 1D). In this sequence, we also observed that the consensus AGAAA (C/T) AT predominant in F2 and CRF12_BF LTRs (Fig 1D), contains a potential recognition site for TCF/LEF family of proteins [64].

Contiguously, the consensus motif (C/T) ATCCGGA (nt -148 to -141) binding site for RBF-1/Ets-1 was found to be very well conserved across all our studied HIV-1 strains except for CRF01_AE isolates mainly in which it was changed to a C (<u>G</u>/A) TCC (<u>T/A</u>) GA variant as previously described [<u>14</u>, 40, 41]. Here, the RBF-1/Ets-1 target overlaps two major consensus motifs CCG (G/C) AGT and CC (<u>T/A</u>) GAGT (mainly CRF01_AE) in 79% and 14% of the analyzed LTRs respectively (Fig 1D). These two consensuses contain a motif homologous to the recognition site the ATF/CREB/AP-1 family of transcription factors. The canonical consensus for LEF-1/TCF factors commonly reported in proximity of the Ets-1 target [<u>82</u>], was found in about 60% of the non-B, non-G and non-CRF01_AE specimens in our study. For this TFBS, a TATAA (A/G) (A/G) variant which includes a TATAA motif was predominant in G (67%)

and CRF01_AE (60%) isolates. Nonetheless, this TATAA motif has been shown to be non-functional in CRF01_AE isolates [41]. The highest variability was observed in clade B LTRs where only 25% of the TCF/LEF variants matched the canonical motif. Adjacent to the binding site for TCF/LEF, an insert of 7 nucleotides with the consensus motif ACTGAGA was specifically found in F2 and CRF 12_BF sequence. In this study, we noticed that this insert reported as a partial RBE site motif [41], was closely related to the AP-1- like element involved in the expression of the tumor suppressor protein p53 [85].

Further downstream, the ACTGCTGA motif of the RBEIII site (nt -129 to -122) targeted by the RBF-2 complex [22, 77], was particularly well conserved (93%) across HIV-1 clades and CRFs in our study. This RBE III intersects an AP1-like element (nt -124 to -118) that was conserved in only 25% of the clade B LTRs. Besides the most frequent variant TGA CACA predominant in sequences from non-B, D, G and non-CRF01_AE isolates, the AP-1-like sequence displayed some strains distinctive motifs (Fig 1D). It was followed by the MFNLP which in accordance with previous reports [21, 22], was displayed by about 33% of the LTRs in our study. Commonly observed in LTRs from CRF22_01A1 specimens as well as in LTRs subtyped as F2, CRF12_BF (80%) and CRF02_AG (67%), this insert was less frequent (< 40%) in clades A1, G, C and D. It was scarcely found in LTRs subtyped as B, and was totally absent in the LTRs from CRF01_AE isolates. The MFNLP includes a duplicate of the RBEIII and/or the AP-1-like motif along with a GATA-like motif in the LTRs subtyped as CRF02 AG, CRF12 BF and F2 or a C/EBP-like motif in LTRs from clade D isolates. At the end of the modulatory segment, the US1 consensus A(A/G)(C/A/T)TTTCTACAfound in clades B (70%) and D (80%) LTRs, was the only in our dataset to be conformed to a reported binding site for C/EBP proteins. In all the other analyzed 5'LTR sequences, the following variants were found: (A/G) AGTT (G/A) CTGAC in A1, G, and CRF02_AG, AAGATTCTAA (G/A) in F2 and CRF12_BF, while AAGTTTCTAAC which overlaps a TCF/LEF-like motif (CTA ACTA) was found in CRF01 AE specimens (Fig 1D). In our study, there was no US1 variant in sequences from clade C isolates as previously reported [76], neither in LTRs from CRF22_01A1 specimens.

U3 enhancer spanning nucleotides -104 to -80. The two canonical sequences GGGA CTTTCC for the binding of NF-κB factor in the enhancer segment of the U3 region were very well conserved. Nevertheless, with an overall percentage of similarity of 85%, NF-κB2 (nt -104 to -95) was slightly less conserved than NF-κB1 (nt -90 to -81) which showed a nucleotide similarity of about 91% with HXB2. Besides the consensus A (G/A) GACTTCC specifically found in CRF01_AE specimens, we observed within the NF-κB2 site some point mutations such as C9A in 20% of CRF02_AG, T6C in 40% of CRF12_BF LTRs and C10T in 40% of the LTRs from CRF22_01A1 isolates (Fig 2). The C10T mutation was also the most frequent NF-κB1variant and was observed only in CRF12_BF (80%) and F2 (40%) LTRs. This C10T variant found was shown to have no impact on the affinity and the functionality of the NF-κB factors [86]. In our study, an additional binding site for NF-kB with the consensus motif GGG<u>G</u>CGTTCC was found in majority of clade C specimens as previously reported [15, 41] and with the canonical NF-kB motif in one-third of CRF02_AG LTRs.

The NF- κ B2/ NF- κ B1 interspace motif GCTG (nt -94 to -91) was overall well conserved. This spacer is embedded within the AP-2 recognition sequence CCGCTGGGGA [87, 88], and overlaps motif targeted by GABP factors. Indeed, it has been shown that GABP binds with high affinity to the variant CTTCCG of overlapping the NF- κ B2 site of CRF01_AE viruses only; and with the low affinity to the variant CTTTCCG present in most of the other studied strains [15]. In our dataset, we observed three major variants of the interspace motif (Fig 2): 1) ACTG scattered among several specimens and predominant in CRF22_01A1, 2) (G/A) CCT found in clade G, and 3) AAAG found in CRF12_BF and F2 LTRs only. This latter variant, by overlapping NF- κ B2, led to a CTTTCCAAA motif conformed to the canonical consensus for the

Pertoninant variant Preparity	Position				Varia	ant fre	quen	cy in							
GGGACTTICC NF-H22 60 100 <t< th=""><th>relative to HXB2</th><th>Predominant variant</th><th>Reported TFBS</th><th>BF</th><th>F2</th><th>в</th><th>D</th><th>С</th><th>At</th><th>G</th><th>AG</th><th>AE</th><th>01A1</th><th>Potential TFBS</th><th>Consensus</th></t<>	relative to HXB2	Predominant variant	Reported TFBS	BF	F2	в	D	С	At	G	AG	AE	01A1	Potential TFBS	Consensus
n1-16 GGGAGUTTOC 40 05480CTTOC 000 500	-	GGGACTITCC	NF-kB2	60	100	100	100	100	100	100	67		60		
no.m. GGAACTTCC 040 U U 010 CGGAAR ARGACTTCC 0APP 20 20 80	nt -104	GGGACTTTCT									-11		40		
MARK GARDACTITAC GARDACTITAC GARDACTICC GARDACTICC GARDACTICC GARDACTICC GARDACTICC CGGAAR 11:34 AAAG 20 5 100 100 20 5 11:34 AAAG 20 5 100 100 20 5 11:30 AAAG 20 5 100 <td>to -95</td> <td>GGGACCTTCC</td> <td></td> <td>40</td> <td></td>	to -95	GGGACCTTCC		40											
MRRACTTCC GABP U 100 33 00 CGGAAR 01-34 ACTG 20 20 20 80 70 33 00 1-34 ACTG 20 20 80 70 33 00 10-31 GRAGATTTCC NF-48 20 60 100 <td>10-95</td> <td>GGGACTITAC</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>22</td> <td></td> <td></td> <td></td> <td></td>	10-95	GGGACTITAC									22				
GCTG 40 96 90 87 70 55 100 20 H1-34 AAAG 20 20 10 30 60 100		ARGACTTCC	GABP									100			CGGAAR
n1.44 ACTG 20 20 20 10 33 60 No.43 RCCT I I 10 100 <td></td> <td>GCTG</td> <td></td> <td></td> <td>40</td> <td>95</td> <td>80</td> <td>88</td> <td>70</td> <td></td> <td>56</td> <td>100</td> <td>20</td> <td></td> <td></td>		GCTG			40	95	80	88	70		56	100	20		
International AAAG AAAG Point Point <td>et al</td> <td>ACTG</td> <td></td> <td>20</td> <td>20</td> <td>5</td> <td>20</td> <td></td> <td>10</td> <td></td> <td>33</td> <td></td> <td>60</td> <td></td> <td></td>	et al	ACTG		20	20	5	20		10		33		60		
Normal RCCT 13 100 ACCGG	to -01	AAAG		80	40										
ACCG NF-MB Column Colu		ROCT						13		100					
n1-90 GGGACTTTOC NF-H31 20 60 100 100 100 100 100 100 100 100 100		ACCG											20		
08-86 GGGACTITIC NF.48 F GGGACTITAC NF.48 75 NF.48 NF.48 GGGRN/YCC GAGGCTTGC SP 10 20 23 NF.48 GGGRN/YCC GAGGCTGGC SP 10 20 25 30 40 40 GAGGTTGGC SP 10 20 10 10 100 100 400 GAGGGGGGGC 20 25 0 10 10 30 40 10	nt - 90	GGGACTITCC	NF-kB1	20	60	100	80	100	100	100	100	100	100		
GGGGCGTTCC NF-HB3 VIET VIET NF-HB GGGRNY VCC GGAGCTTGCC SP 20 10 100 NF-HB GGGRNY VCC GAGGTGTGCC SP 0 10 100 100 100 GAGGTGTGCC SP 0 100 100 100 100 GAGGGCGTGCC B0 60 100	to -81	GGGACTITCT		60	40										
NE-LBNE-LBGGAGCT GCCSPECAL SPECIAL		GGGGCGTTCC	NF-kB3					75							
GGACTITICC SPIN 20 SPIN 20 NF-AB GGGRNYYYCC GAGGTGTGGGC SPIN 20 10 100 <td>insert</td> <td>KGGGCGTKCC</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>25</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	insert	KGGGCGTKCC						25							
AGGCCTTGGC Sp III 20 10 8 40 AGGCGTGGC 50 10 10 10 10 10 AGGCGCGCC 25 67 5 5 50 GAGGGCGCGC 20 40 10 23 5 50 GAGGGGGGC 20 40 10 23 5 50 GAGGGGGGC 20 40 10 23 5 50 TGGGCGGGAC 20 40 10 23 5 50 TGGGCGGGAC 20 40 10 23 5 50 TGGGCGGGAC 20 40 5 50 5 50 TGGGCGGGAC 20 60 60 50 50 5 50 TGGGCGGGAC 20 50 60 50 50 5 50 50 TGGGCGGGAC 20 50 60 50 50 50 50 50 TGGGCGGGAC 20 60 80 25 50 51 50 50 TGGGCGGGATGGT 20 60 10 10 50 10 50 TGGGAGGGC 20 40 <		GGGACTTTCC									33			NF-kB	GGGRNYYYCC
GAGGTETEGGT J J S B0 100 100 nt-77 AAGGCGCGCGC B0 6 50 67 5		GAGGCGTGGC	Sp III			20									
GAGGCTGTGGC 30 10 100 n1-71 AGGCGTAMC 50 50 50 50 0-80 GAGGCGGGC 25 57 50 50 GAGGCGGGC 20 25 57 50 50 GAGGCGGGC 20 40 10 13 30 50 TGGGCGGGAC 20 5 5 50 50 50 TGGGCGGGAC 20 5 5 50 50 50 TGGGCGGGAC 20 5 5 50		GAGGTGTGGT						25	80		89		40		
AGGCCTAARC 80 n1-77 AGGCCKGCC 80 60 GAGGCCKGCC 25 67 5 GAGGCCTGAP 5 75 5 GAGGCCGTGAP 5 10 33 5 AGGCCGTAC 20 40 90 30 88 10 5 AGGCCGCGCAC Sp II 20 40 90 30 88 10 5 TGGGCGGGAC Sp II 20 40 90 30 88 10 5 TGGGCGGAC Sp II 20 5 80 100 5 6ABP CGGAAC TGGGCGGAC 20 5 80 100 5 6ABP CGGAAC TGGGCGGGAC 20 40 25 100 100 5 6ABP CGGAAC TGGGAGGGAC 50 10 13 90 100 67 80 100 5 60 100 100 100		GAGGTGTGGC				30			10			100			
n1-77 AAGGCCKGCC 60 60 60		GAGGCGTAMC					60								
80-68 GAGGCCGCGC 25 67 GAGGCCGTGAT 75 75 GAGGNGCGCT 10 33 AGRGGNGCGCT 20 40 10 10 33 TGGCGCGGAC Sp II 90 30 88 10 10 TGGCGCGGAC Sp II 90 30 88 10 10 TGGCGCGGAC Sp II 90 30 88 10 10 TGGCGCGGAC Sp II 90 80 80 10 10 TGGCGCGGAC 80 60 10 10 10 10 166 GGGGAGGC 80 60 12 33 11 10 TGGCAGGCGC 10 12 33 11 10 10 10 166 GGGGAATGGC 50 10 10 13 90 100 10 10 170GAADTGGC 15 16 12 33 11 10 10 10 10 10 16 12 13 90	nt -77	AAGGCGKGCC		80	60										
GRGGRGTGGT GAGOGOGTGAY ID 10 10 33 AGGOGTGAP GAGOGGGAC 20 40 5 80 100 TGGGCGGAC Sp II 5 80 100 100 TGGCCGGAC Sp II 5 80 100 100 TGGCCGGAC Sp II 5 80 100 100 TGGCCGGAC 80 60 5 80 100 100 CGAGGCGCGAC 80 60 5 80 100	to -68	GAGGCGCGGC				25				67					
GAGGCCTGAY 10 10 33 AGGGGGGAC SpII 90 30 88 10 50 TGGGCGGAAC SpII 90 30 88 10 50 TGGGCGGAAC SpII 50 88 10 50 100 TGGGCGGAAC 20 5 6 100 50 60 GGGAAGGGGAC 20 5 6 50 60 60 GGGAAGGGAC 20 5 6 50 6 7000 RGGAMGGAGC 20 5 6 7000 6 7000 7000 RGGAAGGGC 7000 40 22 20 20 5 GGGAAGGGC 7000 70 7000 7		GRGGRGTGGT						75							
GRG2NWG2CGGAAC 20 40 50 80 88 10 TGG3CGGGAAC Spl 90		GAGGCGTGAY				10			10	33					
AGGGCGTMCC 20 46 TGGGCGGGAC SpII 90 88 10 100 TGGGCGGACC SpII 90 80 90 100 GGGCACGGCGC SpII 20 5 5 5 GGGACGGACC 80 60 7 80 100 5 TGGGACTGGC SpII 20 60 7 80 100 5 TGGGACTGGC SpII 20 6 7 80 100 5 5 5 TGGGACTGGC SpII 80 100 13 90 100 6 5 20 5 50 5 5 5 10 5 5 10 5 5 100 10 <		GAGGWGGGGT											60		
TGGGCGGGAC Sp II 90 30 88 10 TGGGCGGGACG 20 5 80 100 100 1-86 GGGCGCGACC 20 5 80 5 60 GABP CGGAAC 10-57 GACGCGCGCACC 20 5 80 5 60 GABP CGGAAC RGGGAGGGC 20 5 80 12 33 11 5 GGGAAC 50 60 12 33 11 5 5 5 5 60 100 <td></td> <td>AGGGCGTWCC</td> <td></td> <td>20</td> <td>40</td> <td></td>		AGGGCGTWCC		20	40										
TrogGCGGAGAGT 100 16-67 GAGGCGCGGAAC 80 60 5 80 5 60 GAGGCGCGAAC 80 60 5 80 100 GAGGCGCGAAC 80 60 5 80 100 GAGGCGCGAAC 80 60 7 89 60 100 7 80 100 7 </td <td></td> <td>TGGGCGGGAC</td> <td>Sp II</td> <td></td> <td></td> <td>90</td> <td>30</td> <td>88</td> <td>10</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>		TGGGCGGGAC	Sp II			90	30	88	10						
TGGAAGAGT 100 ML-86 GGGGAGGAGC 20 5 80 5 60 ML-86 GGGGAGGAGC 80 5 80 5 60 GAGGCC GGAPP CGGAAC RGGGMGGAGT 100 <		TGGGCGGAGT	- F						90				100		
nt-86 GGGDCGCGGAC 20 5 60 60 50 60 50 60 60 60 60 60 60 60 60 60 60 60 60 60 60 60 60 60 60 60 70 <td></td> <td>TGGGAGGAGT</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>100</td> <td></td> <td></td> <td></td> <td></td>		TGGGAGGAGT									100				
be-57 GAGGGCGCACC B0 60 U U GAGAGCCAC GABP CGGAAC RGGRAGGGRC - - - 100 - 100 -<	nt - 66	GGGGCGGGAC		20		5	60								
RGGMGAGGRC 100 RGGAGGGRC 100 RGGAGGGRC 100 GGGAGGGRC Solution of the second o	to -57	GAGGGCGGGAC		80	60									GABP	CGGAAR
TGGGAGGGRC IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII		RGGGMGGAGT										100			
RGGQAGGGGC 40 50 100 n1-55 GGGAATGGC Sp1 20 60 80 20 25 90 67 38 80 100 n1-56 GGGAATGGC Sp1 20 60 25 20		TGGGAGGGRC								100					
GGGGAGTGGC TGGAATGGC Sp I 20 60 80 20 25 90 87 89 80 100 ri-65 GGGAGTGGC TGGAATGGC 80 12 33 11		RGGGAGGGRC			40										
n1-55 GGGAGTGGC 10 23 31 33 11 10-48 GGGAGTGGT 80 40 25 20 20 TGGGAGTGGC 10 20 20 20 AGGAGTGGC 10 3 90 100 67 80 100 GCTAACCCT 20 40 100 13 90 100 67 80 100 GCTAACCCT 20 40 100 13 90 100 67 80 100 GCTAACCCT 20 40 10 13 90 100 67 80 100 GCTAACCCT 20 40 10 13 90 100 67 80 100 GCAACCT 15 10 10 10 10 10 10 10 GCAGCCT 20 5 100 10 10 10 10 10 GCAGCCT 20 100 10 100 100 10 10 10 GCAGCCT 20 100 100 100 100 10 10 10 10-33 20 100 10 10 10		GGGGAGTGGC	Sol	20	60	80	20	25	90	67	89	60	100		
n1-36 b -48 b -48 b -48 b -48 corport GGGAGTGGT TOGGADTGGT B0 46 25 20 AGGGAGTGGT 10 20 GCTAACCCT 85 20 GTCAACCCT 80 40 30 100 63 31 60 100 32 5 10 33 5 10 34 5 10 35 10 5 36 60 100 100 36 60 100 100 36 60 100 100 100 36 60 100 100 100 100 37 7 25 33 20 37 7 100 100 100 100 38 20 7 100 100 100 38 20 100 100 100 100 39 80 100 100 100 100 10 100 100 100 100 </td <td>0.000</td> <td>TEGGAGTEGC</td> <td></td> <td></td> <td></td> <td></td> <td>80</td> <td>13</td> <td></td> <td>33</td> <td>11</td> <td></td> <td></td> <td></td> <td></td>	0.000	TEGGAGTEGC					80	13		33	11				
10-48 TGGQAQTGGT 38 AGGGAGTGCC 10 20 AGGGAGTGCC GCTAACCCT 20 40 100 13 90 100 67 80 100 GCTAACCCT 20 40 100 13 90 100 67 80 100 GTAACCCT 20 40 10 13 90 100 67 80 100 67 80 100 67 80 100 67 80 100 67 80 100 67 80 100 67 80 100 67 80 100 67 80 100 67 80 100 67 80 100 67 80 100 67 60 67 100 100 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 <td< td=""><td>nt-55</td><td>GGGGAGTGGT</td><td></td><td>60</td><td>40</td><td></td><td></td><td>25</td><td></td><td></td><td></td><td>20</td><td></td><td></td><td></td></td<>	nt-55	GGGGAGTGGT		60	40			25				20			
AGGGAGTGGC 10 20 GCTAAGCCT 20 40 10 13 90 100 67 80 100 100 67 80 100 67 80 100 67 80 100 67 80 100 67 80 100 67 80 100 67 60 70	to -46	TEGGAGTEGT						38							
GGAAGCCT 20 40 100 100 100 Ebax/c-myb YAACKG n1-47 GTTAACCC 80 40 100 100 100 Ebax/c-myb YAACKG 0-38 GGTAGCCT 15 10 100 Ebax/c-myb YAACKG 0-38 GGTAGCCT 20 15 10 100		AGGGAGTGGC				10						20			
GCTAACCCT 20 40 100 13 90 100 F 80 100 nt-47 GTTAACCC 00 40 10 13 90 100 Ebmxle-myb YAACKG 10-38 GCGAACCYT 15 10 Ebmxle-myb YAACKG GCGACGCT 25 33 Ebmxle-myb YAACKG GCTAGCCT 26 33 Ebmxle-myb YAACKG GCTAGCCCT 26 33 Ebmxle-myb YAACKG GCTAGCCCT 26 100		GCGAGCCCT				85									
dTCAACCCT 83 20 Ebsole-myb YAACKG n1-47 GTTAACCC 80 40 Ebsole-myb YAACKG 30 GCAACCTT 15 10 Ebsole-myb YAACKG 30 GCAACCT 25 33 20 Ebsole-myb YAACKG 130 GCTAGCCT 25 33 20 100<		GCTAACCCT		20	40		100	13	90	100	67	80	100		
nt-47 GTTAACCC 60 46 Ebaxle-myb YAACKG 0-39 GCGAGCCCT 15 10 Ebaxle-myb YAACKG GCTAGCCCT 25 23 -<		GTCAACCCT						63				20		Ebox/c-myb	YAACKG
bo-30 GOGAACCYT 15 10 GCTAGCCCT 25 GCTIGCCCT 20 n1-36 CAGAGC 120 10-37 CAGAAG Ebox 100 100 95 100 100 100 89 40 20 CATATAA TATAbax 100 100 100 100 100 100 89 40 20 CATATAA TATAbax 100 100 100 100 100 100 89 40 20 CATATAA TATAbax 100 100 100 100 100 100 89 40 20 TATATAA 14 bax 100 100 100 100 100 100 56 TATATAA 14 bax 100 100 100 100 56 10-10 CAGCCG 20 20 100 44 100 100 100 100 CAGCCG 20 20 100 44 100 100 100 100 CATTIGCCT 50 11 CTTITGCCT 55 70 11 CTTITGCCT 25 20 43 80 CTTITGCCT 25 20 43 80 CTTITGCCT 25 20	nt - 47	GTTAACCC		80	40									Ebox/c-myb	YAACKG
GCCAGCCCT 25 GCTAGCCCT 26 GCTAGCCCT 26 GCTAGCCCT 26 GCTAGCCCT 26 130 CACATG Ebox 131 CACATG Ebox 132 CATATAA TATAbax 1430 CATATAA TATAbax 1430 CATATAA TATAbax 1432 CATATAA TATAbax 143 CACATG Ebox/AP4 143 CATATAA TATAbax 143 CATATAA TATABA 144 100 100 150 CAGCCG 20 141 TOTATA 100 141 100 100 141 100 100 141 100	to -39	GCGAACCYT				15			10					same second	
GCTAGCCCT 23 nt-30 CACATG Ebox 100 <t< td=""><td></td><td>GCCAGCCCT</td><td></td><td></td><td></td><td></td><td></td><td>25</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>		GCCAGCCCT						25							
GCTIGCOCT 20 nt-38 CACATG Ebox 100 <t< td=""><td></td><td>GCTAGCCCT</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>33</td><td></td><td></td><td></td><td></td></t<>		GCTAGCCCT									33				
nt-36 CAGATG Ebex 100 100 100 100 100 100 to 33 CAGAAG 100 100 100 100 33 nt-29 CATATAA TATA.bax 100 100 100 100 100 100 33 to 20 CATAAA TATA.bax 100 100 100 100 100 100 100 80 to 21 TATATAA TATA.bax 100 100 100 100 100 80 80 to 21 TATATAA TATA.bax 100 100 100 100 100 56 to 23 TATATAA TATA.bax 100 100 100 100 56 to 24 CAGCTG Ebox/AP-4 100 80 80 100 100 100 to 24 CAGCTG Ebox/AP-4 100 100 100 100 100 100 to 24 CAGCTG Ebox/AP-4 100 100 100 100 100 100 CTITTGCCT 56 70 11 100 100 100 100 100 to 41 CTITTGCGTT 25 20 <		GCTTGCCCT			20										
10:33 CAGAAG 100 33 nt-29 CATATAA CATATAA TATA.bux 100 <td>nt - 36</td> <td>CAGATG</td> <td>Ebox</td> <td>100</td> <td>100</td> <td>95</td> <td>100</td> <td>100</td> <td>100</td> <td></td> <td>67</td> <td>108</td> <td>100</td> <td></td> <td></td>	nt - 36	CAGATG	Ebox	100	100	95	100	100	100		67	108	100		
n1-29 CATATAA TATA bax 100	to -33	CAGAAG								100	33				
Int-29 CATAAAA 80 80 10-23 TATATAA 11 11 Int-21 CAGCTG Ebox/AP-4 100 80 100 100 56 CATTATAA 11 11 11 11 11 11 11 Int-21 CAGCTG Ebox/AP-4 100 80 100 100 56 CATTITACCT 55 70 11 100 100 100 CITITICGCTT 100 100 75 20 100 100 100 CITITICGCTT 25 20 43 80 20 20 210 25 20 25 20 20		CATATAA	TATA bax	100	100	100	108	100	100	100	89	40	20		
10:23 TATATAA 11 11 n1:21 CAGCTG Ebox/AP-4 100 80 80 100 100 56 to:16 CAGCCG 20 20 100 44 100 100 CTTTTGCCT 55 70 11 11 11 11 110 CTTTTGCCT 100 100 75 20 11 11 110 CTTTGCCTT 100 100 75 20 11 11 110 <td< td=""><td>nt - 29</td><td>CATAAAA</td><td></td><td></td><td></td><td></td><td></td><td>0.000</td><td></td><td>1.17.75</td><td></td><td>60</td><td>80</td><td></td><td></td></td<>	nt - 29	CATAAAA						0.000		1.17.75		60	80		
nl.21 CAGCTG EbowAP-4 100 60 80 100 100 100 56 to-16 CAGCCG 20 100 44 100 100 CTTITGCCT 55 70 11 100 100 78 CTTITGCCT 100 100 78 100 100 78 CTTICGCTT 25 20 430 80 20 100 20 CTTICGCTT 25 80 20 100 20 100 <t< td=""><td>to -23</td><td>TATATAA</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>11</td><td>0.0</td><td>67234</td><td></td><td></td></t<>	to -23	TATATAA									11	0.0	67234		
CASECTE CASECTE Case of the second s			Ebox/AP-4	100	80	80	100	100	100		56				
to:10 CAGECG 20 20 100 44 100 100 CTTITICCCT 55 70 11 100	nt - 21	CAGCTG			1000	200					10				
CTTITICCCT 55 70 11 CTTITICCCT 100 100 75 20 rt-15 CTTTICCCT 30 160 78 CTTTICCCTT 25 20 43 80 CTTTICCCTT 25 60 20 CTTTICCCT 25 0 43 80	to -16	CAGCCG			20	20				100	44	100	100		
CTTITCOCCT 100 75 20 nt-15 CTTITCOCTT 30 100 78 to-6 CTTITCOCTT 25 20 43 80 CTTITCCCCT 25 20 43 80 20 CTTITCCCCT 25 60 20		CTITITICCCT			0.000	55	70				11				
nt-15 CTTIRCGCTT 30 160 78 to-6 CTTIRCGCTT 25 20 43 80 CTTIGEGCTT 25 60 20 20 CTTIGEGCT 25 60 20		CITITEGECT		100	100			75	20		- 65				
nt-15 CITTICGCTT 25 20 43 80 CITTICGCGCTT 25 20 43 20 CITTICGCCTT 25 60 20 CITICICCCT 25 CITICICCCT 25	No. of Concession	CITIKCGCIT			100				30	100	78				
to-6 CTTTGCGCT 25 50 20 CTTTGCGCT 25	nt - 15	CITICOCIT						25	20			40	80		
CTITCIGCCT 25 CISTILIGCT 30	to -6	CITICOGCIT						20	20			80	20		
CISTITICCI 30		CITICISCOL				25						00	6V		
		CISTILGCCI				-	30								



https://doi.org/10.1371/journal.pone.0195661.g002

binding of C/EBP proteins ((C/A) TTNCNN (C/A) A). Furthermore, we noticed that the mutation of the AP-2 target in CRF02_AG appeared only in LTRs containing an extra NF- κ B site.

U3 promoter spanning nucleotides -78 to -1. Three sites named Sp III, Sp II and Sp I for the binding of Sp1 and related factors have been described along with the TATA box in this segment of the U3 region. In our study, the Sp binding sites displayed a high degree of intraclade conservation and some inter-clade variability. Of the three, the sequence of the Sp III proximal to NF-κB1 displayed the highest variability (Fig 2). Thus, the HXB₂ Sp III consensus motif GAGGCGTGGC (nt -77 to -68) was found in 20% of clade B LTR only, while specific variants, such as GAGGCGT<u>A</u> (<u>A/C</u>) C was found in clade D isolates, and GAAGGCG (T/G) GCC which include a GABP-like motif (GAAGGC) was found in F2 (60%) and CRF12_BF (80%) LTRs (Fig 2). For this TFBS, the variant GAGGTGTGGT (5T10T) predominant in LTRs from clades A1 and CRF02_AG viruses (≥ 80%) was also found in sequences from CRF22_01A1 (50%) and clade C (22%), and GAGGTGTGGC (5T) seen in all the LTRs from CRF01_AE was shared with clade B LTRs as previously observed [89, 90]. Overall, variability of the Sp III in our study was concordant with previous studies reporting a high conservation of the central Gs (GGCG) and the frequent C5T/A mutation [90, 91]. The HXB₂ Sp II motif TGGGCGGGAC (nt -66 to -57), mainly conserved in clades B and C sequences was mutated to TGGGCGG<u>AGT</u> in LTRs from clade A1 (90%) and CRF22_01A1 (100%) viruses. In our study, Sp II strain specific variants such as TGGGAGGG (G/A) C, TGGG<u>AGGAGT</u>, and <u>(G/A)</u> GGG (<u>A/C</u>) G<u>GAGT</u> were respectively observed in LTRs from clade G, CRF02_AG and CRF01_AE specimens (Fig 2). These three consensus were not conformed to the GC box consensus (GGGCGGPuPuPy) reported as recognition site for Sp1 family of proteins [92]. Sp I proximal to the TATA box (nt -55 to -46), was the most conserved of the three targets for Sp proteins, with the consensus motif (G/T) GGGAGTGG (C/T) found in more than 90% of the sequences analyzed.

Overlapping with the Sp I site, the subsequent nucleotide sequence GCGAGCCCT in HXB₂ (nt -47 to -39) was conserved in clade B LTRs only (Fig 2). In our study, this sequence displayed several variations such as GTCAACCCT predominant in clade C, GTTAACCC seen only in F2 (40%) and CRF12_BF (80%) sequences, and the consensus GCTAACCCT observed in most of the other studied LTRs. We noted that these variants contained a potential E-box/c-Myb element. Further downstream, the TATA box motif (TATAA) flanked at its 3' and 5' end by an Ebox motif, was extremely well conserved in all our strains studied except for CRF01_AE and CRF22 01A1 where it was changed to TAAAA in 60% and 80% LTR sequence respectively (Fig 2A). The CAGATG motif of the 5'E-box predominant in almost all the LTRs analyzed, was mutated to CAGAAG in clade G (100%) and in CRF02_AG (33%) viruses. However, we noted that in these two HIV-1 strains, a motif similar to the 5'E-box was observed in the sequence adjacent to the US3 target located in the modulatory segment (nt -242 to -237). The 3'E-box consensus sequence CAGCTG reported as a binding site for bHLH factors such as AP-4 [71], was mainly conserved in non-G and non-CRFs specimens where the CAGCCG variant was predominant (Fig 2). Thus, unlike what was previously reported [41, 74], our study suggests that the variability of the 3'E-box motif might not be restricted to clade G and CRF01 AE isolates. The sequence between the 3'E-box and the transcriptional start site was reported to contain a target for Oct-1/Oct-2 factor [93]. In this sequence, the CTTTT (T/C) GCCT consensus (nt -15 to -6) was the major variant in non-G, non-A1 and non CRFs isolates (Fig 2), whereas CTTC TCGC (C/T) T consensus was shared by clade A1 (30%), clade G (100%) and CRF02_AG (78%) LTRs, and CTTT (G/T) CGCTT was predominant in CRF01_AE and CRF22_01A1 specimens.

Variability of the repeat (R) region

The TAR element (nt 1 to 59) fold into a hairpin structure composed of a bulge, a loop and a stem. In our study, we found that all the constitutive elements of the TAR structure were affected by singles and clustered sets of mutations across different HIV-1 strains. In general, the stem displayed the highest variability followed by the bulge (nt 23 to 25, with the TCT motif in HXB₂) and the loop (nt 30 to 35, with a CTGGGA motif in HXB₂).

In accordance with previous reports, we found a C24T change in most of the CRF02_AG and majority of clades D, F2, and G isolates [39, 40], but also in CRF12_BF LTRs. Also, we found a deletion of T25 leading to a two nucleotides bulge in clade A1 and -CRF01_AE specimens as previously observed [5, 89], and in CRF22_01A1 as well (Fig 3). Furthermore, we noted that mutations of the bulge in clade A1 (60%) and CRF01_AE (80%) isolates mainly also affect the overlapping consensus $\underline{T}GAGCC(\underline{T}/C)$ reported as a AP-1 recognition site [29]. The consensus motif of the loop was changed to a CCGGGA variant in most of the CR01_AE viruses as previously reported [89], and also in isolates CRF22_01A1 (60%), clades C (50%), and Al

Position		11010-0010-0010-0010-0000		Varia	int fre	quen	cy in								
relative to HXB2	Predominant variant	Reported TFBS	BF	F2	В	D	C	A1	G	AG	AE	01A1	Potential	TFBS	Consensus
	10T; 51A		100	100	100	100	75	90	ł	10	100	80			
-+ 51.0	10T; 51G						25	10	100	80		20			
10.010	10G; 51A									10					
w 110	11G/T; 50T/G		100	100	80	10	13	50		11		20			
of 50T	11T/A; 50A/T				5	10	8B	50	100	89	100	20			
11.001	11T; 50T				15	80						60			
	13G/T; 48T/G			40	60	70	88	60	33	33		100			
of 13T	13T; 48A		100	60	35	20									
nt 48A	13G/C: 48C/G					10	12		67	67					
	13G; 48A							10			80				
	13G; 48G							30			20				
nt 22A	22A; 40T		100	100	100	100	100	90	100	100	- Marine	20			
nt 40T	22G; 40T							10			100	80			
	TCT	Bulge	20	20	80	30	100	10							
nt 23	Π		80	80	10	70			100	80					
to 25	Π							40			20	100			
	1C							10			80				
	TA	- 222 1						40							
1000	TGAGCCY	AP-1	100	100	85	100	100	50	100	76	20	100			
nt 25	MGAGCCT				15			30		22					
to 31	CGAGUCU										80				
	AGAGICY	10000		-		-		20							
-1.70	CIGGGA	Loop	80	80	95	50	50	/0	100	100	20	40			
11:30	CCGGGA				10210	10	50	20			80	60			
10 35	CTGAGA			00	Э	40		10							
	CIGGGC	ADED St.	20	20	100	100	00	00	100	400					
-1-60	ACTOCITANG	GRED-like	20	0U	100	100	00	90	100	100	100				
10.00	ACTOCITIANAG										100	100			
(0.09	ACTOCITICAAG		00	20								100	OIEB	0	ATTRICKBING
	ATTGGTTAAG		60	40									CIEB	2	MITTICININA.
to 79	AATAAA		100	100	100	100	100	100	100	100	100	100			
nt 88	TGAGTGCY	AP-1	60	100	100	100	100	90	100	100	100	100			
10.95	TGAGCGCT		40												
10.00	TGAGTGTT							10							
	TCAAGTAGT				35	40		40	100	78			AP-WATE	/CREB	TGAKTCA
	TTAAGTAGT		20	60	35	10	13	20							
1.00	TAAAGTAGT				30	30		10			20	20			
nt 9a	CTRAGYAGT						88								
10 104	TAAAGTGGT										80	40			
	TCAAGCAGT							30		22					
	TAAGTGGT											40			
	TCAAGTGGT					20									

Fig 3. Variability in the R region of diverse HIV-1 subtypes and CRFs. N = any base; W = A or T; R = A or G; Y = C or T; K = G or T; M = A or C; S = G or C; D = A, G or T; H = A, C or T; B = C, G or T.

https://doi.org/10.1371/journal.pone.0195661.g003

(20%). Additionally, a CTGAGAG variant of the loop was observed in clade D LTRs (40%) and in few sequences subtyped as A1 (10%) and B (5%). This latter variant of the loop converted the well conserved GGGAGCTCTC sequence reported as a NF- κ B binding site [27], into a GAGAGCTCTC motif.

Mutations in the stem principally affect the A10:51T, G11:T50, T13:A48 and A22:T40 base pairing. We observed that most of the non-B strains displayed a cluster of point mutations rather than a single point mutation (Fig 3). Thus, while the single mutation A48<u>G</u> (affecting the T13:A48 pairing) was found in most of clade B LTRs, this change was associated with G11<u>T</u> clade D or with 11<u>T22G</u> in CRF22_01A1 specimens (Fig 3). In clade G and CRF02_AG specimens, we observed that the pairing T11:A50 and C13:G48 were associated with various other mutations especially in CRF02_AG viruses which displayed the highest variability for this feature of the TAR element. The T:A pairing at position 11 and 50 also found in CRF01_AE and clade C isolates, was associated with 13G and 13G48T co-variation respectively. The stem overlaps the footprint of a sequence reported to contain binding sites for cellular factors such as LBP-1 (nt -4 to +21) and CTF/NF-I [94, 95].

In the Poly-A hairpin (nt 61 to 105), the polyadenylation signal motif AATAAA (nt 74 to 79) as well as the AP-1 target (nt 88 to 95) [96, 97], were extremely well conserved in our study (Fig 3). We observed that mutation affecting the stem of the poly A hairpin lead to some strains specific patterns. Thus, the ACTGCTTAAG sequence (nt 60 to 69) which includes a CREB-like recognition site [98], was changed to ACTGCTTAAAG in CRF01_AE and to ACTGCTTGAAG in CRF22_01A1 specimens. In CRF12_BF (80%) and F2 (40%) LTRs, a C61T mutation transformed the CREB-like target ACTGCTTAA into an ATTGGCTTAA motif conformed to the

canonical sequence for the binding of C/EBP proteins (Fig.3). The highest inter-clade variability of the poly A hairpin was observed within the HXB2 sequence TCAAGTAGT (nt 96 to 104) ending the R region. Indeed, this motif conserved in less than one-third of our analyzed sequences, was changed in a strains specific consensus such as \underline{CT} (A/G) AG (\underline{C}/T) AGT in clade C LTRs and TAA (A) iGTGGT is LTRs subtyped as CRF01_AE (Fig.3). The variant TTAAAGCAGT found in CRF12_BF and F2 LTRs includes a perfect match to the consensus binding site for CREB factors [98]. This potential TFBS may compensate the conversion of the reported CREB-like site (nt 60 to 69) into a potential C/EBP-like observed earlier in these LTR sequences.

Discussion

To the best of our knowledge, this study is the first to describe the diversity of the 5'LTR U3R region from diverse HIV-1 strains including the newly emerging CRF22_01A1 HIV-1 strain. The CRF01_AE subtype assigned to sequences from CRF22_01A1 may be explained by the close relation of the two strains. Indeed, it has been reported that the gag, nef and segments of the env genes of a typical CRF22_01A1 strain, can be subtyped as CRF01_AE [47, 52]. The finding of additional contigs with different subtypes that are different from the primary genotype in some of our specimens can be explained as artefacts and/or contamination during our experiment. Alternatively, they can also result from the intra-host diversity of HIV-1 population. This highlights the fact that Next-generation sequencing, by detecting low-frequency mutation [42], might be a more reliable tool to analyze the genetic diversity of HIV-1. The intra-host heterogeneity of HIV-1 population reflects its high mutation rate and rapid turnover, but also the co-circulation of various HIV-1 strains within the same patient. Thus, the F2 contig found in a CRF02_AG specimen from Cameroon might corroborates the recent report of dual-infection with CRF02_AG and F2 in this country [99, 100]. Three out of five contigs assigned to be CRF12 BF were from clade B specimens collected in Bolivia, Spain and Japan. In these countries, a high prevalence or emerging BF recombinant circulating along with pure B have been reported [101-105].

The U3R region of the HIV-1 5'LTR is involved in the control of both basal and trans-activated transcription of the HIV-1 genome though its interaction with several cellular transcription factors. Therefore, mutations affecting its nucleotide sequence might drive potentials differences in the biological property of diverse HIV-1 strains. Here, we found that the degree of genetic variability of the U3R can vary from very low to fairly high, depending on the segment analyzed. Nevertheless, it has been demonstrated that even minor changes in this region could influence the replication rate and the disease severity of HIV-1 infection [15, 55].

In the U3 modulatory segment, besides binding sites for the RBE III and Ets-1 sites that were conserved in almost all the LTRs, majority of the TFBS were distinctive of one or few HIV-1 strains. Several motifs aligned with the TFBS reported in HXB2 displayed a sequence that varied from the reported consensus. As most of the regulatory elements that were studied belonged to clade B LTRs, functions of these TFBS described in non-B strains remains to be determined. Although the affinity for C/EBP proteins of the motifs found in non-B, C and D is yet to be investigated, it has been suggested that the binding ability and functions of C/EBP proteins can be modulated by interaction with other factors such as ATF/CREB/ AP-1 [106], E-boxes targeted proteins [107], and TATAA-binding proteins [108]. This might explain the finding of potential E-box (in CRF02_AG, clades B, C, D and G), AP-1 like (clade F2, CRF12_BF and CRF22_01A1) and Ets (CRF22_01A1 and CRF01_AE) binding sites in close proximity or embedded into the reported C/EBP binding site in our sequences analyzed. Thus, the differential repartition of these TFBS according to the HIV-1 strain might probably direct a distinctive mechanism of regulation

of HIV-1 transcription. As previously reported, we also observed a high variability of the GATA binding motif. This variability has addressed the affinity, specificity and function of GATA factors [109]. Indeed, it has been reported that the specificity of GATA binding sites along with the spanning TFBS influence the fate of GATA-3 mediated T-cell differentiation and function [110]. Thus, the combination of strains-specific GATA binding sites along with distinctive spanning mutations may potentially impact pathogenicity of HIV-1 according to the strain.

Several TFBS have been shown to be able to activate or repress the transcriptional activity of HIV-1 depending on their affinity with the targeted factor and the spanning nucleotides [35, 71, 83, 84, 111–113]. Thus, in accordance with a recent report [35], the presence of the AP-1 variant TGACACA in CRF02_AG, CRF22_01A1, CRF12_BF, as well as in clades F2, C and A1 isolates may increase their capacity to establish HIV-1 latent infection compared to other strains. This predisposition may be affected by intra-clade variability due to the duplication of this variant within the MNFLP present in some of these specimens. On the other hand, the presence of an insert motif similar to the AP-1 activator of the p53 promoter might contribute to an increase reactivation of HIV-1 in F2 and CRF12_BF, as it has been shown that p53 could reactivate HIV-1 replication from its latency in U1 cells with upregulation/activation of host transcription factors such as AP-1 (Wang; X., et al, 2017, unpublished data).

In our study, the important TATA box element as well as key TFBS such as NF-KB was fairly well conserved. In accordance with previous reports [66, 114–116], the configuration and copy number of NF-KB sites found in our study; suggest inter-strain differences of the NF-kB induced activity. Also, as suggested by our finding in CRF02_AG specimens, this activity might also vary within isolates from the same HIV-1 strain. Furthermore, the variability found in the NF- κ B inter-space required for the optimal binding of factors such as NFAT, Ets and AP-2 [87, 88, 117, 118], may also favor a distinctive modulation of the NF-KB activity in CRF01_AE, CRF22_01A1, CRF12_BF and clade F2. The 5T variant of the Sp III was shown to be able to abrogate the binding of Sp1 factors [90], and to be associated with HIV-1 disease progression [17]. As the mechanism leading to faster HIV-1 disease progression observed with CRF01 AE and some clade B isolates remain to be explored [114, 119–121], the contribution of Sp III along with other TFBS specificities should be considered. Also, it was reported that Sp1 and GABP factors cooperates to activate various genes such as CD18 which overexpression during HIV-1 infection has been related to disease severity [122]. The potential GABP binding site included in the Sp III variant of F2 and CRF12_BF LTRs, could also differentially impact the outcome of HIV-1 infection with these isolates.

In our study, the bulge residue T23, the loop as well as paired nucleotides below (A22:T40; G21:C41) and above (G26:C39 and A27:T38) shown to be important of the TAR activity were conserved in majority of the sequence analyzed. However, strain specific mutations within and outside these the features, might explained some differences in the transcriptional activity and replication rate between subtypes and CRFs [41, 66]. Changes in the Watson-Crick complementarity observed here, might also affect the TAR structure which has been shown to be important for its function, and for the activity of the downstream 5'LTR U5 region and the Gag leader sequence [123–125]. Also, it has been reported that regulation of the transcriptional activity driven by TAR-tat interaction can be enhanced through synergic action with various TFBS such the AP-1 targets with a crucial role in the replication and transcription of HIV-1 [97]. In most of the sequence analyzed in our study, the TFBS in the R region were well conserved assuming that the biological mechanism in which these TFBS are involved might be similar for various HIV-1 strains. Nevertheless, the potential loss of one of the AP-1/ATF/CREBlike sites in CRF01_AE and CRF22_01A1 specimens, and the relocation of the CREB-like in CRF12_BF and some F2 LTRs associated with the presence of a potential C/EBP site might suggest a distinctive TAR mediated activity for these isolates.

It is known that the differential activity of the LTR due to the lack or mutation of a TFBS can be compensated by various mechanisms such as the gain of additional factors, the interplay between TFBS in close proximity or the delocalization of the TFBS. On the other hand, association of potential strains distinctive mutations in the U3R may contribute to strain-specific function of the 5'LTRs [66, 116]. For CRF01_AE isolates for example, it was suggested that its 2nt bulge (TC), 22G31C and TAAAA co-mutations promote its higher transcriptional activity and replication rate compared with clade B [41, 66, 126].

In this study, we have reported distinguishing patterns within and outside the reported regulatory element in the U3R region from diverse HIV-1 strains. Due to the important role of this region in the control of the HIV-1 transcription, it is reasonable to suggest that strain specific variability greatly contributed to the effectiveness of replication and gene expression of different HIV-1 subtypes and CRFs. Intra and inter-clade variability of the U3R region should be further explored in future studies related to the replicative capacity and pathogenicity of HIV-1, as this may lead to a better understanding of phenotypic effects of HIV-1genetic diversity.

Supporting information

S1 Table. Genbank accession number of the 5'LTR sequence from diverse HIV-1 subtypes and CRFs.

```
(XLSX)
```

Acknowledgments

The authors wish to acknowledge NHLBI (IAA No A-HL-12-002), NIAID/DAIDS (IAA No AAI 17073) for funding this project, EQAPOL/Duke University (NIH/DAIDS Contract No. HHSN272201700061C) for providing genetically diverse viral isolates and New-York University for providing plasma sample used to generate additional viral isolates for this project. The authors would also want to thank Corinna Lin, Andrew Hwang, Alex Sposito, Krishnakumar Devadas and Mohan Haleyurgirisetty for their help and revision of this manuscript.

Disclaimer: The findings and conclusions in this article have not been formally disseminated by the Food and Drug Administration and should not be construed to represent any Agency determination or policy.

Author Contributions

Conceptualization: Christelle Mbondji-wonje, Indira Hewlett.

Data curation: Christelle Mbondji-wonje, Ming Dong, Indira Hewlett.

Formal analysis: Christelle Mbondji-wonje, Ming Dong, Jiangqin Zhao.

Funding acquisition: Indira Hewlett.

Investigation: Christelle Mbondji-wonje, Ming Dong, Xue Wang.

Methodology: Christelle Mbondji-wonje, Xue Wang, Jiangqin Zhao, Viswanath Ragupathy.

Project administration: Indira Hewlett.

Resources: Christelle Mbondji-wonje, Ming Dong, Ana M. Sanchez, Thomas N. Denny.

Software: Christelle Mbondji-wonje.

Supervision: Indira Hewlett.

Validation: Christelle Mbondji-wonje, Indira Hewlett.

Writing - original draft: Christelle Mbondji-wonje.

Writing – review & editing: Christelle Mbondji-wonje, Ana M. Sanchez, Thomas N. Denny, Indira Hewlett.

References

- Hemelaar J, Gouws E, Ghys PD, Osmanov S. C W-UNHI: global trends in molecular epidemiology of HIV-1 during 2000–2007. Aids. 2011; 25. <u>https://doi.org/10.1097/QAD.0b013e328342ff93</u> PMID: 21297424
- Pant Pai N, Shivkumar S, Cajas JM. Does Genetic Diversity of HIV-1 Non-B Subtypes Differentially Impact Disease Progression in Treatment-Naive HIV-1–Infected Individuals? A Systematic Review of Evidence: 1996–2010. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2012; 59(4):382–8. https://doi.org/10.1097/QAI.0b013e31824a0628 PMID: 22269800-201204010-00010.
- Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. The challenge of HIV-1 subtype diversity. N Engl J Med. 2008; 358(15):1590–602. <u>https://doi.org/10.1056/NEJMra0706737</u> PMID: <u>18403767</u>; PubMed Central PMCID: PMC2614444.
- Kanki PJ, Hamel DJ, Sankalé J-L, Hsieh C-c, Thior I, Barin F, et al. Human Immunodeficiency Virus Type 1 Subtypes Differ in Disease Progression. The Journal of infectious diseases. 1999; 179(1):68– 73. https://doi.org/10.1086/314557 PMID: <u>9841824</u>
- Rodriguez MA, Shen C, Ratner D, Paranjape RS, Kulkarni SS, Chatterjee R, et al. Genetic and functional characterization of the LTR of HIV-1 subtypes A and C circulating in India. AIDS research and human retroviruses. 2007; 23(11):1428–33. https://doi.org/10.1089/aid.2007.0152 PMID: 18184086.
- Foy HM, Kunanusont C, Kreiss JK, Phanuphak P, Raktham S, Pau CP, et al. HIV-1 subtypes and male-to-female transmission in Thailand. The Lancet. 1995; 345(8957):1078–83. <u>https://doi.org/10.1016/S0140-6736(95)90818-8</u>
- Kiwanuka N, Laeyendecker O, Quinn TC, Wawer MJ, Shepherd J, Robb M, et al. HIV-1 subtypes and differences in heterosexual HIV transmission among HIV-discordant couples in Rakai, Uganda. Aids. 2009; 23(18):2479–84. <u>https://doi.org/10.1097/QAD.0b013e328330cc08</u> PMID: <u>19841572</u>-200911270-00013.
- Baeten JM, Chohan B, Lavreys L, Chohan V, McClelland RS, Certain L, et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. The Journal of infectious diseases. 2007; 195(8):1177–80. <u>https://doi.org/10.1086/512682</u> PMID: <u>17357054</u>.
- Kiwanuka N, Robb M, Laeyendecker O, Kigozi G, Wabwire-Mangen F, Makumbi FE, et al. HIV-1 viral subtype differences in the rate of CD4+ T-cell decline among HIV seroincident antiretroviral naive persons in Rakai district, Uganda. J Acquir Immune Defic Syndr. 2010; 54(2):180–4. <u>https://doi.org/10. 1097/QAI.0b013e3181c98fc0</u> PMID: 20010433; PubMed Central PMCID: PMC2877752.
- Palm AA, Esbjornsson J, Mansson F, Biague A, da Silva ZJ, Norrgren H, et al. Cocirculation of several similar but unique HIV-1 recombinant forms in Guinea-Bissau revealed by near full-length genomic sequencing. AIDS research and human retroviruses. 2015; 31(9):938–45. <u>https://doi.org/10.1089/AID.</u> 2015.0073 PMID: 26066756.
- Beerens N, Klaver B, Berkhout B. A structured RNA motif is involved in correct placement of the tRNA (3)(Lys) primer onto the human immunodeficiency virus genome. Journal of virology. 2000; 74 (5):2227–38. PMID: <u>10666253</u>; PubMed Central PMCID: PMCPMC111704.
- Drosten C, Panning M, Drexler JF, Hänsel F, Pedroso C, Yeats J, et al. Ultrasensitive Monitoring of HIV-1 Viral Load by a Low-Cost Real-Time Reverse Transcription-PCR Assay with Internal Control for the 5' Long Terminal Repeat Domain. Clinical Chemistry. 2006; 52(7):1258–66. <u>https://doi.org/10. 1373/clinchem.2006.066498 PMID: 16627558</u>
- Pereira LA, Bentley K, Peeters A, Churchill MJ, Deacon NJ. A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter. Nucleic acids research. 2000; 28(3):663–8. PMID: 10637316; PubMed Central PMCID: PMC102541.
- 14. van Opijnen T, Jeeninga RE, Boerlijst MC, Pollakis GP, Zetterberg V, Salminen M, et al. Human immunodeficiency virus type 1 subtypes have a distinct long terminal repeat that determines the replication rate in a host-cell-specific manner. Journal of virology. 2004; 78(7):3675–83. <u>https://doi.org/10.1128/</u> JVI.78.7.3675-3683.2004 PMID: 15016888; PubMed Central PMCID: PMC371093.
- Verhoef K, Sanders RW, Fontaine V, Kitajima S, Berkhout B. Evolution of the human immunodeficiency virus type 1 long terminal repeat promoter by conversion of an NF-kappaB enhancer element

into a GABP binding site. Journal of virology. 1999; 73(2):1331–40. PMID: <u>9882338</u>; PubMed Central PMCID: PMC103957.

- Burdo TH, Nonnemacher M, Irish BP, Choi CH, Krebs FC, Gartner S, et al. High-affinity interaction between HIV-1 Vpr and specific sequences that span the C/EBP and adjacent NF-kappaB sites within the HIV-1 LTR correlate with HIV-1-associated dementia. DNA and cell biology. 2004; 23(4):261–9. https://doi.org/10.1089/104454904773819842 PMID: 15142383.
- Nonnemacher MR, Irish BP, Liu Y, Mauger D, Wigdahl B. Specific sequence configurations of HIV-1 LTR G/C box array result in altered recruitment of Sp isoforms and correlate with disease progression. Journal of neuroimmunology. 2004; 157(1–2):39–47. <u>https://doi.org/10.1016/j.jneuroim.2004.08.021</u> PMID: <u>15579278</u>.
- Gaynor R. Cellular transcription factors involved in the regulation of HIV-1 gene expression. Aids. 1992; 6(4):347–63. PMID: 1616633.
- Ou S-HI, Gaynor RB. Intracellular Factors Involved in Gene Expression of Human Retroviruses. In: Levy JA, editor. The Retroviridae. Boston, MA: Springer US; 1995. p. 97–184.
- Estable MC. In search of a function for the most frequent naturally-occurring length polymorphism (MFNLP) of the HIV-1 LTR: retaining functional coupling, of Nef and RBF-2, at RBEIII? International journal of biological sciences. 2007; 3(5):318–27. PMID: <u>17589566</u>; PubMed Central PMCID: PMC1893116.
- Estable MC, Bell B, Hirst M, Sadowski I. Naturally occurring human immunodeficiency virus type 1 long terminal repeats have a frequently observed duplication that binds RBF-2 and represses transcription. Journal of virology. 1998; 72(8):6465–74. PMID: <u>9658089</u>; PubMed Central PMCID: PMC109809.
- Estable MC, Bell B, Merzouki A, Montaner JS, O'Shaughnessy MV, Sadowski IJ. Human immunodeficiency virus type 1 long terminal repeat variants from 42 patients representing all stages of infection display a wide range of sequence polymorphism and transcription activity. Journal of virology. 1996; 70(6):4053–62. PMID: <u>8648743</u>; PubMed Central PMCID: PMC190286.
- Gaynor RB. Regulation of HIV-1 Gene Expression by the Transactivator Protein Tat. In: Chen ISY, Koprowski H, Srinivasan A, Vogt PK, editors. Transacting Functions of Human Retroviruses. Berlin, Heidelberg: Springer Berlin Heidelberg; 1995. p. 51–77.
- Krebs FC, Hogan TH, Quiterio S, Gartner S, Wigdahl B. Lentiviral LTR-directed Expression, Sequence Variation, and Disease Pathogenesis. In: Kuiken C, Foley B, Hahn B, Marx P, McCutchan F, Mellors JW, et al., editors. HIV Sequence Compendium 2001. Los Alamos, NM, LA-UR 02–2877.: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory; 2001. p. 29–70
- Berkhout B, Klaver B, Das AT. A Conserved Hairpin Structure Predicted for the Poly(A) Signal of Human and Simian Immunodeficiency Viruses. Virology. 1995; 207(1):276–81. <u>https://doi.org/10.1006/viro.1995.1077</u> PMID: <u>7755727</u>
- el Kharroubi A, Verdin E. Protein-DNA interactions within DNase I-hypersensitive sites located downstream of the HIV-1 promoter. Journal of Biological Chemistry. 1994; 269(31):19916–24. PMID: 8051074
- Montano MA, Kripke K, Norina CD, Achacoso P, Herzenberg LA, Roy AL, et al. NF-kB Homodimer Binding within the HIV-1 Initiator Region and Interactions with TFII-I. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93(22):12376–81. PMID: 8901589
- Ou SH, Wu F, Harrich D, García-Martínez LF, Gaynor RB. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. Journal of virology. 1995; 69(6):3584–96. PMID: 7745706
- Zoumpourlis V, Ergazaki M, Spandidos D. Ap-1 recognizes sequence elements on hiv-1 LTR in human epithelial tumor-cell lines. Oncology reports. 1994; 1(2):397–401. PMID: <u>21607373</u>.
- Garcia JA, Harrich D, Soultanakis E, Wu F, Mitsuyasu R, Gaynor RB. Human immunodeficiency virus type 1 LTR TATA and TAR region sequences required for transcriptional regulation. The EMBO Journal. 1989; 8(3):765–78. PubMed PMID: PMC400873. PMID: 2721501
- **31.** Karn J. Tackling tat. Journal of molecular biology. 1999; 293(2):235–54. <u>https://doi.org/10.1006/jmbi.</u> 1999.3060 PMID: 10550206
- Kilareski EM, Shah S, Nonnemacher MR, Wigdahl B. Regulation of HIV-1 transcription in cells of the monocyte-macrophage lineage. Retrovirology. 2009; 6:118. <u>https://doi.org/10.1186/1742-4690-6-118</u> PMID: <u>20030845</u>; PubMed Central PMCID: PMC2805609.
- Kingsman SM, Kingsman AJ. The Regulation of Human Immunodeficiency Virus Type-1 Gene Expression. European Journal of Biochemistry. 1996; 240(3):491–507. <u>https://doi.org/10.1111/j.1432-1033.1996.0491h.x</u> PMID: <u>8856047</u>

- Brigati C, Giacca M, Noonan DM, Albini A. HIV Tat, its TARgets and the control of viral gene expression. FEMS Microbiology Letters. 2003; 220(1):57–65. <u>https://doi.org/10.1016/S0378-1097(03)00067-3</u> PMID: <u>12644228</u>
- Duverger A, Wolschendorf F, Zhang M, Wagner F, Hatcher B, Jones J, et al. An AP-1 binding site in the enhancer/core element of the HIV-1 promoter controls the ability of HIV-1 to establish latent infection. Journal of virology. 2013; 87(4):2264–77. <u>https://doi.org/10.1128/JVI.01594-12</u> PMID: <u>23236059</u>; PubMed Central PMCID: PMC3571467.
- 36. Karn J, Stoltzfus CM. Transcriptional and Posttranscriptional Regulation of HIV-1 Gene Expression. Cold Spring Harbor Perspectives in Medicine. 2012; 2(2):a006916. <u>https://doi.org/10.1101/</u> <u>cshperspect.a006916</u> PubMed PMID: PMC3281586. PMID: 22355797
- Terme J-M, Calvignac S, Duc Dodon M, Gazzolo L, Jordan A. E box motifs as mediators of proviral latency of human retroviruses. Retrovirology. 2009; 6(1):81. <u>https://doi.org/10.1186/1742-4690-6-81</u> PMID: <u>19758443</u>
- Van Lint C, Bouchat S, Marcello A. HIV-1 transcription and latency: an update. Retrovirology. 2013; 10 (1):67. https://doi.org/10.1186/1742-4690-10-67 PMID: 23803414
- De Arellano ER, Soriano V, Holguin A. Genetic analysis of regulatory, promoter, and TAR regions of LTR sequences belonging to HIV type 1 Non-B subtypes. AIDS research and human retroviruses. 2005; 21(11):949–54. https://doi.org/10.1089/aid.2005.21.949 PMID: 16386112.
- 40. De Baar MP, De Ronde A, Berkhout B, Cornelissen M, Van Der Horn KH, Van Der Schoot AM, et al. Subtype-specific sequence variation of the HIV type 1 long terminal repeat and primer-binding site. AIDS research and human retroviruses. 2000; 16(5):499–504. <u>https://doi.org/10.1089/088922200309160</u> PMID: 10772536.
- Jeeninga RE, Hoogenkamp M, Armand-Ugon M, de Baar M, Verhoef K, Berkhout B. Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G. Journal of virology. 2000; 74(8):3740–51. PMID: <u>10729149</u>; PubMed Central PMCID: PMC111883.
- **42.** Beerenwinkel N, Zagordi O. Ultra-deep sequencing for the analysis of viral populations. Curr Opin Virol. 2011; 1(5):413–8. <u>https://doi.org/10.1016/j.coviro.2011.07.008</u> PMID: 22440844.
- Forns X, Bukh J, Purcell RH, Emerson SU. How Escherichia coli can bias the results of molecular cloning: preferential selection of defective genomes of hepatitis C virus during the cloning procedure. Proceedings of the National Academy of Sciences of the United States of America. 1997; 94(25):13909– 14. PMID: <u>9391126</u>; PubMed Central PMCID: PMC28406.
- 44. Hora B, Keating SM, Chen Y, Sanchez AM, Sabino E, Hunt G, et al. Genetic Characterization of a Panel of Diverse HIV-1 Isolates at Seven International Sites. PloS one. 2016; 11(6):e0157340. <u>https://</u> doi.org/10.1371/journal.pone.0157340 PMID: 27314585
- Agyingi L, Mayr LM, Kinge T, Orock GE, Ngai J, Asaah B, et al. The evolution of HIV-1 group M genetic variability in Southern Cameroon is characterized by several emerging recombinant forms of CRF02_AG and viruses with drug resistance mutations. Journal of medical virology. 2014; 86(3):385– 93. https://doi.org/10.1002/jmv.23846 PMID: 24248638; PubMed Central PMCID: PMC4011137.
- Ragupathy V, Zhao J, Wood O, Tang S, Lee S, Nyambi P, et al. Identification of new, emerging HIV-1 unique recombinant forms and drug resistant viruses circulating in Cameroon. Virology journal. 2011; 8:185. <u>https://doi.org/10.1186/1743-422X-8-185</u> PMID: <u>21513545</u>; PubMed Central PMCID: PMC3118203.
- Zhao J, Tang S, Ragupathy V, Gaddam D, Wang X, Zhang P, et al. CRF22_01A1 is involved in the emergence of new HIV-1 recombinants in Cameroon. J Acquir Immune Defic Syndr. 2012; 60(4):344– 50. Epub 2012/05/03. https://doi.org/10.1097/QAI.0b013e318258c7e3 PMID: 22549382.
- Sanchez AM, DeMarco CT, Hora B, Keinonen S, Chen Y, Brinkley C, et al. Development of a contemporary globally diverse HIV viral panel by the EQAPOL program. J Immunol Methods. 2014; 409:117– 30. <u>https://doi.org/10.1016/j.jim.2014.01.004</u> PMID: <u>24447533</u>; PubMed Central PMCID: PMCPMC4104154.
- Kumar S, Stecher G, Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets. Molecular biology and evolution. 2016; 33(7):1870–4. <u>https://doi.org/10.1093/</u> molbev/msw054 PMID: 27004904
- 50. Zhao J, Liu J, Vemula SV, Lin C, Tan J, Ragupathy V, et al. Sensitive Detection and Simultaneous Discrimination of Influenza A and B Viruses in Nasopharyngeal Swabs in a Single Assay Using Next-Generation Sequencing-Based Diagnostics. PloS one. 2016; 11(9):e0163175. <u>https://doi.org/10.1371/journal.pone.0163175</u> PMID: 27658193
- Struck D, Lawyer G, Ternes A-MM, Schmit J-CC, Bercoff DP. COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification. Nucleic acids research. 2015;42.

- Zhao J, Tang S, Ragupathy V, Carr JK, Wolfe ND, Awazi B, et al. Identification and genetic characterization of a novel CRF22_01A1 recombinant form of HIV type 1 in Cameroon. AIDS research and human retroviruses. 2010; 26(9):1033–45. Epub 2010/09/04. <u>https://doi.org/10.1089/aid.2009.0197</u> PMID: <u>20812894</u>.
- Schwartz C, Canonne-Hergaux F, Aunis D, Schaeffer E. Characterization of nuclear proteins that bind to the regulatory TGATTGGC motif in the human immunodeficiency virus type 1 long terminal repeat. Nucleic acids research. 1997; 25(6):1177–84. PMID: <u>9092627</u>; PubMed Central PMCID: PMC146561.
- Vemula SV, Veerasamy R, Ragupathy V, Biswas S, Devadas K, Hewlett I. HIV-1 Induced Nuclear Factor I-B (NF-IB) Expression Negatively Regulates HIV-1 Replication through Interaction with the Long Terminal Repeat Region. Viruses. 2015; 7(2):543–58. <u>https://doi.org/10.3390/v7020543</u> PubMed PMID: PMC4353903. PMID: 25664610
- 55. Nonnemacher MR, Pirrone V, Feng R, Moldover B, Passic S, Aiamkitsumrit B, et al. HIV-1 Promoter Single Nucleotide Polymorphisms Are Associated with Clinical Disease Severity. PloS one. 2016; 11(4): e0150835. <u>https://doi.org/10.1371/journal.pone.0150835</u> PubMed PMID: PMC4839606. PMID: 27100290
- Van Lint C, Burny A, Verdin E. The intragenic enhancer of human immunodeficiency virus type 1 contains functional AP-1 binding sites. Journal of virology. 1991; 65(12):7066–72. PubMed PMID: PMC250832. PMID: <u>1942259</u>
- Franza BR Jr, Rauscher FJ 3rd, Josephs SF, Curran T. The Fos complex and Fos-related antigens recognize sequence elements that contain AP-1 binding sites. Science. 1988; 239(4844):1150–3. PMID: <u>2964084</u>.
- Merika M, Orkin SH. DNA-binding specificity of GATA family transcription factors. Molecular and cellular biology. 1993; 13(7):3999–4010. PubMed PMID: PMC359949. PMID: 8321207
- Yamamoto K, Mori S, Okamoto T, Shimotohno K, Kyogoku Y. Identification of transcriptional suppressor proteins that bind to the negative regulatory element of the human immunodeficiency virus type 1. Nucleic acids research. 1991; 19(22):6107–12. PMID: <u>1956769</u>; PubMed Central PMCID: PMCPMC329097.
- Pereira LA, Churchill MJ, Elefanty AG, Gouskos T, Lambert PF, Ramsay RG, et al. Characterization of interactions between transcription factors and a regulatory region spanning nt -320 to -281 of the HIV-1 LTR in T-lymphoid and non-T-lymphoid cells. Journal of biomedical science. 2002; 9(1):68–81. PMID: 11810027.
- Yang Z, Engel JD. Human T cell transcription factor GATA-3 stimulates HIV-1 expression. Nucleic acids research. 1993; 21(12):2831–6. PubMed PMID: PMC309663. PMID: 8332492
- Georgakopoulos T, Aggeletopoulou I, Karagiannis F, Skoutelis A, Mouzaki A. Ets-2 Protein Is a Transcriptional Repressor Of The HIV-1 Virus and Acts Through Binding To The HIV-LTR-RATS Element. Blood. 2013; 122(21):3477-.
- Wasylyk B, Hahn SL, Giovane A. The Ets family of transcription factors. European Journal of Biochemistry. 1993; 211(1–2):7–18. https://doi.org/10.1111/j.1432-1033.1993.tb19864.x PMID: 8425553
- Gustavson MD, Crawford HC, Fingleton B, Matrisian LM. Tcf binding sequence and position determines beta-catenin and Lef-1 responsiveness of MMP-7 promoters. Molecular carcinogenesis. 2004; 41(3):125–39. https://doi.org/10.1002/mc.20049 PMID: 15457508.
- Markovitz DM, Hannibal MC, Smith MJ, Cossman R, Nabel GJ. Activation of the human immunodeficiency virus type 1 enhancer is not dependent on NFAT-1. Journal of virology. 1992; 66(6):3961–5.
 PMID: <u>1533884</u>; PubMed Central PMCID: PMC241190.
- Montano MA, Novitsky VA, Blackard JT, Cho NL, Katzenstein DA, Essex M. Divergent transcriptional regulation among expanding human immunodeficiency virus type 1 subtypes. Journal of virology. 1997; 71(11):8657–65. PMID: <u>9343223</u>
- 67. Argyropoulos C, Nikiforidis GC, Theodoropoulou M, Adamopoulos P, Boubali S, Georgakopoulos TN, et al. Mining microarray data to identify transcription factors expressed in naive resting but not activated T lymphocytes. Genes Immun. 2004; 5(1):16–25. <u>https://doi.org/10.1038/sj.gene.6364034</u> PMID: <u>14735145</u>
- Cron RQ, Bartz SR, Clausell A, Bort SJ, Klebanoff SJ, Lewis DB. NFAT1 enhances HIV-1 gene expression in primary human CD4 T cells. Clinical immunology. 2000; 94(3):179–91. <u>https://doi.org/ 10.1006/clim.1999.4831</u> PMID: <u>10692237</u>.
- Churchill MJ, Ramsay RG, Rhodes DI, Deacon NJ. c-Myb Influences HIV Type 1 Gene Expression and Virus Production. AIDS research and human retroviruses. 2001; 17(16):1481–8. <u>https://doi.org/ 10.1089/08892220152644188</u> PMID: <u>11709092</u>
- 70. Mädge B. E-Box. In: Schwab M, editor. Encyclopedia of Cancer. Berlin, Heidelberg: Springer Berlin Heidelberg; 2009. p. 947–50.

- 71. Ou SH, Garcia-Martínez LF, Paulssen EJ, Gaynor RB. Role of flanking E box motifs in human immunodeficiency virus type 1 TATA element function. Journal of virology. 1994; 68(11):7188–99. PubMed PMID: PMC237158. PMID: <u>7933101</u>
- Akira S, Isshiki H, Sugita T, Tanabe O, Kinoshita S, Nishio Y, et al. A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. The EMBO Journal. 1990; 9(6):1897–906. PubMed PMID: PMC551896. PMID: 2112087
- Ruocco MR, Chen X, Ambrosino C, Dragonetti E, Liu W, Mallardo M, et al. Regulation of HIV-1 Long Terminal Repeats by Interaction of C/EBP(NF-IL6) and NF-κB/Rel Transcription Factors. Journal of Biological Chemistry. 1996; 271(37):22479–86. <u>https://doi.org/10.1074/jbc.271.37.22479</u> PMID: 8798413
- 74. Tesmer VM, Rajadhyaksha A, Babin J, Bina M. NF-IL6-mediated transcriptional activation of the long terminal repeat of the human immunodeficiency virus type 1. Proceedings of the National Academy of Sciences of the United States of America. 1993; 90(15):7298–302. PubMed PMID: PMC47124. PMID: 8346247
- Henderson AJ, Zou X, Calame KL. C/EBP proteins activate transcription from the human immunodeficiency virus type 1 long terminal repeat in macrophages/monocytes. Journal of virology. 1995; 69 (9):5337–44. PubMed PMID: PMC189374. PMID: 7636977
- 76. Liu Y, Nonnemacher MR, Stauff DL, Li L, Banerjee A, Irish B, et al. Structural and functional studies of CCAAT/enhancer binding sites within the human immunodeficiency virus type 1 subtype C LTR. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2010; 64(10):672–80. <u>https://doi.org/10.1016/j.biopha.2010.09.007</u> PMID: 20970301; PubMed Central PMCID: PMC2998390.
- Estable MC, Hirst M, Bell B, O'Shaughnessy MV, Sadowski I. Purification of RBF-2, a transcription factor with specificity for the most conserved cis-element of naturally occurring HIV-1 LTRs. Journal of biomedical science. 1999; 6(5):320–32. doi: 25404. <u>https://doi.org/10.1159/000025404</u> PMID: 10494039.
- 78. Holzmeister J, Ludewig B, Pauli G, Simon D. Sequence-Specific Binding of the Transcription Factor c-Ets1 to the Human Immunodeficiency Virus Type I Long Terminal Repeat. Biochemical and Biophysical Research Communications. 1993; 197(3):1229–33. <u>https://doi.org/10.1006/bbrc.1993.2608</u>. <u>https://doi.org/10.1006/bbrc.1993.2608</u> PMID: 8280137
- 79. Mondal D, Alam J, Prakash O. NF-kappa B site-mediated negative regulation of the HIV-1 promoter by CCAAT/enhancer binding proteins in brain-derived cells. Journal of molecular neuroscience: MN. 1994; 5(4):241–58. <u>https://doi.org/10.1007/BF02736725</u> PMID: <u>7577367</u>.
- Dahiya S, Liu Y, Nonnemacher MR, Dampier W, Wigdahl B. CCAAT enhancer binding protein and nuclear factor of activated T cells regulate HIV-1 LTR via a novel conserved downstream site in cells of the monocyte-macrophage lineage. PloS one. 2014; 9(2):e88116. <u>https://doi.org/10.1371/journal.pone.0088116</u> PMID: 24551078; PubMed Central PMCID: PMC3925103.
- Naghavi MH, Schwartz S, Sonnerborg A, Vahlne A. Long terminal repeat promoter/enhancer activity of different subtypes of HIV type 1. AIDS research and human retroviruses. 1999; 15(14):1293–303. https://doi.org/10.1089/088922299310197 PMID: 10505678.
- Sheridan PL, Sheline CT, Cannon K, Voz ML, Pazin MJ, Kadonaga JT, et al. Activation of the HIV-1 enhancer by the LEF-1 HMG protein on nucleosome-assembled DNA in vitro. Genes Dev. 1995; 9 (17):2090–104. PMID: 7657162.
- d'Adda di Fagagna F, Marzio G, Gutierrez MI, Kang LY, Falaschi A, Giacca M. Molecular and functional interactions of transcription factor USF with the long terminal repeat of human immunodeficiency virus type 1. Journal of virology. 1995; 69(5):2765–75. PMID: <u>7707499</u>
- Naghavi MH, Estable MC, Schwartz S, Roeder RG, Vahlne A. Upstream stimulating factor affects human immunodeficiency virus type 1 (HIV-1) long terminal repeat-directed transcription in a cell-specific manner, independently of the HIV-1 subtype and the core-negative regulatory element. The Journal of general virology. 2001; 82(Pt 3):547–59. <u>https://doi.org/10.1099/0022-1317-82-3-547</u> PMID: <u>11172096</u>.
- Kirch HC, Flaswinkel S, Rumpf H, Brockmann D, Esche H. Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-kappaB and Myc/Max. Oncogene. 1999; 18(17):2728–38. https://doi.org/10.1038/sj.onc.1202626 PMID: 10348347.
- Bachu M, Yalla S, Asokan M, Verma A, Neogi U, Sharma S, et al. Multiple NF-kappaB sites in HIV-1 subtype C long terminal repeat confer superior magnitude of transcription and thereby the enhanced viral predominance. The Journal of biological chemistry. 2012; 287(53):44714–35. <u>https://doi.org/10. 1074/jbc.M112.397158</u> PMID: 23132857; PubMed Central PMCID: PMC3531786.
- 87. Bassuk AG, Anandappa RT, Leiden JM. Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus

enhancer in T cells. Journal of virology. 1997; 71(5):3563–73. PMID: <u>9094628</u>; PubMed Central PMCID: PMC191503.

- Perkins ND, Agranoff AB, Duckett CS, Nabel GJ. Transcription factor AP-2 regulates human immunodeficiency virus type 1 gene expression. Journal of virology. 1994; 68(10):6820–3. PMID: <u>8084021</u>; PubMed Central PMCID: PMC237111.
- Kurosu T, Mukai T, Auwanit W, Ayuthaya PI, Saeng-Aroon S, Ikuta K. Variable sequences in the long terminal repeat and Its downstream region of some of HIV Type 1 CRF01_AE recently distributing among Thai carriers. AIDS research and human retroviruses. 2001; 17(9):863–6. <u>https://doi.org/10.</u> 1089/088922201750252061 PMID: 11429128.
- 90. McAllister JJ, Phillips D, Millhouse S, Conner J, Hogan T, Ross HL, et al. Analysis of the HIV-1 LTR NF-kappaB-proximal Sp site III: evidence for cell type-specific gene regulation and viral replication. Virology. 2000; 274(2):262–77. <u>https://doi.org/10.1006/viro.2000.0476</u> PMID: <u>10964770</u>.
- 91. Shah S, Alexaki A, Pirrone V, Dahiya S, Nonnemacher MR, Wigdahl B. Functional properties of the HIV-1 long terminal repeat containing single-nucleotide polymorphisms in Sp site III and CCAAT/ enhancer binding protein site I. Virology journal. 2014; 11:92. <u>https://doi.org/10.1186/1743-422X-11-92 PMID: 24886416; PubMed Central PMCID: PMC4047001.</u>
- Jones K, Kadonaga J, Luciw P, Tjian R. Activation of the AIDS retrovirus promoter by the cellular transcription factor, Sp1. Science. 1986; 232(4751):755–9. <u>https://doi.org/10.1126/science.3008338</u>
 PMID: 3008338
- **93.** Liu Y-Z, Latchman DS. The octamer-binding proteins Oct-1 and Oct-2 repress the HIV long terminal repeat promoter and its transactivation by Tat. Biochemical Journal. 1997; 322(1):155.
- Jones KA, Luciw PA, Duchange N. Structural arrangements of transcription control domains within the 5'-untranslated leader regions of the HIV-1 and HIV-2 promoters. Genes & Development. 1988; 2 (9):1101–14. <u>https://doi.org/10.1101/gad.2.9.1101</u>
- 95. Moses AV, Ibanez C, Gaynor R, Ghazal P, Nelson JA. Differential role of long terminal repeat control elements for the regulation of basal and Tat-mediated transcription of the human immunodeficiency virus in stimulated and unstimulated primary human macrophages. Journal of virology. 1994; 68 (1):298–307. PubMed PMID: PMC236289. PMID: 8254741
- 96. Roebuck KA, Brenner DA, Kagnoff MF. Identification of c-fos-responsive elements downstream of TAR in the long terminal repeat of human immunodeficiency virus type-1. Journal of Clinical Investigation. 1993; 92(3):1336–48. PubMed PMID: PMC288275. <u>https://doi.org/10.1172/JCI116707 PMID: 8376588</u>
- Van Lint C, Amella CA, Emiliani S, John M, Jie T, Verdin E. Transcription factor binding sites downstream of the human immunodeficiency virus type 1 transcription start site are important for virus infectivity. Journal of virology. 1997; 71(8):6113–27. PMID: <u>9223506</u>; PubMed Central PMCID: PMC191872.
- Sassone-Corsi P. Transcription factors responsive to cAMP. Annu Rev Cell Dev Biol. 1995; 11:355– 77. https://doi.org/10.1146/annurev.cb.11.110195.002035 PMID: 8689562.
- 99. Courtney CR, Agyingi L, Fokou A, Christie S, Asaah B, Meli J, et al. Monitoring HIV-1 Group M Subtypes in Yaoundé, Cameroon Reveals Broad Genetic Diversity and a Novel CRF02_AG/F2 Infection. AIDS research and human retroviruses. 2015; 32(4):381–5. <u>https://doi.org/10.1089/aid.2015.0286</u> PMID: 26681241
- Powell RLR, Urbanski MM, Burda S, Kinge T, Nyambi PN. High Frequency of HIV-1 Dual Infections Among HIV-Positive Individuals in Cameroon, West Central Africa. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2009; 50(1):84–92. <u>https://doi.org/10.1097/QAI.0b013e31818d5a40</u> PMID: 19295338.
- González-Alba JM, Holguín Á, Garcia R, García-Bujalance S, Alonso R, Suárez A, et al. Molecular Surveillance of HIV-1 in Madrid, Spain: a Phylogeographic Analysis. Journal of virology. 2011; 85 (20):10755–63. <u>https://doi.org/10.1128/JVI.00454-11</u> PubMed PMID: PMC3187488. PMID: <u>21795343</u>
- 102. Guimarães ML, Velarde-Dunois KG, Segurondo D, Morgado MG. The HIV-1 epidemic in Bolivia is dominated by subtype B and CRF12_BF "family" strains. Virology journal. 2012; 9:19-. <u>https://doi.org/ 10.1186/1743-422X-9-19</u> PubMed PMID: PMC3285048. PMID: <u>22248191</u>
- Leal É, Villanova FE. Diversity of HIV-1 Subtype B: Implications to the Origin of BF Recombinants. PloS one. 2010; 5(7):e11833. <u>https://doi.org/10.1371/journal.pone.0011833</u> PMID: 20676362
- 104. Shiino T, Sadamasu K, Hattori J, Nagashima M, Iwatani Y, Yokomaku Y, et al. Large MSM Group and Local Heterosexual Transmission Are Major Concerns in the HIV Epidemic in Japan. Conference on Retroviruses and Opportunistic Infections (CROI); March 3–6, 2014 Boston, Massachusetts2014.
- 105. Sierra M, Thomson MM, Ríos M, Casado G, Castro RO-d, Delgado E, et al. The analysis of near fulllength genome sequences of human immunodeficiency virus type 1 BF intersubtype recombinant viruses from Chile, Venezuela and Spain reveals their relationship to diverse lineages of recombinant

viruses related to CRF12_BF. Infection, Genetics and Evolution. 2005; 5(3):209–17. <u>https://doi.org/10.1016/j.meegid.2004.07.010</u> PMID: 15737911

- 106. Ross HL, Nonnemacher MR, Hogan TH, Quiterio SJ, Henderson A, McAllister JJ, et al. Interaction between CCAAT/Enhancer Binding Protein and Cyclic AMP Response Element Binding Protein 1 Regulates Human Immunodeficiency Virus Type 1 Transcription in Cells of the Monocyte/Macrophage Lineage. Journal of virology. 2001; 75(4):1842–56. <u>https://doi.org/10.1128/JVI.75.4.1842-1856.2001</u> PubMed PMID: PMC114094. PMID: <u>11160683</u>
- 107. Schwartz C, Catez P, Rohr O, Lecestre D, Aunis D, Schaeffer E. Functional interactions between C/EBP, Sp1, and COUP-TF regulate human immunodeficiency virus type 1 gene transcription in human brain cells. Journal of virology. 2000; 74(1):65–73. PMID: <u>10590092</u>; PubMed Central PMCID: PMC111514.
- Liu Y, Nonnemacher MR, Wigdahl B. CCAAT/enhancer-binding proteins and the pathogenesis of retrovirus infection. Future microbiology. 2009; 4:299–321. <u>https://doi.org/10.2217/fmb.09.4</u> PubMed PMID: PMC2710768. PMID: 19327116
- 109. Bresnick EH, Katsumura KR, Lee H-Y, Johnson KD, Perkins AS. Master regulatory GATA transcription factors: mechanistic principles and emerging links to hematologic malignancies. Nucleic acids research. 2012; 40(13):5819–31. https://doi.org/10.1093/nar/gks281 PMID: 22492510
- 110. Wei G, Abraham BJ, Yagi R, Jothi R, Cui K, Sharma S, et al. Genome-wide analyses of transcription factor GATA3-mediated gene regulation in distinct T cell types. Immunity. 2011; 35(2):299–311. https://doi.org/10.1016/j.immuni.2011.08.007 PubMed PMID: PMC3169184. PMID: 21867929
- 111. Colin L, Vandenhoudt N, de Walque S, Van Driessche B, Bergamaschi A, Martinelli V, et al. The AP-1 Binding Sites Located in the pol Gene Intragenic Regulatory Region of HIV-1 Are Important for Viral Replication. PloS one. 2011; 6(4):e19084. <u>https://doi.org/10.1371/journal.pone.0019084</u> PubMed PMID: PMC3079759. PMID: <u>21526160</u>
- 112. Imai K, Okamoto T. Transcriptional repression of human immunodeficiency virus type 1 by AP-4. The Journal of biological chemistry. 2006; 281(18):12495–505. <u>https://doi.org/10.1074/jbc.M511773200</u> PMID: 16540471.
- 113. Stojanova A, Caro C, Jarjour RJV, Oster SK, Penn LZ, Germinario RJ. Repression of the human immunodeficiency virus type-1 long terminal repeat by the c-Myc oncoprotein. Journal of Cellular Biochemistry. 2004; 92(2):400–13. <u>https://doi.org/10.1002/jcb.20065</u> PMID: <u>15108364</u>
- 114. Qu D, Li C, Sang F, Li Q, Jiang Z-Q, Xu L-R, et al. The variances of Sp1 and NF-κB elements correlate with the greater capacity of Chinese HIV-1 B'-LTR for driving gene expression. Scientific Reports. 2016; 6:34532. <u>https://doi.org/10.1038/srep34532</u> PubMed PMID: PMC5048295. PMID: <u>27698388</u>
- 115. Kurosu T, Mukai T, Komoto S, Ibrahim MS, Li Y-g, Kobayashi T, et al. Human Immunodeficiency Virus Type 1 Subtype C Exhibits Higher Transactivation Activity of Tat than Subtypes B and E. Microbiology and Immunology. 2002; 46(11):787–99. <u>https://doi.org/10.1111/j.1348-0421.2002.tb02766.x</u> PMID: <u>12516777</u>
- 116. Verma A, Rajagopalan P, Lotke R, Varghese R, Selvam D, Kundu TK, et al. Functional Incompatibility between the Generic NF-kB Motif and a Subtype-Specific Sp1III Element Drives the Formation of the HIV-1 Subtype C Viral Promoter. Journal of virology. 2016; 90(16):7046–65. <u>https://doi.org/10.1128/ JVI.00308-16</u> PMID: 27194770
- Kinoshita S, Su L, Amano M, Timmerman LA, Kaneshima H, Nolan GP. The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells. Immunity. 1997; 6 (3):235–44. PMID: <u>9075924</u>.
- Romanchikova N, Ivanova V, Scheller C, Jankevics E, Jassoy C, Serfling E. NFAT transcription factors control HIV-1 expression through a binding site downstream of TAR region. Immunobiology. 2003; 208(4):361–5. <u>https://doi.org/10.1078/0171-2985-00283</u> PMID: <u>14748509</u>.
- 119. Keller M, Lu Y, Lalonde RG, Klein MB. Impact of HIV-1 viral subtype on CD4+ T-cell decline and clinical outcomes in antiretroviral naive patients receiving universal healthcare. Aids. 2009; 23(6):731–7. https://doi.org/10.1097/QAD.0b013e328326f77f PMID: 19279446.
- 120. Li Y, Han Y, Xie J, Gu L, Li W, Wang H, et al. CRF01_AE subtype is associated with X4 tropism and fast HIV progression in Chinese patients infected through sexual transmission. Aids. 2014; 28(4):521–30. https://doi.org/10.1097/QAD.00000000000125 PMID: 24472744.
- 121. Rangsin R, Piyaraj P, Sirisanthana T, Sirisopana N, Short O, Nelson KE. The natural history of HIV-1 subtype E infection in young men in Thailand with up to 14 years of follow-up. Aids. 2007; 21:S39–S46. https://doi.org/10.1097/01.aids.0000299409.29528.23 PMID: 00002030-200711006-00006.
- 122. Palmer S, Hamblin AS. Increased CD11/CD18 expression on the peripheral blood leucocytes of patients with HIV disease: relationship to disease severity. Clinical and experimental immunology. 1993; 93(3):344–9. PubMed PMID: PMC1554900. PMID: <u>8103716</u>

- 123. Beerens N, Groot F, Berkhout B. Stabilization of the U5-leader stem in the HIV-1 RNA genome affects initiation and elongation of reverse transcription. Nucleic acids research. 2000; 28(21):4130–7. PMID: <u>11058109</u>; PubMed Central PMCID: PMCPMC113157.
- 124. Vrolijk MM, Ooms M, Harwig A, Das AT, Berkhout B. Destabilization of the TAR hairpin affects the structure and function of the HIV-1 leader RNA. Nucleic acids research. 2008; 36(13):4352–63. <u>https:// doi.org/10.1093/nar/gkn364</u> PMID: <u>18586822</u>; PubMed Central PMCID: PMC2490758.
- 125. Berkhout B. Structure and Function of the Human Immunodeficiency Virus Leader RNA. Progress in Nucleic Acid Research and Molecular Biology. 1996; 54:1–34. <u>https://doi.org/10.1016/S0079-6603</u> (08)60359-1. PMID: <u>8768071</u>
- 126. Kozaczynska K, Cornelissen M, Reiss P, Zorgdrager F, van der Kuyl AC. HIV-1 sequence evolution in vivo after superinfection with three viral strains. Retrovirology. 2007; 4(1):59. <u>https://doi.org/10.1186/1742-4690-4-59 PMID: 17716368</u>